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an	 artery	 wall.	 Despite	 the	 significance	 of	 atherosclerotic	 cardiovascular	 disease	 to	
healthcare,	 the	pathophysiology	of	 atherosclerosis	 is	 not	 fully	 understood.	 To	 allow	us	 to	
examine	the	dynamical	process	of	atherogenesis,	a	 theoretical	approach	has	the	potential	




The	model	 has	 been	 developed	 to	 conform	 to	 Systems	 Biology	Markup	 Language	 (SBML)	
and	Systems	Biology	Graphical	Notation	(SBGN)	open	standards.	Collating	parameters	from	
multiple	 sources,	 the	 curated	 model	 displays	 atherosclerosis-like	 behaviour	 such	 as	
lipoprotein	 oxidation,	 cellular	 build-up,	 extra-cellular	 matrix	 formation	 and	 reverse	
cholesterol	transport.		
Publicly	 available	 genomic	 data	 has	 been	 utilised	 to	 evaluate	 the	 changes	 in	 pathway	
dynamics	 across	 population	 subgroups.	 Data	 taken	 from	 the	 1000	 Genome	 Project,	 a	
worldwide	 effort	 to	 create	 an	 expansive	 catalogue	 of	 human	 variation,	 has	 been	 used	 to	
predict	 a	 tertiary	 protein	 structure	 for	 all	 proteins	 contained	 within	 the	 mathematical	
model,	and	the	variation	in	structure	for	a	collection	of	mutations	is	studied.	
A	combination	of	molecular	dynamics	methods	and	electrostatic	potential	analysis	are	then	
used	 to	 estimate	 how	 the	 binding	 rates	 of	 these	 proteins	 are	 affected	 by	 individual	











ABCA	 ATP-binding	cassette	transporter	ABCA1	 LDL	 Low	Density	Lipoprotein	
ABCG1	 ATP-binding	cassette	sub-family	G	member	1	 LDLC	 Low	Density	Lipoprotein	Cholesterol	
ADAM17	 ADAM	metallopeptidase	domain	17	 LDLP	 Low	Density	Lipoprotein	Particle	Number	
AIDS	 Acquired	Immune	Deficiency	Syndrome	 LDLR	 Low	Density	Lipoprotein	Receptor	
AMBER	 Assisted	Model	Building	with	Energy	Refinement	 LPL	 Lipoprotein	Lipase	
APBS	 Adaptive	Poisson–Boltzmann	Solver	 MCP1	 Monocyte	Chemoattractant	Protein	1	
API	 Application	Programming	Interface	 MD	 Molecular	Dynamics	




BD	 Brownian	Dynamics	 MMP	 Matrix	Metalloproteinase	
BRENDA	 BRaunschweig	ENzyme	DAtabase	 MMP1	 Matrix	Metalloproteinase	1	
CAD	 Coronary	Artery	Disease	 MMP13	 Matrix	Metalloproteinase	13	
CAMEO	 Continuous	Automated	Model	Evaluation	 MMP2	 Matrix	Metalloproteinase	2	
CAPRI	 Critical	Assessment	of	Prediction	of	Interactions	 MMP3	 Matrix	Metalloproteinase	3	
CASP	 Critical	Assessment	of	Protein	Structure	Prediction	 MMP9	 Matrix	Metalloproteinase	9	
CCL2	 Chemokine	(C-C	motif)	ligand	2	 MRI	 Magnetic	Resonance	Imaging	
CCL5	 Chemokine	(C-C	motif)	ligand	5	 MySQL	 My	Structured	Query	Language	
CCR2	 Chemokine	(C-C	motif)	Receptor	2	 NF-KB	 Nuclear	Factor	Kappa	B	
CCR5	 Chemokine	(C-C	motif)	Receptor	5	 NHS	 National	Health	Service	
CD34	 Cluster	of	Differentiation	34	 NMR	 Nuclear	Magnetic	Resonance	
CD36	 Cluster	of	Differentiation	36	 ODE	 Ordinary	Differential	Equation	
CD40	 Cluster	of	Differentiation	40	 OLR	 Oxidized	low-density	lipoprotein	receptor	
CETP	 Cholesterylester	Transfer	Protein	 OxLDL	 Oxidised	Low	Density	Lipoprotein	
CHARMM	 Chemistry	at	Harvard	Macromolecular	Mechanics	 PAD	 Peripheral	Artery	Disease	
CMA1	 Gene	for	Chymase	 PCSK9	 Proprotein	convertase	subtilisin/kexin	type	9	
COPASI	 Complex	Pathway	Simulator	 PDB	 Protein	Data	Bank	
CPU	 Central	Processing	Unit	 PDE	 Partial	Differential	Equation	
CRISPR	 Clustered	Regularly	Interspaced	Short	Palindromic	Repeats	 PDGF	 Platelet	Derived	Growth	Factor	
CSF1	 Colony	Stimulating	Factor	1	 PDGFA	 Platelet	Derived	Growth	Factor	A	
CSF1R	 Colony	Stimulating	Factor	1	Receptor	 PDGFB	 Platelet	Derived	Growth	Factor	B	
CVD	 Cardiovascular	Disease	 PDGFRA	 Platelet	Derived	Growth	Factor	Receptor	A	
CXCL10	 C-X-C	motif	chemokine	10	 PDGFRB	 Platelet	Derived	Growth	Factor	Receptor	B	





CXCL9	 C-X-C	motif	chemokine	10	 PMR2	 Physiome	Model	Repository	2	
DbSNP	 Database	of	Single	Nucleotide	Polymorphisms	 PPI	 Protein	Protein	Interaction	
EBI	 European	Bioinformatics	Institute	 PROCAM	 Prospective	Cardiovascular	Munster	
ECM	 Extra	Cellular	Matrix	 PRODIGY	 PROtein	binDIng	enerGY	prediction	
EGF	 Epidermal	Growth	Factor	 PTM	 Post-Translational	Modification	




EU	 European	Union	 RHD	 Rheumatic	Heart	Disease	
FFT	 Fast	Fourier	Transform	 RMSD	 Root	Mean	Square	Deviation	
FRODOCK	 Fast	Rotational	Docking	 SASA	 Surface	Accessable	Surface	Area	
GLG1	 Golgi	apparatus	protein	1	 SBGN	 Systems	Biology	Graphical	Notation	
GO	 Gene	Ontology	 SBGN-ML	 Systems	Biology	Graphical	Notation	-	Markup	Language	
GPU	 Graphical	Processing	Unit	 SBML	 Systems	Biology	Markup	Language	
GWAS	 Genome	Wide	Association	Study	 SCOP	 Structural	Classification	of	Proteins		
HDL	 High	Density	Lipoprotein	 SCOPe	 Structural	Classification	of	Proteins	Extended		
HPF	 High	Power	Field	 SDA	 Simulation	of	Diffusional	Association	
ICAM	 intercellular	adhesion	molecules	 SELP	 Gene	for	P-Selectin	
ICHEC	 Irish	Centre	for	High-End	Computing	 SEM	 Standard	Error	of	the	Mean	
IFNG	 Interferon	Gamma	 SMC	 Smooth	Muscle	Cells	
IFNGR1	 Interferon	Gamma	Receptor	Subunit	1	 SMPDB	 Small	Molecule	Pathway	Database	
IFNGR2	 Interferon	Gamma	Receptor	Subunit	2	 SNP	 Single	Nucleotide	Polymorphism	
IL10	 Interleukin	10	 SODE	 Stochastic	Ordinary	Differential	Equation	
IL10RA	 Interleukin	10	Receptor	Subunit	A	 SPF	 Spherical	Polar	Fourier	Technique	
IL12A	 Interleukin	12	Subunit	A	 SPR	 Surface	Plasmon	Resonance	
IL12B	 Interleukin	12	Subunit	B	 SPSS	 Statistical	Package	for	the	Social	Sciences	
IL12RB1	 Interleukin	12	Receptor	Subunit	B1	 SREBP	 Sterol	Regulatory	Element	Binding	Protein	
IL12RB2	 Interleukin	12	Receptor	Subunit	B2	 TACE	 Tumor	necrosis	factor-α-converting	enzyme	
IL17A	 Interleukin	17	A	 TCFA	 Thin-cap	Fibroatheroma	
IL17RA	 Interleukin	17	Receptor	A	 TGFB1	 Transforming	Growth	Factor	Beta	
IL18	 Interleukin	18	 TGFBR1	 Transforming	Growth	Factor	Beta	Receptor	Subunit	1	
IL18R1	 Interleukin	18	Receptor	1	 TGFBR2	 Transforming	Growth	Factor	Beta	Receptor	Subunit	2	
IL18RAP	 Interleukin	18	Receptor	Accessory	Protein	 TIA	 Transient	Ischaemic	Attack	
IL1B	 Interleukin	1B	 TIMP1	 Tissue	Inhibitor	of	Matrix	Metalloproteinases	1	
IL1R1	 Interleukin	1	Receptor	1	 TIMP2	 Tissue	Inhibitor	of	Matrix	Metalloproteinases	2	
IL1RL1	 Interleukin	1	Receptor-like	1	 TIMP3	 Tissue	Inhibitor	of	Matrix	Metalloproteinases	3	






IL21R	 Interleukin	21	Receptor	 TNF	 Tumor	necrosis	factor	
IL21R	 Interleukin	21	Receptor	 TNFR	 Tumor	necrosis	factor	Receptor	
IL2RA	 Interleukin	2	Receptor	Subunit	A	 TNFSFR1A	 Tumor	necrosis	factor	Superfamily	Receptor	1	A	
IL2RB	 Interleukin	2	Receptor	Subunit	B	 TNFSFR1B	 Tumor	necrosis	factor	Superfamily	Receptor	1	A	
IL2RG	 Interleukin	2	Receptor	Subunit	G	 TPSB2	 Tryptase	Beta	2	
IL33	 Interleukin	33	 TPSG1	 Tryptase	Gamma	1	
IL4	 Interleukin	4	 UK	 United	Kingdom	
IL4R	 Interleukin	4	Receptor	 USA	 United	States	of	America	




IL6	 Interleukin	6	 VCAM	 Vascular	cell	adhesion	protein	
IL6R	 Interleukin	6	Receptor	 VLDL	 Very	Low	Density	Lipoprotein	
I-TASSER	 Iterative	Threading	ASSEmbly	Refinement	 WES	 Whole	Exome	Sequencing	
KEGG	 Kyoto	Encyclopaedia	of	Genes	and	Genomes	 WGS	 Whole	Genome	Sequencing	
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Stratified	 medicine	 combines	 therapeutic	 strategies	 with	 a	 coinciding	 diagnosis	 to	
determine	patient	 subgroups	 for	 treatment	 optimisation	 (Trusheim	et	 al.,	 2011).	Dividing	
patients	 into	 subgroups	 using	 indicative	 biomarkers	 can	 allow	 for	 more	 targeted	
therapeutics,	creating	efficiencies	in	drug	response,	medication	cost,	treatment	length	and	
patient	 safety.	 Stratified	 medicine,	 alongside	 personalised	 and	 precision	 medicine,	 could	
lead	 to	 a	 new	 era	 of	 healthcare	 customisation,	 utilising	 pharmacogenomics	 to	maximise	
drug	efficacy	while	minimising	adverse	effects	(Mizzi	et	al.,	2014).	Patient	stratification	can	
be	 seen	 as	 a	 more	 practical	 and	 immediately	 feasible	 healthcare	 methodology	 than	
personalised	 medicine,	 due	 to	 the	 more	 simplistic	 nature	 of	 identifying	 groups	 with	 a	
particular	drug	response,	rather	than	individual	patient	therapeutic	optimisation	(Lonergan	
et	al.,	2017).	Discovery	of	biomarkers	that	 indicate	drug	response	efficacy	and	drug	target	
identification	 are	 two	 of	 the	 main	 goals	 in	 stratified	 medicine.	 Increase	 in	 quantities	 of	
publicly	available	genome	sequence	data	recently,	due	to	cost	reduction	and	technological	
advancements,	 have	 allowed	 for	 developments	 in	 pharmacogenomics	 and	 stratified	
medicine	 leading	 to	 a	 reduction	 in	 adverse	 drug	 reactions,	 increase	 in	 drug	 efficacy	 and	
reduced	therapeutic	cost	(Trusheim	et	al.,	2011).		
 Systems	Biology	
Understanding	 biological	 networks	 at	 the	 molecular	 level	 through	 biochemistry,	
mathematics,	 informatics,	 computer	 science	 and	 statistics	 is	 the	 primary	 goal	 of	 systems	
biology.	 The	 study	 of	 complex	 biological	 systems	 through	mathematical	modelling	 allows	
for	 predictions	 on	 how	 disruptions	 and	 perturbations	 affect	 disease	 pathophysiology.	
Biological	 networks,	 including	 protein-protein	 interaction	 (PPI),	 signalling	 and	 metabolic	









hypotheses,	discovery	of	disease	biomarkers	and	 the	 identification	of	drug	 targets	 (Hood,	
2013).	
 Atherosclerosis	
Atherosclerosis	 describes	 the	 build-up	 of	 fatty	material	 embedded	within	 the	 artery	wall	
causing	swelling	and	thickening.	Damage	to	the	endothelium,	the	layer	of	cells	forming	the	
interior	surface	within	the	vessel	wall,	 leads	to	an	 influx	of	 lipoproteins	and	 immune	cells	
(including	 monocytes,	 T	 cells,	 dendritic	 cells	 and	 mast	 cells)	 into	 the	 tunica	 intima,	 the	
innermost	layer	of	the	artery	wall	(Davignon	and	Ganz,	2004;	Libby,	2002).	Smooth	muscle	
cells	 (SMCs)	proliferate	 from	the	tunica	media	 into	the	tunica	 intima	and	produce	several	
matrix	 proteins,	 while	 long-term	 accumulation	 of	 these	 materials	 inside	 the	 vessel	 wall	
leads	 to	 intimal	 thickening	 and	 a	 reduction	 in	 blood	 flow	 through	 the	 artery	 due	 to	 the	
reduced	size	of	the	lumen.		
 Cardiovascular	Disease	
Cardiovascular	 disease	 (CVD)	 is	 responsible	 for	 more	 deaths	 worldwide	 than	 any	 other	
disorder	(World	Health	Organisation,	2011),	and	has	contributed	to	morbidity	and	mortality	
more	 than	 any	 other	 condition	 in	 the	western	world	 (Singh	 et	 al.,	 2002).	 CVD	 is	 an	 age-
related	collection	of	diseases	of	 the	circulatory	system	and	heart	 that	can	 lead	 to	angina,	
stroke	and	heart	failure	(World	Health	Organisation,	2015).	Types	of	CVD	include	coronary	
artery	disease	(CAD)	(Hansson,	2005),	rheumatic	heart	disease	(RHD)	(Sliwa	and	Zilla,	2012)	
and	 cerebrovascular	 diseases	 (Postiglione	 and	 Napoli,	 1995).	 Atherosclerosis	 can	 lead	 to	
different	 types	 of	 CVD	depending	 on	 the	 location	 and	 the	 stability	 of	 the	 atheroma.	 It	 is	

















an	 artery	 wall.	 The	 intima	 contains	 the	 endothelium,	 the	 layer	 of	 cells	 within	 an	 artery,	
which	are	constantly	 in	contact	with	blood	flowing	through	the	vessel.	The	subendothelial	
section	of	the	tunica	intima	contains	permeable	connective	tissue	to	provide	strength	and	







vasoconstriction	and	vasodilation.	 In	 atherosclerotic	 vessels,	 SMCs	 from	 the	 tunica	media	
can	 proliferate	 into	 the	 tunica	 intima	 to	 help	 form	 a	 fibrous	 cap	 around	 the	 lipid	 core	
(Wagenseil	and	Mecham,	2009).	
The	outermost	 layer,	the	tunica	adventitia,	 is	mainly	composed	of	collagen	and,	similar	to	
the	 tunica	 intima,	 is	 supported	 by	 an	 external	 elastic	 lamina.	 Fibroblasts	 are	 the	 most	
common	cell	 type	found	within	the	adventitia	 (Stenmark	et	al.,	2013).	The	outer	 layers	of	
the	 adventitia	 merge	 with	 the	 connective	 tissue	 that	 surrounds	 the	 artery,	 holding	 the	
vessel	in	place.	
 Atherosclerosis	Incidence	and	Statistics	













in	 most	 children	 who	 are	 older	 than	 three	 years	 old	 (Joseph	 et	 al.,	 1993).	 In	 addition,	
atherosclerotic	 lesions	 have	 been	 found	 in	 foetal	 arteries	 in	 cases	 of	 severe	 maternal	
hypercholesterolemia	(Palinski	and	Napoli,	2002).	
In	addition	 to	 the	human	cost	of	cardiovascular	disease,	 the	economic	costs	of	 treatment	
and	 production	 loss	 are	 significant.	 More	 than	 1.6	 million	 episodes	 of	 CVD	 resulted	 in	
inpatient	episodes	in	NHS	hospitals	in	2014.	Additionally,	twice	as	many	of	these	inpatient	
episodes	were	for	men	than	women.	In	2014,	approximately	369	million	prescriptions	were	
dispensed	 for	CVD	 in	 the	UK,	with	 total	CVD	expenditure	within	 the	NHS	reaching	£4.292	





nursing	 home	 care	 costs	 in	 the	 prediction	 calculation	 gives	 a	 projection	 of	 $918	 billion	







In	 the	21st	 century,	 assessing	 the	 risk	of	 cardiovascular	disease	 in	 individuals	has	become	












Cardiovascular	Munster	 (PROCAM),	 which	 focus	 on	 different	 risk	 factors	 including	 family	
history	 of	 myocardial	 infarction	 and	 triglyceride	 concentrations	 (Assmann	 et	 al.,	 2002).	
Focus	 on	 newly	 discovered	 and	 elucidated	 risk	 factors,	 alongside	 new	 combinations	 of	
previously	known	risk	factors,	could	potentially	allow	for	the	development	of	a	new	method	
for	assessing	cardiovascular	disease	risk.	





Atherosclerosis	 usually	 begins	 in	 childhood,	 and	 can	 remain	 asymptomatic	 for	 decades	
(Hong,	 2010).	 Clinical	 outcomes	 are	 dependent	 on	 the	 location	 and	 the	 stability	 of	 an	
atheroma.	Coronary	artery	disease,	the	most	common	form	of	CVD,	is	caused	by	presence	
of	an	atheroma	within	 the	coronary	arteries,	which	can	 lead	 to	angina,	dizziness,	nausea,	
sweating	and	arrhythmia.	Reduced	blood	flow	in	the	coronary	arteries	can	lead	to	ischemia	
in	 myocardial	 cells,	 leading	 to	 myocardial	 infarction	 (MI,	 or	 heart	 attack).	 Coronary	
thrombosis	can	also	lead	to	MI	(Hansson,	2005).	CAD	is	more	common	in	men	than	women,	
and	symptoms	are	more	likely	to	present	earlier	in	life	in	men	(Townsend	et	al.,	2015b).	
Cerebrovascular	 disease,	 caused	 by	 atherosclerosis	 leading	 to	 reduced	 blood	 flow	 to	 the	
brain,	 can	 cause	 stroke,	 transient	 ischemic	 attack	 (TIA),	 subarachnoid	 haemorrhage	 and	
vascular	 dementia.	 Rupture	 of	 a	 plaque	 within	 the	 cerebral	 arterial	 network	 leads	 to	





Bleeding	 within	 the	 cerebral	 circulation	 can	 also	 cause	 stroke	 (Postiglione	 and	 Napoli,	
1995).		
Peripheral	artery	disease,	induced	when	atherosclerosis	leads	to	reduced	blood	flow	to	the	
arms	 and	 legs,	 can	 lead	 to	 claudication,	 numbness,	 skin	 discolouration	 and	 muscle	
weakness.	 In	 extreme	 cases	 critical	 limb	 ischemia	 can	 lead	 to	 gangrene,	 requiring	
amputation	(Abdulhannan	et	al.,	2012).	
Additionally,	 atherosclerosis	 can	 lead	 to	 fatigue,	 shortness	 of	 breath,	 muscle	 pain,	
confusion,	 vision	 problems,	 erectile	 dysfunction,	 hair	 loss,	 cold	 hands	 and	 feet,	 loss	 of	
kidney	 function	 and	 flash	 pulmonary	 oedema	 (Abdulhannan	 et	 al.,	 2012;	 Chiurlia	 et	 al.,	
2005;	 Chrysochou	and	Kalra,	 2010;	Muntner	 et	 al.,	 2005;	 Shahar	 et	 al.,	 2008;	Vinkers	DJ,	
Stek	ML,	van	der	Mast	RC,	de	Craen	AJM,	Le	Cessie	S,	Jolles	J,	Westendorp	RGJ,	2005).	
1.2 Progression	of	Atherosclerosis	
Damage	 to	 the	 endothelium	 triggers	 a	 series	 of	 interconnected	 processes	 leading	 to	
atheroma	 formation,	 including	 cell	 signalling	 (Tall	 and	 Yvan-Charvet,	 2015),	 lipoprotein	
transfer	(Kaazempur-Mofrad	and	Ethier,	2001),	haemodynamics	(Glagov	et	al.,	1988),	 lipid	
oxidation	 (Young	 and	 McEneny,	 2001)	 and	 cell	 migration	 (Kraemer,	 2000).	 Lipoproteins,	
including	 proatherogenic	 low	 density	 lipoproteins	 (LDL),	 enter	 the	 artery	 wall	 at	 sites	 of	
endothelial	damage	(Singh	et	al.,	2002).	Free	oxygen	radicals	embedded	within	the	tunica	
intima	react	with	these	lipoproteins,	creating	an	oxidized	form	(Sato	et	al.,	1990).	Damaged	
endothelial	cells	release	cytokines	which	recruit	 immune	cells	 to	the	site	of	 inflammation.	
Recruited	 monocytes	 enter	 the	 tunica	 intima,	 differentiate	 into	 macrophages	 and	
subsequently	phagocytose	 the	oxidized	 form	of	 low	density	 lipoprotein	 (oxLDL)	 (Zhang	et	
al.,	2013).	These	cholesterol	filled	macrophages,	also	known	as	foam	cells,	will	go	through	
apoptosis,	leading	to	fatty	streak	formation	within	the	arterial	wall	(Stoneman	and	Bennett,	
2004).	 Chemotaxis	 factors	 released	 by	 immune	 cells	 within	 the	 lesion	 lead	 to	 smooth	
muscle	cell	proliferation	from	the	tunica	media	into	the	tunica	intima,	leading	to	formation	
of	a	fibrous	cap	around	the	lesion	in	advanced	atheroma	(Bennett	et	al.,	2016).	Depending	






wall	 into	 the	 blood	 stream,	 potentially	 leading	 to	 thrombosis,	 or	 other	 downstream	
complications	(Green	et	al.,	2002).	
 Lesion	Categorisation	
Structural	 characteristics	 of	 atherosclerotic	 lesions	 allow	 for	 classification	 based	 on	
histology	 and	 morphological	 description.	 Multiple	 categorisations	 of	 lesions	 have	 been	
developed	over	the	years	(Cai	et	al.,	2002;	Stary	et	al.,	1995;	Virmani	et	al.,	2000),	with	the	






Smooth	 muscle	 cells	 can	 accumulate	 naturally	 within	 the	 tunica	 intima	 without	 the	






Intimal	xanthomas,	or	 ‘fatty	streaks,’	 contain	 layers	of	 foam	cells	without	a	necrotic	core.	
The	 majority	 of	 the	 lipid	 content	 within	 the	 lesion	 is	 contained	 within	 foam	 cells	 and	




Extracellular	 pools	 of	 lipid	 form	 beneath	 the	 layers	 of	 macrophages	 and	 foam	 cells	
contained	within	 the	 tunica	 intima,	 disrupting	 the	 smooth	muscle	 cells	within	 the	 tunica	















Intraplaque	 haemorrhage	 can	 occur	 within	 a	 plaque	 when	 angiogenesis	 has	 occurred	 to	






A	 lesion	 with	 a	 fibrous	 cap	 thinner	 than	 65	 μm	 is	 classified	 as	 a	 thin-cap	 fibroatheroma	
(TCFA)	 (Yahagi	 et	 al.,	 2016).	 These	 lesions,	 often	 called	 vulnerable	 plaques,	 have	 a	 high	













Plaque	 erosion	 can	 occur	 during	 pathological	 intimal	 thickening,	 or	 during	 the	
fibroatheroma	 stage	 of	 lesion	 development.	 Endothelial	 cells	 at	 the	 atheroma	 site	 are	
eroded	 and	 an	 abrasion	 is	 formed.	 Eroded	 plaques	 are	 more	 common	 in	 the	 young,	
smokers,	and	female	patients	(Lafont,	2003).	
1.2.4.3 Calcified	Nodule	
A	 fibrocalcific	 plaque	 can	 lead	 to	 the	 jettison	 of	 a	 calcified	 nodule	 through	 unknown	








The	 early	 stages	 of	 atherosclerosis	 are	 usually	 asymptomatic.	 Lesions	 can	 form	 over	
decades	within	an	artery	without	knowledge	and	symptoms	do	not	occur	until	blood	flow	is	
sufficiently	 reduced	 or	 thrombosis	 occurs	 (NHLBI,	 2016).	 While	 knowledge	 of	 how	
atherogenic	lipoproteins	lead	to	plaque	formation	is	significant,	considerably	less	is	known	
about	 the	 mechanisms	 behind	 plaque	 rupture.	 Bentzon	 et	 al.	 have	 written	 an	 excellent	
review	considering	the	reasons	behind	this	(Bentzon	et	al.,	2014).	
Acute	 coronary	 syndromes	 are	 almost	 always	 caused	 by	 the	 presence	 of	 thrombus	 or	
plaque	 haemorrhage	 (Davies,	 2000).	 Plaque	 rupture	 is	 the	 most	 common	 cause	 of	
thrombosis	(Badimon	and	Vilahur,	2014).	Rupture	occurs	on	the	fibrous	cap	at	points	where	
thinning	 has	 occurred,	 potentially	 due	 to	 infiltration	 by	 foam	 cells.	 The	 thinnest	 point	 is	
often	located	in	the	shoulder	region	(Bentzon	et	al.,	2014).		










fibrous	 cap	 is	 often	 a	 sign	 of	 a	 vulnerable	 plaque,	 alongside	 a	 significant	 lipid	 core	 and	




Features	 of	 plaques	 prone	 to	 rupture	 are:	 large	 necrotic	 core,	 thin	 fibrous	 cap,	 high	



























Computational	modelling	 can	 provide	 a	mechanism	and	 a	 framework	 to	 analyse	 pathway	
dynamics	 of	 a	multi-scale	 system	 such	 as	 atherosclerosis.	 An	 approach	 like	 this	 can	 yield	
many	 benefits	 —	 there	 are	 examples	 of	 computational	 and	 mathematical	 modelling	
approaches	 assisting	 in	 the	 development	 of	 therapeutic	 hypotheses,	 and	 identifying	
potential	 drug	 targets	 (Berg,	 2014).	 Development	 of	 a	 mathematical	 model	 of	
atherosclerosis	 would	 allow	 for	 the	 study	 of	 how	 model	 kinetics	 vary	 across	 multiple	
populations	as	part	of	a	stratified	medicine	program.	Computational	biology	methods	have	
been	 successful	within	 stratified	medicine	 contexts	previously	 (Velikova	et	 al.,	 2014).	 This	
topic	will	be	discussed	further	in	Chapters	2	and	3.	
 Predicting	Tertiary	Structure	
Atherosclerosis	 is	 a	 disorder	 heavily	 dependent	 on	 protein-protein	 binding	 interactions.	
Protein	function	is	directly	related	to	protein	structure.	Calculating	the	tertiary	structure	of	
a	 protein	 from	 its	 amino	 acid	 sequence	 is	 a	 problem	 that	 has	 been	 tackled	 by	
bioinformaticians	and	theoretical	chemists	 for	years	 (Dorn	et	al.,	2014).	Vast	quantities	of	
amino	 acid	 sequence	 data	 have	 been	 generated	 by	 sequencing	 groups,	 such	 as	 1000	
Genome	 Project	 (Abecasis	 et	 al.,	 2012)	 and	 UK10K	 (Muddyman	 et	 al.,	 2013),	 and	 while	
significantly	 more	 sequence	 data	 exists	 than	 experimentally	 derived	 structural	 data,	
refinement	 of	 structural	 prediction	 methods	 would	 be	 of	 great	 benefit	 to	 the	 biological	
community.	 Prediction	 of	 tertiary	 and	 quaternary	 structure	 for	 a	 collection	 of	 proteins	








surface	 plasmon	 resonance	 (SPR)	 techniques	 have	 allowed	 for	 the	 calculation	 of	 vast	
quantities	 of	 enzyme	 kinetics	 data,	 the	 ability	 to	 predict	 association	 constants	 through	
bioinformatics	 methods	 has	 been	 a	 challenge	 tackled	 by	 multiple	 groups	 with	 varying	
results	 (Pattnaik,	2005).	Estimation	of	protein-protein	association	rate	constants	has	been	
tackled	using	molecular	dynamics	methods	by	multiple	groups	 (Qin	et	al.,	2011;	Yu	et	al.,	
2015b).	 Association	 constants	 can	 be	 used	 to	 establish	 how	 individual	 mutations	 alter	
model	 dynamics,	 and	 can	 subsequently	 be	 used	 to	 predict	 how	 the	 dynamics	 of	
atherosclerosis	 will	 differ	 between	 population	 subgroups.	 This	 topic	 will	 be	 discussed	
further	in	Chapters	5	and	6.	
 Thesis	Summary	




In	 Chapter	 3,	 the	 	 ordinary	 differential	 equation	 (ODE)	 model	 of	 atherosclerosis	 is	
developed.	The	literature	mining	procedure	undertaken	to	construct	the	model	 is	studied,	
and	 the	 differential	 equations	 used	 in	 model	 formation	 are	 discussed.	 Each	 biochemical	
reaction	 contained	 within	 the	 model	 is	 justified	 within	 the	 literature	 and	 sources	 for	
corresponding	 rate	 parameters	 are	 given.	 Experimental	 validity	 and	 multi-drug	
interventions	are	additionally	examined.	
In	 Chapter	 4,	 protein	 structures	 are	 predicted	 for	 the	 proteins	 involved	 in	 the	model	 of	
atherosclerosis.	This	is	completed	by	utilising	relevant	genomic	data	from	the	1000	Genome	
Project.	The	bioinformatics	tools	used	to	isolate	data,	formulate	predictions,	evaluate	error	






In	 Chapter	 5,	 protein	 structure	 data	 is	 used	 to	 predict	 association	 rates	 for	 the	 protein-
protein	 interactions	 involved	 within	 the	model.	 The	 tools	 used	 to	 isolate	 data,	 generate	
protein	complexes	and	estimate	association	rates	are	examined.	
In	 Chapter	 6,	 calculated	 association	 rates	 are	 used	 to	 reparametrize	 the	 model	 of	
atherosclerosis.	 The	 generation	 of	 a	 series	 of	 models,	 representing	 different	 population	
subgroups,	is	discussed	and	the	implications	of	mutations	on	the	dynamics	of	our	model	are	
evaluated.	A	 series	of	 therapeutic	hypotheses	based	on	our	 in	 silico	 experimental	 system	
are	developed.	
In	Chapter	7,	the	work	undertaken	in	this	thesis	and	PhD	project	as	a	whole	is	summarised	
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Cardiovascular	 disease	 (CVD)	 is	 the	 primary	 cause	 of	 death	 globally	 (World	 Health	
Organisation,	 2011)	 and	 contributes	 to	 morbidity	 and	 mortality	 more	 than	 any	 other	
disorder	in	the	western	world	(Singh	et	al.,	2002).	In	2012,	CVD	was	responsible	for	31%	of	
deaths	 worldwide,	 47%	 of	 all	 deaths	 within	 Europe	 and	 40%	 of	 all	 deaths	 within	 the	
European	Union	(Nichols	M		Luengo-Fernandez	R,	Leal	J,	Gray	A,	Scarborough	P,	Rayner	M,	
2012;	 Organisation,	 2015).	 CVD	 covers	 a	 collection	 of	 disorders	 that	 can	 be	 split	 into	






At	 least	 75%	 of	 all	 CVD-related	 deaths	 occur	 in	 low	 and	middle-income	 countries	 (World	
Health	Organisation,	2015).	In	China,	more	than	4%	of	the	gross	national	income	is	directly	
spent	on	the	treatment	of	CVD	(Federation,	2012)	and	 in	 the	EU,	 it	 is	estimated	that	CVD	
costs	 the	 economy	 approximately	 €196	 billion	 per	 year	 (Nichols	M		 Luengo-Fernandez	 R,	
Leal	 J,	Gray	A,	Scarborough	P,	Rayner	M,	2012).	 Improvements	 in	atherosclerosis	and	CVD	
treatment	therefore	have	the	potential	to	make	a	dramatic	impact,	not	only	on	the	quality	
of	care,	but	also	on	the	economics	of	healthcare.		





















inter-	 and	 intra-cellular	 signalling	 (Boisvert,	 2004).	 These	monocytes	will	migrate	 into	 the	
artery	wall	 (Kraemer,	2000),	alongside	 lipoproteins,	and	phagocytose	oxidised	 low	density	
lipoproteins	(oxLDL)	(Schrijvers	et	al.,	2007;	Yoshida	and	Kisugi,	2010).	The	migration	rate	of	





this	 type	 is	 mathematical	 and	 computational	modelling.	 A	 comprehensive	 programme	 of	
mathematical	modelling	and	simulation	can	provide	many	benefits.	 	Principally,	 it	 yields	a	
framework	for	therapeutic	hypothesis	generation	and	for	in	silico	drug	target	identification	
with	 the	 potential	 to	 streamline	 the	 drug	 development	 pipeline.	 	 This	 framework	 can	 be	
applied	across	populations	or	can	be	tuned	to	describe	individual	patients	or	patient	groups	
as	 part	 of	 a	 programme	 of	 stratified,	 personalised	 and	 precision	 medicine	 (Auffray	 and	
Hood,	2012).		












2009;	 Pedersen	 and	 Plotkin,	 2008).	 	 Statistical	 models	 that	 infer	 pathway	 structure	 have	
been	 used	 to	 generate	 hypotheses	 from	existing	 datasets	 (Grzegorczyk	 et	 al.,	 2008;	 Vert,	
2010).			
Computational	 biology	 approaches	 have	 previously	 been	 applied	 to	 a	 range	 of	 dynamical	
disease	 processes,	 examples	 include	 Alzheimer’s	 disease	 (Lewis	 et	 al.,	 2010),	 diabetes	
(Ajmera	 et	 al.,	 2013)	 and	 breast	 cancer	 (Faratian	 et	 al.,	 2009).	 	 Furthermore,	 these	
computational	 models	 have	 been	 applied	 to	 pathway	 systems	 such	 as	 in	 nuclear	 factor	
kappa	 beta	 (NF-κB)	 signalling	 (Nelson	 et	 al.,	 2004),	 macrophage	 processing	 (Raza	 et	 al.,	
2010),	human	metabolism	(Thiele	et	al.,	2013)	and	iron	metabolism	(Mitchell	and	Mendes,	







Hucka	 et	 al.,	 2003)	 and	 CellML	 (Cuellar	 et	 al.,	 2003)	 file	 formats	 capture	 ODE	 models	
describing	the	kinetics	of	pathway	interactions	and	the	Systems	Biology	Graphical	Notation	
Markup	 Language	 (SBGN-ML)	 (Van	 Iersel	 et	 al.,	 2012;	 Le	 Novere	 et	 al.,	 2009)	 encodes	






modelled	 in	 a	 series	 of	 computational	 studies	 (Bhattacharya	 et	 al.,	 2014;	 Lu	 et	 al.,	 2015;	
Mazein	 et	 al.,	 2013;	Mc	 Auley	 et	 al.,	 2012;	Watterson	 et	 al.,	 2013)	 and	 the	 role	 of	 lipid	
metabolism	and	CVD	in	aging	has	been	reviewed	(Mc	Auley	and	Mooney,	2015).		However,	
no	 review	 has	 yet	 brought	 together	 the	 significant	 volume	 of	 recent	work	 completed	 on	









Low	 density	 lipoproteins	 (LDL)	 will	 transfer	 into	 the	 artery	 wall	 at	 a	 site	 of	 endothelial	
damage.	 The	 role	 of	 arterial	 wall	 shear	 stress	 (WSS)	 and	 its	 relationship	 to	 lipoprotein	
transfer	into	the	artery	wall	has	been	studied	by	Liu	et	al	(Liu	and	Tang,	2010).	Lipoproteins	
pass	 into	 the	 artery	 wall	 at	 a	 rate	 that	 depends	 on	 the	WSS,	 lipoprotein	 diffusivity	 and	
















In	 Figure	 2.1,	 we	 can	 see	 a	 representation	 of	 the	 processes	 that	 lead	 to	 atherosclerosis	
(Douglas		 Channon,	 KM.,	 2014;	 Lusis,	 2000;	 Weber	 and	 Noels,	 2011).	 Damage	 to	 the	
endothelial	layer	of	the	artery	wall	triggers	an	inflammatory	response	in	which	monocytes,	T	
lymphocytes	 and	 other	 immune	 cells	 are	 recruited	 to	 the	 region	 of	 damage.	 	 These	 cells	
penetrate	 the	 endothelial	 layer,	 reaching	 the	 tunica	 intima,	 along	 with	 low	 density	
lipoprotein	(LDL)	and	high-density	lipoprotein	(HDL)	particles.	Stimulated	by	the	presence	of	
interferon	 gamma	 (IFN-γ)	 and	macrophage	 colony	 stimulating	 factor	 (M-CSF),	 monocytes	
differentiate	 into	macrophages	 once	 they	 have	 entered	 the	 artery	wall.	While	 embedded	
within	 the	 tunica	 intima,	 both	 LDL	 and	 HDL	 become	 oxidized	 by	 free	 oxygen	 radicals.	
Macrophages	 will	 phagocytose	 oxidized	 LDL	 (oxLDL),	 but	 not	 oxidized	 HDL.	Macrophages	
heavily	loaded	with	oxLDL	transform	into	foam	cells	that	eventually	undergo	apoptosis.		The	
resulting	mass	 of	 debris	 embedded	 in	 the	 tunica	 intima	 is	 known	 as	 an	 atheroma.	 Foam	
cells,	along	with	endothelial	cells,	secrete	monocyte	chemoattractant	protein-1	(MCP-1)	to	
recruit	 more	 monocytes	 to	 the	 site	 of	 inflammation.	 Naïve	 T	 cells	 contained	 within	 the	
artery	wall	differentiate	 into	 individual	T	cell	types	and	secrete	IFN-γ.	Smooth	muscle	cells	
(SMCs)	 are	 also	 recruited	 into	 the	 tunica	 intima	 where	 they	 undergo	 apoptosis	 and	
contribute	 to	 the	 formation	of	a	 fibrous	cap	 in	 the	artery	wall.	 	This	accumulation	of	cells	
and	 debris	 can	 cause	 a	 swelling	 of	 the	 artery	 wall	 that	 restricts	 blood	 flow,	 leading	 to	
stenosis.	 	When	the	fibrous	cap	ruptures,	the	build-up	in	the	tunica	intima	 is	released	into	
the	blood	stream	increasing	the	risk	of	blockages	downstream.	 	Further	complications	can	




Vascular	 damage	 is	 a	 key	 trigger	 for	 the	 onset	 of	 atherosclerosis	 that	 can	 be	 induced	 by	
factors	such	as	hypertension	(Alexander,	1995),	smoking	(Powell,	1998)	and	oxidative	stress	
(Harrison	et	al.,	2003).		The	elastic	properties	of	arteries	under	hypertensive	pressure	have	
been	 modelled	 previously	 (Goriely	 and	 Vandiver,	 2010).	 Obstructions	 to	 blood	 flow	 are	







A	 number	 of	 computational	 studies	 have	 modelled	 the	 dynamics	 of	 blood	 flow	
(haemodynamics)	 and	 its	 relationship	 to	 vascular	 structure.	 Navier-Stokes	 equations	 are	
typically	used	to	describe	blood	flow	through	arterial	structures	(Ai	and	Vafai,	2006;	Calvez	









Silva	 et	 al.,	 2013;	 Stroud	 et	 al.,	 2002;	 Sun	 et	 al.,	 2006;	 Tomaso	 et	 al.,	 2011;	 Vincent	



















Simpler	 models	 of	 this	 process	 have	 been	 developed	 that	 enable	 atherosclerosis	 to	 be	
considered	as	 a	bistable	 system	 (Bulelzai	 and	Dubbeldam,	2012).	 	Haemodynamic	models	
have	 also	 been	 developed	 to	 explore	 the	 turbulence	 downstream	 of	 an	 atherosclerotic	





been	 modelled	 as	 constant	 (Ai	 and	 Vafai,	 2006;	 Calvez	 and	 Ebde,	 2010;	 Filipovic	 et	 al.,	
2011a;	Gessaghi	et	al.,	 2011),	or	as	a	 variable	 (Cilla	et	al.,	 2014;	 Filipovic	and	Kojic,	 2004;	
Filipovic	et	al.,	2011a;	Gabriel	et	al.,	2014;	Girke	et	al.,	2014;	McKay	et	al.,	2005;	Olgac	et	al.,	
2008;	Vincent	Calvez		Nicolas	Meunier,	Annie	Raoult	and	Gabriela	Rusnakova,	2010;	Wada	
















have	 modelled	 the	 artery	 wall	 as	 a	 semi-permeable	 membrane	 by	 utilising	 Kedem-
Katchalsky	 equations	 (Filipovic	 et	 al.,	 2011a,	 2011b,	 2013;	 Tomaso	 et	 al.,	 2011;	 Vincent	





and	 they	 are	 coupled	 to	 LDL	penetration	 to	differing	 extents.	 	Many	 studies	 consider	 the	
synthesis	and	turnover	of	oxLDL	directly	 (Bulelzai	and	Dubbeldam,	2012;	Calvez	and	Ebde,	
2010;	 Cilla	 et	 al.,	 2014;	 Cobbold	 et	 al.,	 2002b;	 Cohen	 et	 al.,	 2014;	 Filipovic	 et	 al.,	 2011a,	
2013;	Friedman	and	Hao,	2014;	Gessaghi	et	al.,	2011;	Girke	et	al.,	2014;	Hao	and	Friedman,	
2014;	 Ibragimov	 et	 al.,	 2005;	McKay	 et	 al.,	 2005;	 Ougrinovskaia	 et	 al.,	 2010;	 Silva	 et	 al.,	
2013;	 Vincent	 Calvez		 Nicolas	 Meunier,	 Annie	 Raoult	 and	 Gabriela	 Rusnakova,	 2010).	 In	





recruitment	 (Bulelzai	 and	 Dubbeldam,	 2012)	 or	 a	 constant	 (Cohen	 et	 al.,	 2014;	










having	 an	 atheroprotective	 effect	 on	 foam	 cells	 (Cohen	 et	 al.,	 2014;	 Friedman	 and	 Hao,	
2014).	
Elsewhere,	the	interplay	between	LDL,	HDL,	oxidising	free	radicals	and	antioxidant	vitamins	
C	 and	 E	 have	 been	 studied	 (Cobbold	 et	 al.,	 2002b)	 with	 predictions	 of	 comparable	
atheroprotective	power	between	HDL	and	vitamin	C.	
 Monocyte	recruitment	and	chemoattractants	




2009;	 McKay	 et	 al.,	 2005;	 Zohdi	 et	 al.,	 2004).	 	 Elsewhere,	 the	 process	 of	 monocyte	
recruitment	 and	 differentiation	 has	 also	 been	 simplified	 and	 incorporated	 into	 one	 step	
governing	macrophage	turnover,	where	this	is	linked	to	driving	factors	such	as	shear	stress,	
diffusion	 and	 LDL	penetration	 (Calvez	 and	Ebde,	 2010;	 Cohen	et	 al.,	 2014;	 Filipovic	 et	 al.,	
2011b,	 2013;	 Friedman	 and	 Hao,	 2014;	 Girke	 et	 al.,	 2014;	 Hao	 and	 Friedman,	 2014;	
Ibragimov	 et	 al.,	 2005;	Ougrinovskaia	 et	 al.,	 2010;	 Silva	 et	 al.,	 2013;	 Tomaso	 et	 al.,	 2011;	
Vincent	Calvez		Nicolas	Meunier,	Annie	Raoult	and	Gabriela	Rusnakova,	2010).			
Similarly,	the	turnover	of	MCP-1	as	a	chemoattractant	has	been	described	explicitly	in	some	


















The	 transformation	 of	 macrophages	 to	 foam	 cells	 due	 to	 the	 phagocytosis	 of	 oxLDL	 is	 a	
critical	 stage	 in	 the	 formation	of	atheroma	that	has	been	 included	 in	many	studies.	These	
are	 typically	 modelled	 as	 a	 combination	 of	 mass	 action	 and	 Michaelis-Menten	 terms	
(Bulelzai	and	Dubbeldam,	2012;	Calvez	and	Ebde,	2010;	Cilla	et	al.,	2014;	Cohen	et	al.,	2014;	
Friedman	and	Hao,	2014;	Hao	and	Friedman,	2014;	Ougrinovskaia	et	al.,	2010;	Silva	et	al.,	
2013;	 Tomaso	 et	 al.,	 2011;	 Vincent	 Calvez		 Nicolas	 Meunier,	 Annie	 Raoult	 and	 Gabriela	
Rusnakova,	 2010),	 and	 in	 some	 cases	 reverse	 cholesterol	 efflux	 is	 included	 in	 the	model	
(Cohen	et	al.,	2014;	Friedman	and	Hao,	2014;	Zhang	et	al.,	2013).	Many	studies,	however,	
omit	foam	cell	formation	as	a	step,	instead	taking	the	volume	of	macrophages	recruited	to	
be	 representative	 of	 atheroma	 formation	 (Filipovic	 et	 al.,	 2013;	 Ibragimov	 et	 al.,	 2005;	 El	
Khatib	et	al.,	2007;	McKay	et	al.,	2005;	Zohdi	et	al.,	2004).		
 T	cell	recruitment	and	the	role	of	interferon-gamma	(IFN-γ)	
The	 role	of	 T	 cells	 in	 coordinating	 the	 inflammatory	 response	has	 rarely	been	 included	 in	
computational	studies.	Where	they	have	been	 included	as	a	 factor,	T	cells	yield	 IFN-γ	that	
modulates	macrophage	differentiation	(Friedman	and	Hao,	2014;	Hao	and	Friedman,	2014;	
Little	et	al.,	2009;	McKay	et	al.,	2005)	and	are	 themselves	modelled	as	being	activated	by	










has	 been	 incorporated,	 SMC	 recruitment	 occurs	 in	 response	 to	 MCP-1,	 platelet	 derived	
growth	 factor	 (PDGF)	 and	 extracellular	matrix	 (ECM)	 either	modelled	 explicitly	 as	 factors	
(Friedman	 and	 Hao,	 2014;	 Hao	 and	 Friedman,	 2014)	 or	 as	 a	 generic	 recruitment	 process	
(Cilla	et	al.,	2014;	Girke	et	al.,	2014;	Ibragimov	et	al.,	2005;	McKay	et	al.,	2005).	One	study	in	




that	 takes	 the	 form	 of	 a	 solution	 to	 a	 third	 order	 non-linear	 ODE	 (Green	 et	 al.,	 2002).	
Separate	 studies	 have	 established	 stability	 by	 evaluating	 the	 eigenvalues	 of	 a	 perturbed	




formation	 in	 the	absence	 (Xue	et	al.,	 2009)	and	presence	of	 shear	blood	 flow	 (Guy	et	al.,	
2007;	Li	et	al.,	2006).		
2.4 Discussion	
The	 majority	 of	 the	 work	 presented	 here	 has	 been	 published	 in	 the	 last	 10	 years,	
demonstrating	 that	 computational	modelling	 of	 atherosclerosis	 is	 a	 developing	 field	with	
growing	 support.	 	 These	 studies	 operate	 at	 a	 range	 of	 levels	 of	 abstraction	 and	 have	
variable	scope.		However,	they	have	all	been	produced	as	separate	bespoke	computational	
models	with	little	capacity	for	reuse	by	the	wider	modelling	community.	 	The	introduction	
of	 community	modelling	 standards	 such	as	SBML	 (Frank	T.	Bergmann,	2015;	Hucka	et	al.,	
2003)	 and	 SBGN-ML	 (Van	 Iersel	 et	 al.,	 2012;	 Le	 Novere	 et	 al.,	 2009)	 would	 enable	 the	
community	 to	 progress	 together	 on	 the	 development	 of	 atherosclerosis	modelling	 and	 it	
would	 be	 valuable	 to	 translate	 the	 most	 biologically	 detailed	 models	 (Cilla	 et	 al.,	 2014;	
















understanding	 of	 atherosclerosis	 as	 a	 dynamical	 process.	 Triglyceride	 rich	 lipoproteins	
contribute	 to	 plaque	 build-up	 with	 some	 studies	 showing	 that	 they	 trigger	 foam	 cell	
formation	 through	 mechanisms	 that	 bypass	 LDL	 oxidation	 (Gotto,	 1998;	 Le	 and	 Walter,	
2007;	 Talayero	 and	 Sacks,	 2011).	 Elsewhere,	 it	 has	been	proposed	 that	 categories	of	HDL	
and	their	relative	proportions	may	be	more	important	than	the	absolute	abundance	of	HDL	
(Douglas		 Channon,	 KM.,	 2014;	 Umaerus	 et	 al.,	 2012),	 suggesting	 that	 models	 could	 be	
adapted	 to	 incorporate	 a	 HDL	 profile	 that	 influences	 oxidation	 and	 reverse	 cholesterol	
efflux.	 	 It	 has	 also	 been	 shown	 that	 HDL	 can	 inhibit	 the	 recruitment	 of	 monocytes	 and	
subsequently	reduce	atherogenesis	(Umemoto	et	al.,	2013)	suggesting	further	 interactions	
to	model.		Clinically,	it	has	been	suggested	that	LDL	particle	number	is	a	stronger	risk	factor	
for	 atherosclerosis	 than	 the	 abundance	 of	 LDL-bound	 cholesterol,	 implying	 that	 future	
models	should	 include	a	description	of	the	cholesterol	 load	of	 lipoproteins	as	well	as	their	




al.,	 2013),	 	 and	 miRNAs	 (Nazari-Jahantigh	 et	 al.,	 2014)	 have	 not	 been	 modelled	 in	 this	
context.			
By	 far	 the	majority	of	work	 to	date	has	been	on	 the	buildup	of	 atheroma.	 	 Some	 studies	



















to	 model	 the	 interaction	 between	 a	 stent	 and	 artery	 wall	 when	 widening	 constricted	
arteries	during	angioplasty	(Eftaxiopoulos	and	Atkinson,	2005;	Holzapfel	et	al.,	2000).	
Creating	more	 comprehensive	models	of	 atherosclerosis	has	 the	potential	 to	 improve	 the	
efficiency	of	 therapy	development	with	benefits	 for	both	 the	patient	 and	 the	 commercial	
vendor.	 	 However,	 obtaining	 accurate	 parameterisations	 for	 the	models	 is	 a	 fundamental	
challenge.	 	 The	 lack	 of	 appropriate	 published	 experimental	 data	 is	 a	 critical	 obstacle	 to	
generating	high	confidence	predictive	models.			
 Difficulties	in	model	generation	
Developing	 a	 comprehensive	 predictive	 model	 of	 atherogenesis	 comes	 with	 many	
challenges.	Our	 knowledge	 of	 the	 processes	 involved	 has	 increased	 significantly	 in	 recent	
years	 with	 the	 development	 of	 genomic	 technologies	 such	 as	 genome	 wide	 association	
studies	(GWAS)	(Schunkert	et	al.,	2011).	As	atherosclerosis	is	a	cardiovascular	condition	that	
affects	 critical	 circulatory	 systems,	 studying	 human	 atheroma	 poses	 logistical	 and	 ethical	
problems	as	access	 to	 live	atherosclerotic	 tissue	 is	 limited	and	disturbances	 risk	 triggering	
plaque	rupture.	Consequently,	data	is	limited.	Animal	studies	of	atherosclerosis	do	exist	for	







the	 molecular	 biology	 involved.	 As	 a	 result,	 establishing	 biologically	 relevant	 kinetic	
parameters	 that	 can	 be	 used	 to	 simulate	 pathway	 dynamics	 will	 be	 challenging	 and	
comprehensive	 data	 for	 the	 pathogenesis	 of	 atherosclerosis	 is	 not	 available	 in	 the	 public	








Computational	modelling	 of	 atherosclerosis	 presents	 an	 opportunity	 to	 contribute	 to	 the	
reduction	of	the	global	burden	of	CVD.			By	introducing	accurate	and	quantitative	models	of	
atherosclerosis,	we	can	create	an	 in	silico	experimental	system	with	the	potential	not	only	
to	 displace	 in	 vivo	 experimentation	 but	 also	 to	 enable	 us	 to	 study	 details	 that	 cannot	 be	
measured	in	vivo.	However	this	necessitates	a	physiologically	accurate	parameterisation	and	
such	data	is	not	currently	available	in	a	comprehensive	form.		
Historically,	 little	 work	 has	 been	 completed	 developing	 computational	 modelling	 of	
atherosclerosis,	 although	 recent	 years	 have	 seen	 a	 clear	 growth	 of	 interest	 and	 the	
formation	 of	 a	 nascent	 field.	 	 Here	 we	 have	 gathered	 together	 and	 reviewed	 the	 recent	
results	 with	 a	 view	 to	 identifying	 where	 the	 gaps	 in	 our	 understanding	 lie	 and	 where	
progress	can	be	made.			
Most	of	the	work	completed	in	this	area	to	date	has	focussed	on	the	inflammatory	response	
and	 shear	 stress	 of	 the	 artery	 wall	 and	 has	 involved	 modelling	 at	 a	 range	 of	 levels	 of	
abstraction.			
The	majority	of	work	has	focused	on	describing	atheroma	formation	and	few	studies	have	
addressed	 the	mechanics	 of	 plaque	 rupture	 and	 its	 subsequent	 consequences.	 	 	 In	most	





oxidation,	 monocyte	 recruitment	 and	 differentiation	 and	 foam	 cell	 formation.	 	 However,	
many	additional	factors	remain	outside	this	canonical	picture	that	are	known	to	contribute	































































































































































































































































































































































































































































































































































































































































































































































































































































































































Since	 August	 2015,	 the	 date	 of	 submission	 of	 the	 literature	 review	 ‘Computational	
Modelling	 in	 Atherosclerosis’,	modelling	within	 atherosclerosis	 has	 continued	 to	 improve.	
Multiple	 models	 detailing	 the	 effect	 of	 blood	 flow	 dynamics	 on	 atherosclerosis	
development,	arterial	 remodelling,	 lesion	size	and	thrombus	growth	have	been	developed	
(Cuomo	 et	 al.,	 2017;	 Filipovic	 et	 al.,	 2017;	 Mehrabadi	 et	 al.,	 2016).	 Models	 designed	 to	
predict	 lesion	 location	 and	 rate	 of	 thrombus	 growth	 from	 initial	 arterial	 geometry	 and	
arterial	wall	 shear	 stress,	validated	using	 in	vitro	experiments	across	a	variety	of	different	
blood	vessels,	providing	 insight	 into	 the	consequences	of	arterial	occlusion	 (Mehrabadi	et	
al.,	2016).	Filipovic	et	al	have	provided	updates	to	their	earlier	work	utilising	Navier-Stokes	
equations	 and	 Kadem-Katchalsky	 equations	 to	 represent	 fluid	 dynamics	 and	 the	
environmental	changes	between	the	artery	wall	and	lumen,	demonstrating	methods	which	
predict	 atheroma	 location	and	 size	 from	 initial	 arterial	 geometry	 (Filipovic	et	 al.,	 2017).	A	
study	 into	non-Newtonian	oscillating	 flow	 in	biomechanical	analysis	within	a	human	aorta	
has	been	undertaken,	concluding	that	non-Newtonian	methods	of	modelling	blood	flow	can	
be	more	accurate	in	capturing	molecular	viscosity	(Soulis	et	al.,	2016).		
Age-related	 effects	 of	 cardiovascular	 disease	 on	 arterial	 stiffness	 have	 been	 modelled	
through	 a	 collection	 of	 blood-flow	 models	 on	 arterial	 segments	 considered	 as	 an	
incompressible	 elastic	membrane	where	 external	 tissue	 stability	 support	 is	modelled	 as	 a	
boundary	condition,	 limiting	oscillations	within	the	blood	vessel	wall	 (Cuomo	et	al.,	2017).	
The	 influence	of	aging	on	cholesterol	metabolism,	 including	 reverse	cholesterol	 transport,	
has	 been	 modelled	 using	 SBGN-ML	 open	 standards,	 encouraging	 model	 adaptation	 and	
revision	as	knowledge	into	these	processes	improves	(Morgan	et	al.,	2016).	LDL	composition	
and	 lipoprotein	 metabolism	 has	 been	 modelled	 (including	 different	 lipoprotein	 forms,	
apolipoprotein	 concentrations	 and	 cholesteryl	 ester	 transfer	 protein	 (CETP)	mechanisms),	
leading	to	the	prediction	of	lipoprotein	metabolism	rate	constants	(Jansen	et	al.,	2016).		
Lipoprotein	transfer	into	the	tunica	intima	has	been	considered	by	multiple	groups	(Filipovic	
et	 al.,	 2017;	 Iasiello	 et	 al.,	 2016;	 Mel’nyk,	 2017;	 Mpairaktaris	 et	 al.,	 2017).	 The	 role	 of	







and	 Friedman,	 2014).	 Lipoprotein	 transfer	 under	 hyperthermia	 conditions	 has	 been	
considered	(Iasiello	et	al.,	2016).		
Different	 subtypes	of	macrophages,	M1	 and	M2	 (or	 classically	 and	alternatively	 activated),	
have	 been	 considered	within	models	 which	 consider	 LDL	 transfer,	monocyte	 recruitment	
and	 inflammatory	mechanisms	(Mel’nyk,	2017).	Foam	cell	 formation	through	phagocytosis	
has	 been	 considered	 in	 the	 context	 of	 oxLDL	 consumption	 by	 pro-inflammatory	
macrophages	 (Mel’nyk,	2017)	and	a	 function	of	 shear	 forces	within	 the	blood	 (Filipovic	et	
al.,	2017).		
T-Cell	recruitment	and	their	subsequent	secretion	of	cytokines	have	been	considered	in	an	
ODE	 model	 of	 abdominal	 aortic	 aneurysm	 (Hao	 et	 al.,	 2017),	 however	 all	 T-Cells	 are	
assumed	 to	be	Th1	cells	 -	 individual	T-Cell	 subtypes	have	not	been	considered	within	 this	
model.	SMC	density	within	the	tunica	media	 is	also	considered	as	part	of	 this	ODE	model,	
however	 proliferation	 into	 the	 intima	 and	 fibrous	 cap	 formation	 are	 not	 considered	 here	
(Hao	et	al.,	2017).		
 The	future	of	atherosclerosis	modelling	
The	 complexity	 of	 atheroma	 formation	 and	 the	 sheer	 quantity	 of	 proteins,	 cell	 types,	
environments	 and	biological	 processes	 involved	 in	 atherogenesis	 is	 a	 distinct	 challenge	 in	
computational	 modelling.	 As	 such,	 many	 aspects	 of	 atherosclerosis	 have	 not	 yet	 been	
modelled	to	a	sufficient	quality	to	allow	for	a	clear	and	complete	picture	of	atherosclerosis-
related	 cardiovascular	 disease.	 Models	 exist	 to	 represent	 cholesterol	 metabolism,	
lipoprotein	metabolism,	diet,	haemodynamics	and	plaque	formation,	and	a	combination	of	
each	of	these	processes	is	required	to	provide	a	complete	representation	of	the	underlying	
biology.	 HDL	 mechanisms	 are	 enigmatic	 and	 unclear,	 and	 computational	 modelling	 of	
known	processes	involving	HDL	could	lead	to	clarification.	Plaque	calcification	and	its	effects	



























































































































































































































































A Computational Model of 
Atherosclerosis: 


































Cardiovascular	disease	(CVD)	 is	 the	primary	cause	of	global	mortality.	CVD	 is	estimated	to	
account	 for	 17m	 deaths	 worldwide	 each	 year	 (Go	 et	 al.,	 2014),	 representing	 31%	 of	 all-
cause	 mortality	 worldwide	 and	 47%	 of	 all-cause	 mortality	 within	 Europe	 (Nichols	
M		Luengo-Fernandez	R,	Leal	J,	Gray	A,	Scarborough	P,	Rayner	M,	2012).	Such	a	prevalent	
condition	 incurs	 a	 significant	 financial	 burden,	 accounting	 for	 17%	 of	 all	 healthcare	
expenditure	 in	 the	 USA	 (Heidenreich	 et	 al.,	 2011).	 Age	 is	 a	 significant	 risk	 factor	 for	
cardiovascular	disease	and	with	an	aging	population,	 the	 cost	of	CVD	 related	 therapies	 is	
predicted	 to	 almost	 triple	 in	 the	 USA	 from	 $273	 billion	 in	 2010	 to	 $818	 billion	 by	 2030	
(Heidenreich	et	al.,	2011).		
	
Atherosclerosis	 is	 estimated	 to	 account	 for	 71%	 of	 CVD	 diagnoses	 (Nichols	 M		 Luengo-
Fernandez	 R,	 Leal	 J,	 Gray	 A,	 Scarborough	 P,	 Rayner	M,	 2012).	 	 It	 is	 characterised	 by	 the	
hardening	of	an	artery	wall,	and	 the	 formation	of	a	 fibrous-fatty	 lesion	within	 the	 intimal	
layer.		As	the	disorder	progresses,	thick	extracellular	cores	of	lipids	occur	within	the	artery	
wall,	occluding	 the	artery	and	subsequently	 reducing	blood	 flow.	 	Thrombosis	can	 further	
occlude	 the	 artery	 either	 as	 a	 result	 of	 plaque	 rupture	 or	 turbulent	 blood	 flow	 induced	
around	the	site	of	the	atheroma.		
	
Atherosclerosis	 is	understood	to	be	a	chronic	 inflammatory	condition	 facilitated	by	a	high	
blood	 lipid	 profile	 that	 involves	 arterial	 damage,	 low-density	 lipoprotein	 (LDL)	 and	 high-
density	 lipoproteins	 (HDL)	 penetration	 and	 oxidation,	 monocyte	 and	 T-cell	 recruitment,	
monocyte	differentiation	and	foam	cell	creation,	smooth	muscle	cell	 (SMC)	migration	and	
fibrous	 cap	 formation	 and	 plaque	 rupture.	 	 Despite	 our	 increasing	 knowledge	 of	 the	
mechanisms	 driving	 this	 disorder,	 the	 pathogenesis	 of	 atherosclerosis	 is	 still	 not	 fully	
understood.	 	 In	 part,	 this	 is	 due	 to	 the	 significant	 challenge	 inherent	 in	 studying	 live,	
dynamic	 plaques.	 	 Accessing	 plaques	 in	 vivo	 is	 logistically	 difficult,	 necessitating	
catheterization,	and	ethically	challenging	as	it	can	increase	the	risk	of	plaque	rupture.		As	a	
result,	 alternative	 approaches	 to	 studying	 atherosclerosis	 dynamics	 are	 needed.		










In	 previous	modelling	 studies	 the	majority	 of	 work	 has	 focused	 on	 plaque	 initiation	 and	
haemodynamics	(Parton	et	al.,	2015),	where	Navier-Stokes	dynamics	have	described	blood	
flow	and	wall	shear	stress	has	been	calculated	as	an	pro-atherogenic	output	(Tomaso	et	al.,	
2011),	 although	 plaque	 rupture	 and	 thrombosis	 have	 not	 gone	 unaddressed	 (Guy	 et	 al.,	
2007).	 We	 are	 interested	 in	 the	 molecular	 and	 cellular	 biology	 that	 mediate	 plaque	
formation	 and	 can	 furnish	 targets	 for	 therapeutic	 interventions.	 	 However,	 in	 previous	
studies	these	details	have	been	routinely	omitted	or	simplified	for	reasons	of	mathematical	
expediency	 (Bulelzai	 and	 Dubbeldam,	 2012;	 Friedman	 and	 Hao,	 2014).	 Furthermore,	 the	
resulting	 models	 have	 not	 been	 made	 publicly	 available.	 	 Reusing	 this	 work	 would	
necessitate	reconstruction	of	the	models	in	their	entirety,	a	complex,	time	consuming	and	
error-prone	 task.	 	 At	 the	 present	 time,	 the	 European	 Bioinformatics	 Institute	 (EBI)	
BioModels	 database	 (Novère,	 2006),	 a	 publically	 available	 repository	 for	 mathematical	
models	of	biological	processes,	contains	only	one	model	pertaining	to	atheroma	formation,	
focussing	on	lipoprotein	action	and	B-cell	signaling	with	 little	detail	on	the	mechanisms	of	
plaque	 formation	 (Gomez-Cabrero	 et	 al.,	 2011).	 KEGG	 (Kanehisa	 et	 al.,	 2017),	 Reactome	
(Fabregat	 et	 al.,	 2016),	 SMPDB	 (Frolkis	 et	 al.,	 2009),	Wikipathways	 (Kutmon	 et	 al.,	 2016)	
contain	no	molecular	biology	maps	of	atherosclerosis.		
	
Here	 we	 develop	 the	 first	 detailed,	 predictive	 dynamical	 computational	 model	 of	
atherogenesis	using	Systems	Biology	standards.	The	model	is	described	as	a	map	using	the	
Systems	Biology	Graphical	Notation	(SBGN)	(Le	Novere	et	al.,	2009)	and	is	made	available	to	
the	 research	 community	 for	 reuse	 and	 refinement	 using	 the	 Systems	 Biology	 Graphical	
Notation	Markup	Language	(SBGN-ML)	(Van	Iersel	et	al.,	2012).	This	map	is	accompanied	by	
a	mathematical	model	describing	the	dynamics	of	the	interactions	in	the	map	as	a	system	of	










combined	 statin-PCSK9	 inhibitor	 treatment	 (SJ	 et	 al.,	 2016)	 or	 Cyclodextrin	 treatment	
(Zimmer	et	 al.,	 2016)	may	 yield	 a	modest	plaque	 reduction.	New	drug	 combinations	 that	
yield	a	substantial	reduction	in	plaque	size	could	have	a	dramatic	impact	on	CVD	morbidity	





A	 list	 of	 the	 cell	 types	 involved	 in	 atherosclerosis	 was	 compiled	 from	 descriptions	 of	
atherosclerosis	in	the	existing	literature	(see	Appendix	3).	Each	article	was	also	searched	for	
references	 to	 proteins	 and	 small	 molecules	 with	 each	 entity	 found	 considered	 for	 the	
model.		A	protein	or	small	molecule	was	incorporated	into	the	model	if	its	biological	source,	
presence	 within	 a	 relevant	 compartment	 and	 its	 influence	 on	 atherogenesis	 (however	
minor)	were	all	 described.	 The	model	was	assembled	with	CellDesigner	 (Funahashi	 et	 al.,	
2008)	 using	 the	 SBGN	 schema	 and	 with	 mass	 action	 and	 Michaelis-Menten	 equations	
primarily	used	to	describe	the	dynamics.		The	resulting	model	was	exported	to	SBGN-ML	file	
format	 to	 disseminate	 the	 visual	 map	 and	 to	 SBML	 file	 format	 to	 disseminate	 the	
mathematical	model	describing	the	dynamics.		
	
PubMed	 and	 Google	 Scholar	 searches	 were	 undertaken	 to	 find	 studies	 describing	
representative	 concentrations	 of	 the	 cells,	 proteins	 and	 small	 molecules.	 	 The	 BRENDA	
enzyme	database	was	searched	for	relevant	known	rate	parameters	(Placzek	et	al.,	2017).		
Values	 for	 unknown	 parameters	 were	 calculated	 by	 constraining	 the	 model	 to	 show	
dynamics	 in	 agreement	with	 published	 CVD	 studies.	 	 	We	 considered	 dynamics	 for	 three	









representative	 time	 scale	 of	 80	 years.	 High	 risk,	 medium-risk	 and	 low-risk	 lipid	 profiles	
comprised	LDL	concentrations	of	190	mg/dlc,	110	mg/dlc	and	50mg/dl	(O'Keefe	et	al.,	2004),	



















V)	Blood	 serum	concentrations	of	MCP1/CCL2	were	estimated	 from	myocardial	 infarction	
and	ischemic	stroke	patients,	ranging	from	100	pg/ml	to	775	pg/ml	(Arakelyan	et	al.,	2005).	
VI)	 Blood	 serum	 concentrations	 of	 CXCL9	 were	 estimated	 from	 patients	 assessed	 for	
coronary	artery	calcium	deposits,	ranging	from	17.4	pg/ml	to	271.2	pg/ml	(Yu	et	al.,	2015a).		
VII)	 Blood	 serum	 concentrations	 of	 CXCL10	 were	 estimated	 from	 patients	 assessed	 for	
coronary	artery	disease,	ranging	from	127.6	pg/ml	to	956.5	pg/ml	(Tavakolian	Ferdousie	et	
al.,	2017).	









IX)	 Blood	 serum	 concentrations	 of	 triglycerides	 were	 estimated	 from	 control	 and	
hyperlipidemic	patients,	corresponding	to	58	mg/dl	and	1005	mg/dl,	respectively	(Sakai	et	
al.,	2003).	
X)	 Blood	 serum	 concentrations	 of	 chylomicrons	 were	 estimated	 from	 control	 and	
hyperlipidemic	patients,	corresponding	to	1.4	μg/ml	and	52.6	μg/ml,	respectively	(Sakai	et	
al.,	2003).	































XXIV)	 Plaque	 concentrations	 of	 TGFβ	 were	 estimated	 from	 control	 and	 coronary	 artery	
disease	patients,	ranging	from	0.33	mg/g	to	0.76	mg/g	of	protein	(Herder	et	al.,	2012).	
XXV)	 Plaque	 density	 ratios	 of	 chymase	 to	 tryptase	 were	 recorded	 to	 be	 107.8:135.1	 in	
plaques	(Ramalho	et	al.,	2013).	
XXVI)	 Plaque	 concentrations	 of	 elastin	 were	 estimated	 from	 acute	 coronary	 syndrome	
patients,	giving	1.58	mg/g	wet	weight	of	plaque	(Gonçalves	et	al.,	2003).	
XXVII)	 Plaque	 concentrations	 of	 collagen	 were	 estimated	 from	 acute	 coronary	 syndrome	
patients,	giving	6.26	mg/g	wet	weight	of	plaque	(Gonçalves	et	al.,	2003).	
















In	 order	 to	 demonstrate	 the	 utility	 of	 the	 resulting	 model,	 we	 undertook	 to	 identify	 an	
optimal	 multi-drug	 intervention	 hypothesis	 that	 would	 reprogram	 the	 dynamics	 of	 the	
model	 leading	 to	 regression	 of	 advanced	 plaques.	 	 It	 has	 been	 demonstrated	 that	multi-
drug	 approaches	 have	 the	 potential	 to	 exploit	 compound	 effects	 to	 yield	 effective	














We	 used	 the	 MATLAB	 software	 system	 (https://www.mathworks.com)	 and	 a	 genetic	
algorithm	 with	 a	 population	 size	 of	 10000	 for	 70	 generations	 to	 identify	 the	 optimal	
combination	 of	 drugs	 that	would	 drive	 atherosclerosis	 regression.	 	 The	 genetic	 algorithm	
started	from	one	instance	of	a	set	of	drug	concentrations	and	from	this	generated	a	further	
19999	 instances	of	 sets	of	drug	concentrations	 from	the	 first	by	adding	Gaussian	noise	 to	
the	 concentration	 of	 each	 drug	 (with	 standard	 deviation	 1).	 These	 20000	 instances	
comprised	the	first	generation	of	candidate	interventions.		All	instances	were	evaluated	for	
their	 efficacy	 at	 plaque	 reduction	 and	 10000	 new	 instances	 were	 created	 as	 a	 second	
generation	 of	 candidate	 interventions	 from	 the	 two	most	 effective	 instances	 of	 the	 first	
generation	 with	 the	 addition	 of	 Gaussian	 noise.	 	 The	 10000	 new	 instances	 were	 then	
themselves	 evaluated	with	 the	 two	most	 effective	 instances	 to	 generate	 a	 further	 10000	
new	instances,	the	third	generation.		This	process	was	iterated	until	we	arrived	at	instances	
from	which	no	improvement	in	efficacy	could	be	found,	at	which	point	we	interpreted	the	
best	 performing	 instance	 as	 optimal.	 	 In	 order	 to	 evaluate	 the	 efficacy	 of	 a	 particular	
instance,	we	 constructed	 a	 scoring	 function	 that	 allowed	 the	model	 to	 develop	 using	 the	





and	T-cells	 that	would	occur	at	eighty	years	 in	the	absence	of	any	drugs.	T	 is	 the	collegen	
concentration	observed	 and	Tmax	 is	 the	 collagen	 concentration	 that	would	occur	 at	 eighty	
years	in	the	absence	of	any	drugs.		This	score	describes	the	efficacy	of	the	instance	of	a	set	







concentrations	 of	 the	 drugs	 used.	 	 Low	 scores	 also	 ensure	 that	 the	 dosages	 are	minimal,	
yielding	 therapeutic	 hypotheses	 with	 the	 least	 risks	 of	 off-target	 effects.	 	 At	 each	






A	visual	map	of	 the	model	obtained	 is	 shown	 in	 Figure	3.1	using	 the	SBGN	schema.	 	 The	
model	covers	five	distinct	organs	and	tissues:	the	liver,	 intestine,	 lumen,	endothelium	and	
tunica	 intima.	 	 It	 covers	 LDL	 retention,	 LDL	 oxidation,	 monocyte	 recruitment,	 monocyte	
differentiation,	 smooth	 muscle	 cell	 proliferation,	 phagocytosis,	 reverse	 cholesterol	
transport	 and	T-cell	 proliferation.	 	 The	 cell	 types	 involved	 include	monocytes,	 endothelial	






















The	 initial	 conditions	 identified	 are	 described	 in	 Appendix	 3,	 Table	 3	 and	 unknown	
parameters	 were	 optimised	 so	 that	 the	 model	 maximally	 satisfied	 all	 the	 constraints	







































IX)	 Figure	 3.4.6	 shows	 triglyceride	 blood	 serum	 concentration,	 yielding	 754	 mg/dl	 (1005	
mg/dl)	a	value	that	does	not	change	for	low	LDL	profiles	(58	mg/dl).		





















XVIII)	 Figure	3.4.15	 shows	TNFα	plaque	 concentration,	 yielding	24	ng/g	 (27	ng/g)	 and	0.3	
ng/g	(15	ng/g)	for	high	and	low	LDL	profiles,	respectively.	
XIX)	Figure	3.4.16	shows	 IL2	plaque	concentration,	yielding	27	ng/g	 (24	ng/g)	 for	 the	high	
LDL	profile.		




XXII)	 Figure	 3.4.19	 shows	 IL12	 plaque	 concentration,	 yielding	 5.2	 ng/g	 (4.6	 ng/g)	 and	 0.7	
ng/g	(3.6	ng/g)	for	high	and	low	LDL	profiles,	respectively.			












XXIX)	 Figure	 3.4.26	 shows	 foam	 cell	 aggregation	 after	 the	 parameter	 determining	 rate	 of	
differentiation	to	Th1	cells	has	been	increased	by	10%	and	the	parameter	determining	the	









mg/dl	 and	 40	 mg/dl,	 respectively,	 to	 50mg/dl	 and	 50mg/dl,	 respectively	 after	 40	 years,	
demonstrating	plaque	reduction.	






























XXXIII)	Deficiency	 of	 ABCA1	 function	 impairs	 reverse	 cholesterol	 transport	 and	 increases	




(Qiao	 et	 al.,	 1997).	 Figure	 3.5.3	 shows	 that	 with	 a	 reduction	 in	 the	 initial	 MCSF	
concentrations	 from	100	μg/mg	of	 tissue	 to	0,	macrophage	abundance	drops	significantly	
within	the	plaque.	
XXXV)	 T-cells	 abundance	 is	 reduced	 as	 a	 result	 of	 IFNGR	 knockout	 (Gupta	 et	 al.,	 1997).		





XXXVII)	 Reduction	 in	 proteoglycan	 concentration	 reduces	 intimal	 oxLDL	 concentrations	
(Delgado-Roche	et	al.,	2015).		Figure	3.5.7	shows	that	decreasing	the	initial	concentration	of	
proteoglycan	concentration	 from	500	μg/mg	of	 tissue	to	100	pg/mg	of	 tissue	reduces	 the	
concentration	of	oxidized	LDL	within	the	plaque.	




















The	 visual	 map	 is	 available	 as	 a	 file	 encoded	 using	 the	 SBGN-ML	 format	 and	 the	
mathematical	model	 is	 available	 as	 a	 file	 encoded	using	 the	 SBML	 format,	both	 from	 the	




standards.	 	 SBML	 compliant	 software	 includes	 Copasi	 (Bergmann	 et	 al.,	 2017),	 Cytoscape	









shows	 the	 graphical	 map	 opened	 in	 three	 representative	 SBGN	 compliant	 editors:	 Newt	







Running	 the	analysis	described	 in	 section	3.2.2,	we	were	able	 to	determine	 the	 following	
drug	 combination	 as	 an	 optimal	 intervention	 that	 drove	 plaque	 regression:	 Ustekinumab	
(IL12R)	 –	 7.6279,	 GSK1070806	 (IL18R)	 -	 7.5937,	 Bindarit	 (CCL2)	 –	 36.9922,	 where	
concentrations	are	described	as	multiples	of	the	corresponding	inhibition	constants,	Ki.		This	
combination	 was	 identified	 relatively	 quickly	 by	 the	 model,	 in	 1080	 minutes,	 with	
approximately	 optimal	 results	 being	 identified	 much	 more	 quickly,	 within	 300	 minutes.		
Figure	 3.7B,	 Figure	 3.7C	 and	 Figure	 3.7D	 show	 the	 dynamics	 of	 the	 model	 after	 this	












studies	 present	 logistical	 and	ethical	 challenges	 and	 there	 are	 few	 in	 vitro	 resources	 that	
can	contribute	increasing	our	understanding	of	plaque	development.		Whilst	they	are	not	a	






refined	 and	 expanded	 in	 future.	 	 The	 model	 we	 have	 produced	 has	 the	 potential	 to	
contribute	to	therapy	development	through	multiple	avenues.		Primarily,	the	model	can	be	
used	to	predict	the	consequences	for	the	dynamics	of	atherosclerosis	of	interventions	that	








drug	 development,	 by	 identifying	 the	 components	 of	 the	 model	 that	 have	 the	 greatest	
impact	 on	 foam	 cell	 accumulation	 and	 smooth	 muscle	 cell	 recruitment	 or	 to	 multi-drug	
interventions	 that	 achieve	 similar	 goals	 through	 the	 compound	 effect	 of	 suppressing	
multiple	pathway	components,	but	to	smaller	individual	degrees	(Benson	et	al.,	2017).		It	is	
known	 that	 atherosclerosis	 is	 a	 comorbidity	 of	 diseases	 such	 as	 rheumatoid	 arthritis	 and	
depression	(Gibson	et	al.,	2017).	 	By	using	proteomic	data	from	studies	of	other	diseases,	
this	model	can	also	be	used	to	explore	the	role	of	atherosclerosis	as	a	comorbidity	of	other	
conditions.	 Similarly	 it	 can	be	used	 to	 explore	 the	possible	 off-target	 impact	 of	 therapies	
targeting	 a	 separate	 conditions,	 where	 the	 therapeutics	 are	 known	 to	 also	 target	
components	of	the	pathways	associated	with	atherosclerosis.			
	
Although	 we	 often	 consider	 disease	 pathologies	 in	 isolation,	 atherosclerosis	 is	 part	 of	 a	
much	 larger	 network	of	 interactions	 and	we	 can	use	 the	model	 to	 explore	 the	 impact	 of	
interventions	on	the	components	of	pathways	and	networks	that	regulate	atherosclerosis.		




A	 predictive	model	 of	 this	 type	 has	 the	 potential	 to	move	 the	 discussion	 around	 disease	
from	an	understanding	of	 behaviour	 of	 individual	 disease	 components	 (such	 as	 foam	 cell	





the	model	 describes	 spatial	 effects	 and	 cellular	 function	 at	 extremely	 simple	 levels,	 it	 is	
unlikely	to	be	able	to	recreate	all	clinical	results	exactly.		Doing	so	would	require	a	model	of	
greater	 complexity	 across	 length	 scales.	 	 However,	 the	 model	 demonstrates	 order	 of	
magnitude	agreement	in	almost	all	cases	and	shows	the	correct	qualitative	dose	responses.		
In	many	cases,	we	found	it	particularly	challenging	to	constrain	parameters	so	as	to	ensure	
sufficiently	 large	 responses	 to	changes	 in	 lipoprotein	profile.	 	As	a	 result,	 the	model	does	










to	 develop	 therapeutic	 hypothesis.	 	 Such	 a	 model	 can	 be	 adapted	 to	 individuals	 or	 to	
patient	subgroups	by	tuning	the	parameters	of	the	interactions.		Creating	parameterisations	
that	are	tailored	to	 individuals	could	be	achieved	by	optimizing	the	model	to	patient	time	
course	 data	 or	 through	 computational	 inference	 from	 patient	 genome	 data.	 	 However,	
adapting	the	model	in	this	way	to	represent	the	disease	dynamics	of	individuals	or	patient	




CVD	 is	a	 large	burden	on	healthcare	worldwide.	 	Front	 line	 therapies	 for	 the	primary	and	
secondary	 prevention	 of	 atherosclerotic	 vascular	 disease	 include	 smoking	 cessation,	 lipid	
management,	 blood	 pressure	 control,	 optimal	 control	 of	 diabetes	 and	 the	 use	 of	
antiplatelet	agents.		By	far	the	most	commonly	used	class	of	lipid	lowering	drugs	is	statins,	
which	 inhibit	 HMG-CoA	 reductase.	 Ezetimibe,	 a	 cholesterol	 absorption	 inhibitor,	 may	 be	
used	 in	 patients	 who	 are	 statin	 intolerant	 or	 who	 are	 not	 achieving	 lipid	 targets	 on	 the	
highest	 maximally	 targeted	 dose	 of	 statin.	 A	 new,	 recently	 licenced	 class	 of	 drugs,	
proprotein	convertase	subtilisin/kexin	type	9	(PCSK9)	inhibitors	suppress	LDLR	degradation	
by	PCSK9	are	associated	with	significant	reduction	 in	serum	LDL	cholesterol	concentration	




Amongst	 the	drugs	 identified	as	part	of	 the	multi-drug	 intervention,	numerous	 studies	of	
CCR2	 inhibition	 in	 atherosclerosis	 have	 shown	 a	 reduction	 in	 intima	media	 thickness	 and	
plaque	 area,	 lowered	 monocyte	 infiltration	 and	 increased	 lesion	 stability	 (Zhao,	 2010).	









The	 scale	 of	 global	 CVD	 burden	 means	 that	 there	 is	 a	 pressing	 need	 to	 develop	 new	
pharmaceutical	therapeutics	in	this	area	that	both	address	clinical	need	and	can	sustain	the	
pharmaceutical	 industry	 as	 intellectual	 property	 protection	 expires	 around	 current	






















The	study	of	protein-protein	 interactions	 (PPIs)	 is	 vital	 to	 improving	our	understanding	of	
disease	dynamics.	PPIs	are	heavily	 involved	 in	atherosclerosis,	driving	the	subprocesses	of	
lipoprotein	 oxidation	 (Yoshida	 and	 Kisugi,	 2010),	 immune	 cell	 recruitment	 (Bobryshev,	
2006),	monocyte	migration	(Moore	et	al.,	2013a),	macrophage	differentiation	(Qiao	et	al.,	
1997),	 T	 cell	 differentiation	 (Tse	 et	 al.,	 2013a),	 extra	 cellular	 matrix	 (ECM)	 remodelling	
(Newby,	2005),	and	fibrous	cap	formation	(Rudijanto,	2007).	Using	the	model	described	in	
Chapter	 3	 of	 this	 thesis,	 we	 intend	 to	 show	 how	 variation	 in	 protein	 structure	 affects	
atherosclerosis	dynamics	in	silico.	Protein	structure	determines	function,	and	subsequently	
molecular	 processes	 and	 biochemical	 events	 driven	 by	 PPIs	 are	 influenced	 by	 structural	
changes.	 Proteins	 obtain	 their	 3D	 structure	 through	 protein	 folding,	 where	 polypeptides	
spontaneously	form	their	functional	structure	based	on	their	amino	acid	sequence.	Protein	
folds	 have	 been	 greatly	 studied	 by	 the	 scientific	 community	 in	 recent	 years,	 with	 great	
progress	 seen	 in	 protein	 structure	 prediction	 strategies.	 Variants	 caused	 by	 single	
nucleotide	 polymorphisms	 (SNPs),	 insertions	 or	 deletions	 (indels)	 and	 other	 mutations	
which	 lead	 to	 a	 change	 in	 the	 amino	 acid	 sequence	 of	 a	 protein	 can	 cause	 significant	






cost	of	next	generation	sequencing	 techniques,	 such	as	whole	genome	sequencing	 (WGS)	
and	whole	exome	sequencing	(WES),	led	to	the	creation	of	the	project	devised	to	provide	a	
publicly-available	 database	 of	 human	 genetic	 variation.	 In	 phase	 3	 of	 the	 1000	 Genome	
Project,	whole	genome	sequence	data,	generated	 from	the	 Illumina	 sequencing	platform,	
derived	from	2504	samples	was	integrated	into	the	repository	for	use	by	the	wider	scientific	
community	 (Sudmant	 et	 al.,	 2015).	 These	 2504	 samples	 were	 taken	 from	 unrelated	
individuals	with	 genetic	 lineage	 from	26	 different	 populations.	 84.4	million	 variants	were	
found	 across	 phase	 3	 of	 the	 project.	 	 The	majority	 of	 these	 variants	 (81.3	million)	 were	







expected	 to	 have	 between	 4.1	million	 and	 5	million	 variations	 that	 differ	 from	 the	 1000	







Simulating	 polypeptides	 folding	 into	 unique	 structures	 has	 been	 a	 problem	 tackled	 by	




other	 proteins.	 Structural	 Classification	 of	 Proteins	 (SCOP),	 a	manually-curated	 repository	
describing	the	structural	relationships	between	proteins,	contains	1195	different	 ‘folds’	or	
‘motifs’	 found	within	multiple	protein	structures	with	no	common	homologues	(Murzin	et	
al.,	 1995).	 SCOP	 has	 been	 extended	 (SCOPe)	 in	 recent	 years,	 using	 automation	 alongside	
manual	curation	to	provide	classifications	of	protein	superfamilies	(Chandonia	et	al.,	2017).	
Identifying	 the	 amino	 acid	 sequences	 that	 lead	 to	 these	 motifs	 has	 led	 to	 significant	
advances	in	the	prediction	of	three-dimensional	structure	from	amino	acid	sequences.	
 Protein	structure/function	
As	 of	 July	 2017,	 approximately	 88	 million	 protein	 sequences	 exist	 in	 the	 UniProt	
knowledgebase	 (Bateman	 et	 al.,	 2015),	 and	 122,500	 experimentally	 validated	 structures	
exist	 in	 the	Protein	Data	Bank	 (PDB)	 (Rose	et	al.,	2015),	meaning	 that	 there	are	validated	
structures	for	approximately	0.14%	of	proteins	with	a	known	amino	acid	sequence.	
Structures	 can	 be	 divided	 into	 four	 categories,	 or	 levels,	 depending	 on	 their	 complexity.	














Secondary	 structure	 involves	 the	 formation	of	motifs,	 or	 individual	 segments	 of	 proteins.	
These	motifs,	 such	as	alpha	helices	or	beta	sheets,	 typically	 form	before	the	 formation	of	
the	 full	 tertiary	 structure.	 Local	 segments	 of	 the	 tertiary	 structure	 form	 as	 part	 of	 a	









carbon	 atoms,	 fundamentally	 define	 the	 tertiary	 structure,	 chemical	 properties	 and	
interaction	mechanisms	 of	 a	 protein.	 This	 three-dimensional	 shape	 gives	 the	 protein	 the	
ability	to	achieve	its	biological	function.	
Quaternary	 structure	 refers	 to	 the	 three-dimensional	 complex	 formed	by	arrangement	of	
multiple	 tertiary	 structure	 subunits,	 including	 oligomers	 and	 complexes	 formed	 through	
PPIs.	 Certain	 proteins	 are	 only	 active	 in	 their	 oligomer	 form.	 Most	 protein	 structures	
perform	their	biological	function	when	part	of	a	quaternary	structure,	rather	than	in	their	










stored	 as	 a	 series	 of	 atomic	 coordinates	 in	 a	 .pdb	 file.	 	 The	 PDB	 contains	 tertiary	 and	
quaternary	 structures	 for	 more	 than	 122,000	 proteins	 (12/7/17),	 derived	 using	 X-ray	
crystallography,	 nuclear	 magnetic	 resonance	 (NMR),	 electron	 microscopy,	 microelectron	
diffraction	and	combinations	of	these	methods.	The	PDB	file	format,	 .pdb,	 is	the	standard	
format	 for	collating	 three-dimensional	molecular	structures,	and	allows	 for	 the	storage	of	





The	 tertiary	 structure	of	 a	 protein	 is	 determined	by	 its	 amino	 acid	 sequence.	 The	 almost	
instantaneous	nature	of	protein	 folding	 leads	 to	a	 series	of	questions.	What	 forces	 cause	
the	 protein	 to	 quickly	 conform	 to	 its	 native	 structure?	 How	 is	 the	 protein	 capable	 of	
avoiding	 unwanted	 conformations?	 These	 questions	 are	 beyond	 the	 scope	 of	 this	 thesis;	
however	 they	 are	 questions	 that	 require	 some	 elucidation	 to	 provide	 high	 quality	
predictions	of	tertiary	protein	structure	from	amino	acid	sequences.	
Protein	 structural	 prediction	 methods	 can	 be	 advantageous	 in	 filling	 in	 the	 gaps	 in	 our	
knowledge	due	to	the	significant	quantity	of	known	amino	acid	sequences	with	no	known	
structure.	 As	 these	methods	 develop,	 understanding	 of	 how	 protein	 folding	mechanisms	
operate	will	improve.			
Currently,	 protein	 structure	 prediction	 tools	 can	 be	 inserted	 into	 one	 of	 four	 broad	
categories:	
4.1.5.1 Homology	Modelling	
Homology	 modelling	 relies	 on	 the	 concept	 of	 conservation	 of	 structure	 between	 similar	
proteins	 (Martí-Renom	 et	 al.,	 2000).	 Evolutionarily	 linked	 proteins	 generally	 have	 similar	







our	 target	 protein.	 Sequence	 alignment	 and	 structural	 templates	 with	 expected	 shared	
motifs	are	then	combined	to	predict	a	protein	structure.	
4.1.5.2 Threading	
Threading	 is	a	 similar	process	 to	homology	modelling;	however	proteins	of	 the	 same	 fold	
are	identified	and	used	to	infer	a	protein	structure,	rather	than	predicting	structure	through	
comparison	 to	evolutionary	homologues	 (Xu	et	 al.,	 2008).	 The	number	of	 folds	 that	have	
been	 identified	 is	 relatively	 small	 compared	 to	 the	number	of	proteins	 in	 the	PDB,	which	
allows	 for	 the	 statistical	 inference	 of	 protein	 structures	 from	 amino	 acid	 sequences	
(Chandonia	et	al.,	2017;	Rose	et	al.,	2015).	
4.1.5.3 Ab	Initio	
Ab	 Initio,	or	de	 novo,	protein	 structure	 prediction	 relies	 on	 calculating	 protein	 structures	
with	 no	 available	 homologue	 or	 protein	 folding	 data.	 (Hardin	 et	 al.,	 2002).	 The	 most	
efficient	 protein	 structure	prediction	methods	utilise	 structural	 data	 taken	 from	 the	PDB,	






insight	 into	 protein	 structure	 and	 function	 can	 be	 derived	 from	 a	 secondary	 structure	
prediction.	
 Critical	Assessment	of	Protein	Structure	Prediction	(CASP)	
There	 are	multiple	 different	 bioinformatics	 tools	 that	 predict	 a	 protein	 structure	 from	an	
amino	acid	sequence,	using	a	wide	range	of	different	methods	and	algorithms	to	reach	their	
predicted	 result.	 The	 Protein	 Structure	 Prediction	 Centre	 have	 developed	 a	 series	 of	









al.,	 2014,	 2016).	 This	 provides	 the	 research	 community	 and	 potential	 users	 with	 a	 non-
partisan	review	and	assessment	of	the	predictive	power	of	all	of	the	algorithms	involved	in	
the	study.		
At	 its	 core,	 CASP	 participants	 are	 provided	 with	 an	 amino	 acid	 sequence	 and	 asked	 to	
provide	 a	 tertiary	 structure	 to	 be	 compared	 with	 a	 recently-elucidated	 experimentally-
derived	 structure.	 In	 CASP11,	 performed	 in	 2014,	 207	 modelling	 groups	 entered	 from	
approximately	100	research	laboratories	(Moult	et	al.,	2016).	
Categories	where	modelling	performance	 is	 judged	 include	homology	modelling	methods,	
ab	 initio	 methods,	 model	 refinement,	 model	 accuracy	 prediction	 and	 contact	 point	 and	
binding	 site	 prediction.	 Model	 refinement	 and	 model	 accuracy	 prediction	 have	 seen	
significant	 improvements	 recently	 (Heo	 et	 al.,	 2013;	 Moult	 et	 al.,	 2016).	 Refinement	
methods	can	additionally	help	with	minimising	template	bias.	






Lab,	 designed	 to	 heuristically	 predict	 protein	 structure	 and	 function	 from	 amino	 acid	
sequences	 (Roy	 et	 al.,	 2010).	 I-TASSER	 has	 been	 consistently	 successful	 in	 recent	
community-wide	CASP	experiments,	ranked	as	the	top	protein	structure	prediction	method	
four	 times	out	of	 the	 last	 five	experiments.	 In	 summary,	 I-TASSER	will	 initially	 establish	 a	
secondary	structure	for	a	given	amino	acid	sequence	by	matching	the	query	sequence	to	an	
existing	 database	 (to	 select	 homologues)	 and	 performing	multiple	 alignments	with	 these	
evolutionary	relatives	(McGuffin	et	al.,	2000).	Multiple	threading	programs	are	then	used	to	
predict	 templates,	 and	 their	 quality	 is	 ranked	 based	 on	 the	 significance	 of	 the	 threading	








fragments.	 An	 additional	 structural	 assembly	 simulation	 is	 completed,	 with	 additional	






An	oligomeric	 protein	 structure	 is	 a	 complex	 that	 consists	 of	 two	or	more	monomers	 (or	
tertiary	structures),	held	together	by	non-covalent	bonds.	Homo-oligomers	are	complexes	




for	 cell	 signalling)	 is	 a	heterodimer,	built	 from	 two	 separate	proteins	 coded	by	 the	genes	
IFNGR1	and	IFNGR2	(Tau	and	Rothman,	1999).	 	Oligomeric	structures	can	be	composed	of	
different	numbers	of	subunits.	
Certain	 proteins	 can	 only	 perform	 their	 biological	 function	 when	 they	 become	 part	 of	 a	
complex.	 Environmental	 differences	 can	 alter	 function	 for	 the	 same	 complex	 (Nooren,	
2003).		
Methods	for	predicting	oligomeric	status	and	quaternary	structure	from	primary	structure	







structure	 (Davis	 and	 Baker,	 2009),	 and	methods	 have	 been	 developed	 to	 predict	 homo-
oligomeric	 status	 and	 structure	 from	 tertiary	 structure	 (Baek	 et	 al.,	 2017).	 Continuous	
Automated	 Model	 Evaluation	 (CAMEO)	 is	 a	 community	 effort	 to	 evaluate	 tertiary	 and	
quaternary	structure	prediction	methods	(Haas	et	al.,	2013).	Docking	of	rigid-body	tertiary	
structures	 is	 the	 primary	method	 used	 to	model	 complex	 structures;	 however	 homology	
modelling	methods	 and	methods	 to	model	 complexes	 from	 primary	 structure	 have	 seen	
success	recently.	
 Comparing	Protein	Structures	
Algorithms	 to	 compare	 protein	 structures	 and	 quantify	 differences	 are	 continually	
progressing.	 There	 are	 two	 primary	 categories	 of	 structural	 comparison	 methods,	
depending	 on	 the	 existence	 of	 an	 alignment	 between	 matching	 residues	 within	 the	
structure.	 The	 root-mean-square	 derivation	 (RMSD)	 uses	 an	 optimal	 alignment	 and	
compares	the	pairwise	distance	between	residues.	However,	when	this	optimal	alignment	is	
not	 given	 then	 alignments	 require	 to	 be	 identified,	 or	 alignment-independent	 algorithms	
must	be	used	(Kufareva	and	Abagyan,	2012).		
Predicted	protein	 structures	often	 see	an	 increased	amount	of	 variation	and	noise	at	 the	
terminals	due	to	fewer	constraints	from	other	residues	in	the	system.	RMSD	evaluates	the	
distances	 between	 each	 residue	 pairing	 equally,	 potentially	 misrepresenting	 the	 overall	
accuracy	 if	 there	 is	 significant	variance	at	either	 terminal.	The	TM-Score	 is	a	method	that	













ABCA1	 ABCG1	 CCL2	in	Intima	 CCL2	in	Lumen	 CXCL9	
CXCL10	 CXCL11	 Chymase	 Collagen	 EGF	
Elastin	 Interferon	Gamma	 IL-1B	 IL-10	 IL-12	
IL-17	 IL-18	 IL-2	 IL-21	 IL-33	
IL-4	 IL-5	 IL-6	 MCSF	 MMP1	
MMP2	 MMP3	 MMP9	 MMP13	 PDGF	
PLA2	 Proteoglycans	 SMAse	 TGF-Beta	 TIMP1	
TIMP2	 TIMP3	 TIMP4	 TNF-Alpha	 Tryptase	
TACE	 	 	 	 	
	
A	 literature	 mining	 process	 was	 undertaken	 to	 establish	 the	 genes	 that	 encode	 each	 of	
these	proteins,	and	whether	the	protein	is	an	oligomer	in	its	active	form.	For	each	protein,	a	
Google	Scholar	search	was	undertaken	with	 the	query	 ‘PROTEINNAME	gene’,	and	the	 top	
five	papers	were	searched	for	a	gene	name	to	correspond	with	each	protein.	Four	of	these	
proteins	describe	a	 class	of	proteins	 (collagen,	elastin,	proteoglycans	and	 tryptase)	 rather	
than	 a	 single	 macromolecule,	 and	 are	 not	 included	 within	 this	 dataset.	 Experimentally	
validated	versions	of	these	proteins	within	the	protein	data	bank	were	found	and	their	PDB	
codes,	encoding	genes	and	the	proteins	they	interact	with	in	the	model	is	described	in	Table	














1	 TACE	 ADAM17	 TIMP3	 TIMP3	 3CKI	 	
2	 MCP1	 CCL2	 CCR2	 CCR2	 3IFD	(1)	5T1A	(2)	 	
3	 RANTES	 CCL5	 CCR5	 CCR5	
1HRJ	(1)	
4MBS(2)	 	
4	 Chymase	 CMA1	 MMP1	 MMP1	 1NN6	 	
5	 MCSF	 CSF1	 CSF1R	 CSF1R	 4WRL	 	
6	 CXCL10	 CXCL10	 CXCR3	 CXCR3	 1o80	 	
7	 CXCL11	 CXCL11	 CXCR3	 CXCR3	 1RJT	 	
8	 CXCL9	 CXCL9	 CXCR3	 CXCR3	 	 	
9	 EGF	 EGF	 EGFR	 EGFR	 1IVO	 	
















	 IFNGR2	 	 IFNGR	is	heterodimeric	
11	 IL1B	 IL1B	 IL1R	 IL1R1	 	 	
12	 IL10	 IL10	 IL10R	 IL10RA	 1J7V	 	
13	 IL12	 IL12A	IL12B	 IL12R	 IL12R1,	IL12R2	 1F45	 IL12	and	IL12R	are	Heterodimeric	
14	 IL17A	 IL17A	 IL17RA	 IL17RA	 4SHA	 	
15	 IL18	 IL18	 IL18R	 IL18RA	IL18RAP	 4R6U	 IL18R	is	Heterodimeric	
16	 IL2	 IL2	 IL2R	 IL2RA	 2B5I	 	
17	 IL21	 IL21	 IL21R	 IL21R	 3TGX	 	
18	 IL33	 IL33	 IL1R	 IL1R1	 4KC3	 	
19	 IL4	 IL4	 IL4R	 IL4R	 3BPL	 	
20	 IL5	 IL5	 IL5R	 IL5RA	 3QT2	 IL5	is	Homodimeric	
21	 IL6	 IL6	 IL6R	 IL6R	 4J4L	 	
22	 PDGFA	 PDGFA	 PDGFRA	 PDGFRA	 	 	
23	 PDGFB	 PDGFB	 PDGFRB	 PDGFRB	 3MJG	 PDGFB	is	Homodimeric	
24	 PDGFA	 PDGFA	 PDGFRB	 PDGFRB	 	 	





	 TGFBR2	 	 TGFBR	is	Heterodimeric	
27	 TIMP1	 TIMP1	 MMP1	 MMP1	 2J0T	 	
28	 TIMP1	 TIMP1	 MMP2	 MMP2	 	 	
29	 TIMP1	 TIMP1	 MMP3	 MMP3	 1OO9	 	
30	 TIMP1	 TIMP1	 MMP9	 MMP9	 1L6J	 	
31	 TIMP1	 TIMP1	 MMP13	 MMP13	 2E2D	 	
32	 TIMP2	 TIMP2	 MMP1	 MMP1	 	 	
33	 TIMP2	 TIMP2	 MMP2	 MMP2	 1GXD	 	
34	 TIMP2	 TIMP2	 MMP3	 MMP3	 	 	
35	 TIMP2	 TIMP2	 MMP9	 MMP9	 	 	
36	 TIMP2	 TIMP2	 MMP13	 MMP13	 	 	
37	 TIMP3	 TIMP3	 MMP1	 MMP1	 	 	
38	 TIMP3	 TIMP3	 MMP2	 MMP2	 	 	
39	 TIMP3	 TIMP3	 MMP3	 MMP3	 	 	
40	 TIMP3	 TIMP3	 MMP9	 MMP9	 	 	
41	 TIMP3	 TIMP3	 MMP13	 MMP13	 	 	
42	 TIMP4	 TIMP4	 MMP1	 MMP1	 	 	
















44	 TIMP4	 TIMP4	 MMP3	 MMP3	 	 	
45	 TIMP4	 TIMP4	 MMP9	 MMP9	 	 	
46	 TNFA	 TNF	 TNFR	 TNFSFR1A	TNFSFR1B	 3ALQ	 TNFR	is	Heterodimeric	
	
In	 Table	 4.2,	 PDB	 Codes	 are	 provided	 for	 bound	 complexes	 containing	 the	 two	 protein	




















access	 to	 an	 underlying	 MySQL	 database,	 allowing	 for	 the	 development	 of	 a	 software	


































For	 each	 I-TASSER	 run,	 multiple	 structural	 confirmations	 are	 created	 and	 subsequently	
clustered	together	to	then	create	a	final	prediction.	Multiple	clusters	are	then	created,	and	
the	most	 accurate	 prediction	 is	 then	 isolated	 through	 the	 use	 of	 a	 scoring	 function.	 For	








structure.	 Proteins	 isolated	 in	 this	 manner	 were	 named	 in	 the	 format:	 {Gene	 Name}	 –	




TM-Align	 is	 used	 to	 compare	 monomeric	 protein	 structures	 (Zhang	 and	 Skolnick,	 2005).	
Experimentally	 validated	 structures	 as	 detailed	 in	 Table	 4.2	 have	 been	 isolated	 from	 the	
protein	 data	 bank,	 and	 I-TASSER	 structures	 as	 predicted	 from	 the	 wildtype	 have	 been	
aligned	 to	 these	 experimentally	 validated	 structures.	 An	 observed	 accuracy	 value	 is	
calculated	by	utilising	root-mean-square-deviations	(RMSDs)	and	TM-Scores,	obtained	while	
performing	 this	 alignment	 using	 TM-Align.	 I-TASSER	will	 predicted	 values	 for	 both	 RMSD	
and	 TM-Score	 to	 assess	 model	 quality,	 and	 these	 values	 are	 compared	 to	 our	 observed	
accuracy.	An	 initial	alignment	 is	chosen	by	aligning	secondary	structure	elements	 (helices,	
sheets	or	coils)	to	maximise	the	TM-Score,	an	evaluation	of	similarity	between	two	tertiary	
structures	 that	 prioritises	 alignment	 in	 the	 centre	 of	 the	 protein	 due	 to	 the	 increased	




protein	 structures,	 and	 to	 give	 confidence	 in	 the	 quality	 assessments	 of	 I-TASSER	where	
native	structures	are	unavailable.	
 Accuracy	
I-TASSER	 provides	 a	 local	 per	 residue	 ‘L-score’	 as	 well	 as	 a	 global	 C-score	 to	 quantify	
prediction	accuracy.	An	L-score	has	been	calculated	for	each	protein	model	using	secondary	
structure	information	and	predictions	of	solvent	accessibility	to	give	a	per-residue	maximal	
RMSD	 (in	 Angstrom)	 from	 the	 native	 structure.	 For	 more	 information	 on	 the	 ResQ	
algorithms	used	to	calculate	the	residue	specific	accuracy,	see	(Yang	et	al.,	2016).	To	study	






validated	structure	within	 the	PDB	as	described	 in	Table	4.2	has	been	aligned	to	 this	PDB	
structure,	 and	 a	 per-residue	 RMSD	 has	 been	 calculated	 to	 study	 the	 quality	 of	 these	 L-
scores.	
A	collection	of	graphs	have	been	generated	to	compare	this	L-Score	value	to	an	observed	
















compare	 our	 structures.	 TM-Align	 was	 used	 for	 each	 mutation	 to	 provide	 an	 optimal	
superposition	with	 its	corresponding	wildtype.	TM-Align	will	align	 two	proteins	by	using	a	
variation	 of	 the	 Levitt-Gerstein	 weight	 factor,	 weighting	 closer	 residue	 pairs	 more	 than	
further	 distant	 pairs.	 This	 prevents	 large	 variation	 at	 terminals,	 a	 common	 occurrence	 in	









mutations	 associated	 with	 a	 particular	 splice	 variant	 of	 a	 protein.	 These	 SEM	 values	 are	
then	 heatmapped	 onto	 the	wildtype	 of	 the	 protein,	 giving	 a	 coloured	 description	 of	 the	
protein	areas	most	likely	to	be	highly	varied.	
The	 primary	 aim	 of	 this	 chapter	 is	 to	 study	 how	 protein	 structures	 involved	 in	
atherosclerosis	vary	between	population	subgroups.	A	heatmap	image	has	been	generated	




A	 heatmap	 was	 generated	 by	 manually	 replacing	 column	 10	 (b-factor	 or	 temperature	
factor)	 in	 the	 pdb	 file	 for	 the	 wildtype	 with	 this	 SEM	 value,	 and	 utilising	 Jmol	 with	 the	
commands:	











































































830	 amino	 acid	 sequences	were	 isolated	 from	 the	 1000	Genome	Project	 Phase	 3	MySQL	
database,	 over	 a	 total	 of	 65	 genes	 and	 146	 splice	 variants,	 based	 on	 the	 gene	 names	
described	in	Table	4.2	and	formula	described	in	section	4.2.1.	I-TASSER	was	used	to	predict	





























ABCA1-001	 5	 IL12A-001	 5	 IL5RA-003	 4	
ABCA1-004	 3	 IL12A-005	 14	 IL5RA-004	 4	
ABCG1-001	 1	 IL12A-006	 13	 IL5RA-005	 4	
ABCG1-002	 1	 IL12B-001	 9	 IL5RA-006	 4	
ABCG1-004	 1	 IL12RB1-001	 9	 IL5RA-007	 4	
ABCG1-006	 1	 IL12RB1-002	 9	 IL5RA-201	 5	
ADAM17-
001	 5	 IL12RB1-003	 8	 IL6-001	 12	





















CCL2-004	 1	 IL12RB2-004	 8	 IL6-004	 6	
CCL5-001	 6	 IL12RB2-201	 7	 IL6-005	 11	
CCL5-002	 6	 IL12RB2-202	 8	 IL6-006	 14	
CCR2-001	 3	 IL17A-001	 8	 IL6-201	 12	
CCR2-002	 2	 IL17RA-001	 5	 IL6R-001	 4	
CCR2-201	 3	 IL17RA-201	 4	 IL6R-003	 2	
CCR5-001	 4	 IL18-001	 6	 IL6R-201	 2	
CD36-001	 4	 IL18-003	 6	 MMP1-001	 3	
CD36-006	 4	 IL18-006	 6	 MMP13-001	 2	
CD36-019	 1	 IL18R1-001	 4	 MMP13-002	 2	
CMA1-001	 14	 IL18R1-201	 4	 MMP13-201	 2	
CMA1-002	 16	 IL18R1-202	 7	 MMP2-001	 2	
CSF1-001	 7	 IL18RAP-001	 1	 MMP2-008	 4	
CSF1-002	 7	 IL18RAP-002	 2	 MMP3-001	 3	
CSF1-003	 4	 IL1B-001	 1	 MMP9-001	 7	
CSF1-004	 5	 IL1R1-001	 4	 PDGFA-001	 12	
CSF1R-001	 4	 IL1R1-006	 4	 PDGFA-002	 14	
CSF1R-201	 10	 IL1R1-013	 3	 PDGFB-001	 11	
CXCL10-001	 9	 IL2-001	 5	 PDGFB-002	 17	
CXCL11-001	 4	 IL21-001	 3	 PDGFRA-001	 8	
CXCL11-003	 4	 IL21-201	 3	 PDGFRA-002	 1	
CXCL9-001	 6	 IL21R-001	 3	 PDGFRB-001	 5	
CXCR3-001	 1	 IL21R-003	 3	 PLA2G6-001	 3	
CXCR3-002	 1	 IL21R-006	 3	 PLA2G6-002	 1	
EGF-001	 9	 IL2RA-001	 2	 TGFB1-001	 4	
EGF-002	 9	 IL2RA-002	 13	 TGFBR1-001	 3	
EGF-003	 7	 IL2RA-004	 5	 TGFBR1-003	 1	
EGFR-001	 3	 IL33-001	 6	 TGFBR2-001	 2	
EGFR-002	 4	 IL33-201	 6	 TGFBR2-002	 2	
EGFR-003	 2	 IL33-202	 12	 TIMP1-001	 14	
EGFR-004	 3	 IL33-203	 12	 TIMP1-002	 11	
EGFR-005	 1	 IL4-001	 11	 TIMP1-003	 10	
EGFR-201	 2	 IL4-002	 10	 TIMP2-001	 4	
EGFR-202	 1	 IL4-201	 8	 TIMP2-003	 3	
IFNG-001	 4	 IL4R-001	 13	 TIMP2-008	 6	
IFNGR1-001	 5	 IL4R-004	 13	 TIMP3-001	 8	
IFNGR1-201	 5	 IL4R-201	 14	 TIMP4-001	 11	
IFNGR2-001	 4	 IL4R-202	 1	 TNF-001	 2	
IL10-001	 8	 IL5-001	 8	 TNFSFR1A-001	 3	





















IL10RB-001	 5	 IL5RA-002	 4	 	 	
	
 Global	Accuracy	
Each	 I-TASSER	 run	 provides	 up	 to	 five	 models	 of	 each	 structure	 based	 on	 the	 sequence	
given.	The	C-Score	is	calculated	for	each	of	these	models	as	described	in	section	4.2.1.	
Of	 these	 830	 sequences,	 the	 mean	 C-score	 is	 -1.4134,	 the	 maximum	 is	 1.55	 and	 the	

















generated	 as	 described	 in	 section	 4.2.3	 and	 are	 shown	 in	 collectively	 in	 Figure	 4.5	 and	
individually	in	Appendix	4.	
 Error	
A	 subset	of	 the	generated	wildtype	models	 can	be	 compared	 to	experimentally	observed	












































Protein	Name	 TM-Score	 Protein	Name	 TM-Score	
ADAM17-001	 0.74	 IL21R-001	 0.54	
CCL2-001	 0.87	 IL2RA-001	 0.37	
CCL5-001	 0.80	 IL33-001	 0.89	
CCR2-001	 0.73	 IL4-001	 0.83	
CCR5-001	 0.85	 IL4R-001	 0.33	
CMA1-001	 0.91	 IL5-001	 0.30	
CSF1-001	 0.40	 IL5RA-001	 0.34	
CSF1R-001	 0.63	 IL6-001	 0.23	
CXCL10-001	 0.79	 IL6R-001	 0.45	
CXCL11-001	 0.49	 MMP1-001	 0.98	






Protein	Name	 TM-Score	 Protein	Name	 TM-Score	
EGFR-001	 0.36	 MMP2-001	 0.96	
IFNG-001	 0.60	 MMP3-001	 0.92	
IFNGR1-001	 0.33	 MMP9-001	 0.79	
IL10-001	 0.55	 PDGFA-001	 0.86	
IL10RA-001	 0.33	 PDGFB-001	 0.87	
IL12A-001	 0.22	 PDGFRB-001	 0.35	
IL12B-001	 0.94	 TGFB1-001	 0.68	
IL17A-001	 0.82	 TGFBR1-001	 0.34	
IL17RA-001	 0.33	 TGFBR2-001	 0.31	
IL18-001	 0.21	 TIMP1-001	 0.30	
IL18R1-001	 0.31	 TIMP2-001	 0.34	
IL18RAP-001	 0.26	 TIMP3-001	 0.28	
IL1B-001	 0.93	 TNF-001	 0.97	
IL1R1-001	 0.23	 TNFSFR1A-001	 0.27	
IL2-001	 0.82	 TNFSFR1B-001	 0.25	
IL21-001	 0.26	 	 	
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Heatmap	No	 Gene	Name	 Heatmap	No	 Gene	Name	
1	 ABCA1	 32	 IL12RB1	
2	 ADAM17	 33	 IL12RB2	
3	 CCL2	 34	 IL17A	
4	 CCL5	 35	 IL17RA	
5	 CCR2	 36	 IL18	
6	 CCR5	 37	 IL18R1	
7	 CMA1	 38	 IL18RAP	
8	 CSF1	 39	 IL21	
9	 CSF1R	 40	 IL21R	
10	 CXCL9	 41	 IL33	
11	 CXCL10	 42	 MMP1	
12	 CXCL11	 43	 MMP2	
13	 EGF	 44	 MMP3	
14	 EGFR	 45	 MMP9	
15	 IFNG	 46	 MMP13	
16	 IFNGR1	 47	 PDGFA	
17	 IFNGR2	 48	 PDGFB	
18	 IL1R1	 49	 PDGFRA	
19	 IL2	 50	 PDGFRB	
20	 IL2RA	 51	 PLA2G6	
21	 IL4	 52	 TGFB1	
22	 IL4R	 53	 TGFBR1	
23	 IL5	 54	 TGFBR2	
24	 IL5RA	 55	 TIMP1	
25	 IL6	 56	 TIMP2	
26	 IL6R	 57	 TIMP3	
27	 IL10	 58	 TIMP4	
28	 IL10RA	 59	 TNF	








30	 IL12A	 61	 TNFSFR1B	
31	 IL12B	 	 	
	
With	this	gradient	colour	scheme,	blue	areas	of	the	protein	show	the	least	variance,	while	
green/red	 sections	 correspond	 to	 increased	 variance	 across	 the	 population	 within	 these	
areas.	For	each	protein	heatmap,	the	range	and	SEM	of	temperature	values	were	calculated	





























an	 estimated	 RMSD	 of	 13.8	 +-	 3.9.	 As	 shown	 in	 Figure	 4.6	 (Graph	 32),	 the	 predicted	
accuracy	of	our	wildtype	is	reliable.	
The	mutation	has	caused	a	significant	structural	difference	between	models.	A	TM-Score	of	
0.32569	 has	 been	 calculated	 between	 the	 two	models,	 which	 is	 a	 score	 suggesting	 that	
similarity	 between	 the	 two	 structures	 is	 only	 slightly	 better	 than	 random	 (Zhang	 and	
Skolnick,	2005).	
















against	 atopy,	 and	 that	 IL4R-001-75	 gives	 a	 susceptibility	 to	 AIDS.	 With	 the	 known	 link	

























The	 graphs	 in	 Figure	 4.6	which	 relate	 predicted	 structural	 accuracy	 to	 observed	 accuracy	
show	that	the	L-Score	is	a	strong	indicator	of	quality;	however	it	is	not	perfect.	Of	all	of	the	
graphs,	 10	 show	 a	 global	 disparity	 between	 observed	 and	 predicted	 accuracy:	 CXCL11,	
EGFR,	 IFNGR1,	 IL18,	 IL5,	 IL6,	 TGFBR1,	 TIMP1,	 TIMP2	 and	 TIMP3.	 However,	 each	 of	 these	
structures	show	a	weak	alignment	to	the	predicted	structure,	as	only	1	structure	 (CXCL11	
with	 0.49)	with	 a	 TM-Score	when	 aligned	 to	 its	wildtype	 of	 greater	 than	 0.37	 shows	 this	









structures	 that	 are	 more	 likely	 to	 have	 different	 function	 than	 the	 wildtypes.	 If	 we	 can	
identify	which	mutations	are	more	 likely	to	cause	variation	 in	active	sites	of	proteins,	 this	
procedure	could	be	refined	further.	














The	 line	of	best	 fit	drawn	 in	Figure	4.11	and	Figure	4.12	was	drawn	using	Matlab’s	polyfit	
function.	 This	 is	 due	 to	 the	 inclusion	 of	 scoring	 functions	 from	 I-TASSER’s	 subprocess	
threading	algorithms	which	 incorporate	sequence	 length.	However,	 I-TASSER	studies	have	
shown	a	 correlation	between	C-Score	and	RMSD	of	0.75	 (Yang	et	 al.,	 2014).	 In	 summary,	
structural	quality	 can	be	assessed	 in	multiple	different	ways	and	 care	 should	be	 taken	 to	
ensure	awareness	of	the	limitations	of	solely	using	one	metric	to	study	quality.	
What	qualities	 in	 a	 protein	 lead	 to	 a	 stronger	more	 accurate	prediction?	With	 I-TASSER’s	
reliance	 on	 homologue	 discovery	 to	 improve	 the	 results	 from	 threading	 algorithms,	 it	 is	
assumed	 that	 the	 number	 of	 homologues	 identified	 is	 related	 to	 prediction	 quality.	
However,	 only	 approximately	 50%	of	 known	 sequences	 can	 be	 shown	 to	 be	 related	 to	 a	












structures.	 Five	 heatmap	 models	 show	 a	 red	 section	 (an	 area	 where	 the	 pairwise	 SEM	
between	 residues	 is	 greater	 than	 50A),	 showing	 a	 significant	 amount	 of	 variance.	 These	
severe	mutations	 exist	 on	 regions	 of	 CCR2,	 IL21,	 IL21R,	 IL6R	 and	 TNFSFR1A;	 a	 subset	 of	
proteins	with	a	wide	range	of	C-Score	values	(-1.11,	-0.64,	-3.39,	-2.47	and	-1.39),	suggesting	
a	low	likelihood	of	this	variance	being	due	to	weaknesses	in	the	prediction	algorithms.			
Identification	 of	 binding	 site	 location	 within	 a	 tertiary	 structure	 is	 an	 important	 part	 of	
elucidating	 function	 and	 drug	 design.	 However,	 experimentally-derived	 binding	 site	
information	is	limited.	With	accurate	binding	site	data,	the	local	variance	could	be	used	to	
assess	the	likelihood	that	a	variation	will	be	less	severe,	and	subsequently	more	likely	to	be	
benign.	 Utilising	 a	 relative	 scale	 for	 the	 heatmap	 by	 colouring	 the	 protein	 based	 on	 the	
maximum	variance	seen	within	the	structure	itself	rather	than	a	fixed	global	value	across	all	
proteins	would	 allow	 for	 the	 isolation	of	 areas	 showing	most	 variance	 and	potentially	 be	
useful	 in	 identifying	 severe	 mutations.	 Particular	 heatmaps,	 such	 as	 IL12BR2,	 show	
increased	 variance	 in	 localised	 regions,	 which	 could	 be	 good	 or	 bad	 depending	 on	 the	
binding	site	location.	
Future	work	 in	 this	area	 can	 focus	on	many	different	 topics.	 Improving	 the	quality	of	 the	
predictions	 utilised	 through	 computational	 methods	 would	 benefit	 every	 computational	
pipeline	where	modelling	 is	 required.	 These	methods	 are	developing	quickly	 and	 as	 each	
new	structure	 is	 included	in	the	Protein	Data	Bank,	the	average	quality	of	each	prediction	
increases	 for	 structures	 calculated	 through	 homology	 modelling	 methods.	 Increases	 in	
quality	 of	 binding	 site	 identification,	 intramolecular	 contact	 elucidation	 and	 unstructured	








function	 and	 drug	 development.	 Multiple	 bioinformatics	 tools	 have	 been	 developed	 to	
tackle	 this	problem,	 focusing	on	sequence	data	or	 structural	data	 (Xie	and	Hwang,	2015).	
CAMEO	experiments	have	been	set	up,	as	a	continuous	evaluation	alongside	the	bi-annual	
CASP	tests,	which	evaluates	the	quality	of	ligand-binding	sites	as	part	of	its	analysis.	Current	
results	 suggest	 that	 a	 combination	 of	 structural	 and	 sequence	 based	 methods	 are	 the	
current	industry	standards.	
Gene	Ontology	 (GO)	 is	 an	 attempt	 to	 create	 a	 standardised	 vocabulary	 to	 discuss	 genes,	
their	 attributes	 and	 their	 products.	 Through	 the	 identification	 of	 homologues	 during	 the	
model	formation	process,	predictions	can	be	made	into	the	biological	processes	in	which	a	
protein	 is	 involved,	 their	 explicit	 function	 and	 the	 cellular	 component(s)	 involved	 in	
construction.	
Due	 to	 computational	 intensity	 requirements,	 limitations	 were	 added	 to	 the	 number	 of	
structures	 that	were	 predicted	 and	 analysed	 in	 this	 chapter.	 The	 heatmaps	 generated	 in	
section	Figure	4.7	would	be	a	more	useful	descriptor	of	the	variation	across	the	protein	if	all	





discovery,	 motif	 identification	 and	 discovery,	 complex	 formation,	 function	 prediction,	
homologue	 identification,	 fold	 recognition	 and	 many	 more.	 PDB	 files	 can	 be	 used	 to	


























Determining	 the	 rate	of	 association	 and	dissociation	 for	 a	 PPI	 is	 an	 important	 step	 in	 the	
study	of	binding	kinetics,	theoretical	drug	design	and	the	general	study	of	the	biochemical	
interaction.	 These	molecular	 interactions	 drive	 almost	 all	 cellular	 processes	 (Phizicky	 and	
Fields,	1995).	Modification	of	proteins	 requires	 such	an	 interaction	 to	 take	place,	and	 the	
rate	 of	 protein-protein	 association	 and	 dissociation	 influences	 the	 consequences	 of	 the	
interaction	and	 subsequent	downstream	effects.	Additionally,	 variation	 in	binding	 kinetics	
can	have	significant	effect	on	drug	efficacy	(Pan	et	al.,	2013).	Quantifying	binding	kinetics	of	
PPIs	can	be	completed	experimentally	or	predicted	computationally.	Our	intention	is	to	use	
the	 mathematical	 model	 described	 in	 Chapter	 3,	 and	 the	 protein	 structures	 derived	 in	









This	 outlines	 the	 processes	 of	 enzyme-substrate	 binding,	 substrate	modification,	 product	
formation	 and	 enzyme	 unbinding.	 This	 interaction	 can	 be	 simplified	 if	 we	 remove	 the	
















































accessibility	of	 the	binding	site	areas	provide	a	hard-limit	 to	 the	speed	of	 the	biochemical	
reaction	due	to	the	greater	 impositions	added	when	binding	to	an	obstructed	site	over	an	















Electrostatic	 properties	 within	 protein-protein	 interactions	 are	 a	 vital	 component	 in	 the	
determination	of	binding	kinetics	and	complex	stability.	The	electrostatic	strength	involved	
in	an	interaction	between	proteins	varies	depending	on	the	pH	and	the	ionic	strength	of	the	
surrounding	 environment.	 An	 increase	 in	 ionic	 strength	will	 decrease	 kon	while	 having	 an	
insignificant	effect	on	koff	(Pan	et	al.,	2013;	Wendt	et	al.,	1997).	The	electrostatic	component	
of	the	total	binding	free	energy	involved	in	a	PPI	can	be	studied	using	continuum	solvation	
methods,	 a	modelling	 approach	 where	 the	 solvent	 is	 represented	 as	 a	 single	 continuous	
element	 rather	 than	 a	 collection	 of	 individual	 molecules.	 Electrostatic	 potentials	 can	 be	
calculated	 using	 the	 Poisson-Boltzmann	 equation	 when	 temperature,	 ionic	 strength,	
molecular	 structure,	 atomic	 radii	 and	 atomic	 charges	 are	 known	 (Baker	 et	 al.,	 2001).	
Alterations	to	electrostatic	potentials	of	proteins	to	improve	steering	within	PPIs	have	been	
shown	to	lead	to	increases	in	the	association	rate	(Phillip	et	al.,	2009).	The	arrangement	of	
charged	and	polar	 atoms	within	 the	 three	dimensional	 structure	of	 the	polypeptides,	 and	




The	 study	 and	 development	 of	 computational	 methods	 leading	 to	 calculation	 of	 PPI	
association	rates	has	seen	significant	progress	recently.	Reducing	a	collection	of	microscopic	










have	 allowed	 for	 characterization	of	 binding	 kinetics	 by	 estimating	 the	 effects	 on	binding	
caused	 by	 electrostatics,	 hydrodynamic	 forces	 and	 structural	 flexibility	 (Pang	 and	 Zhou,	

















Bioinformatics	 approaches	 to	protein	 ligand	binding	have	been	developed	with	 increasing	



















the	 native	 complex	 although	 short	 range	 interactions	 have	 not	 commenced	 leading	 to	
complex	formation.	If	the	rate	of	the	transient	complex	forming	the	native	complex	through	
conformational	rearrangement,	or	R*L	→	C,	is	significantly	faster	than	the	rate	of	unbinding,	
or	 R*L	 →	 R	 +	 L,	 then	 the	 transient	 complex	 theory	 used	 in	 TransComp	 states	 that	 the	
association	rate	is	approximately	equal	to	the	rate	of	transient	complex	formation,	or	R	+	L	
→	R*L	(Qin	et	al.,	2011).	In	short,	the	theory	holds	when	kon	>>	kcat.	This	situation	describes	
















SDA7	 is	 a	 tool	 developed	 to	 estimate	 protein-protein	 association	 rate	 constants	 using	 a	
Brownian	 Dynamics	 approach	 to	 bind	 rigid	 solutes.	 SDA	 has	 been	 used	 in	 studies	 of	
association	of	soluble	proteins	to	membrane	bound	proteins	(Spaar	et	al.,	2009)	and	drug-
receptor	 complexes	 (Elsawy	 et	 al.,	 2012).	 SDA7	 uses	 the	 Northrup-Allison-McCammon	
method	to	calculate	the	association	constant	kon	(Northrup	et	al.,	1984),	using	ready-made	
interaction	 grids	 to	 calculate	 forces	 acting	 on	 individual	 atoms,	 reducing	 computational	








Predicting	 how	 tightly	 a	 protein-ligand	 complex	 is	 bound	 is	 a	 vital	 step	 in	 estimating	 the	
dissociation	 rate	 of	 a	 ligand-protein	 complex.	 PRODIGY	 is	 a	 bioinformatics	 tool	 that	
estimates	 the	 dissociation	 constant	 kd	 by	 looking	 at	 the	 number	 of	 connections	 between	
each	protein	and	individual	surface	features,	utilizing	the	identified	correlation	between	the	
number	of	contact	points	between	two	proteins	in	a	complex	and	its	binding	affinity	while	
considering	 structural	 properties	 away	 from	 the	 interface	 (Kastritis	 et	 al.,	 2011,	 2014).	
PRODIGY	has	been	shown	to	be	a	more	accurate	predictor	of	kinetic	parameters	than	similar	
models.	By	using	the	binding	affinity	benchmarking	algorithm	established	 in	Kastritis	et	al.	
(Kastritis	 et	 al.,	 2014),	 PRODIGY	 has	 become	 one	 of	 the	 best	 performing	 protein-protein	
binding	affinity	predictors	that	are	publically	available	(Xue	et	al.,	2016).	The	chemical	and	




The	 problem	 of	 modelling	 and	 combining	 the	 variety	 of	 factors	 that	 determine	 protein-
protein	 kinetic	 rates,	 including	 structural	 diffusion,	 electrostatics,	 short-range	 interaction	
properties	and	solvent	properties,	has	seen	significant	effort	applied	 to	 it	by	 the	scientific	
community	in	recent	years.	Methods	have	been	developed	to	consider	the	involvement	of	
macromolecular	crowding	(Martinez	et	al.,	2015;	Mereghetti	et	al.,	2010).	Two-dimensional	
models	 considering	 the	 role	 of	 hydrodynamic	 forces	 are	 available,	 however	 standalone	
results	 from	 these	 algorithms	 are	 not	 sufficiently	 accurate	 (Cheung	 and	 Konstantopoulos,	




Most	 proteins	 within	 a	 cell	 become	 functional	 when	 part	 of	 a	 complex	 or	 a	 quaternary	
structure,	 including	 simple	 dimers	 or	 more	 advanced	 oligomers	 and	 complexes.	 PPIs	 are	
vital	in	biological	processes	such	as	cell	signaling,	proteolysis	and	protein	transport	(Aldridge	
et	al.,	2006;	Saunders	et	al.,	2005;	Yvan-Charvet	et	al.,	2010).	Proteins	which	remain	in	their	










Quaternary	 structures	 include	 oligomers	 and	 complexes	 with	 different	 quantities	 of	
subunits.	Complex	formation	often	serves	to	activate	or	inhibit	one	of	the	protein	subunits	












(Critical	 Assessment	 of	 PRediction	 of	 Interactions),	 a	 community	 study	 into	 modelling	
quaternary	 structure	 from	 tertiary	 structure	 and	 evaluating	 docking	 procedures,	 have	
recently	collaborated	with	CASP	in	order	to	assess	oligomeric	model	quality	and	to	evaluate	
docking	procedures.	Recent	results	have	shown	that	 the	oligomeric	state	of	a	protein	 (i.e.	




Experimental	 elucidation	 of	 quaternary	 structure	 can	 be	 performed	 with	 multiple	
experimental	 techniques.	 Electron	 microscopy	 can	 be	 used	 to	 ascertain	 large	
macromolecular	 complex	 structures	 due	 to	 the	 high	 resolution	 provided	 (Nayeem	 et	 al.,	
1994).	 X-ray	 crystallography	 can	 also	 be	 used;	 however	 crystallization	 can	 be	 particularly	









Homology	 modelling	 methods	 are	 generally	 considered	 to	 provide	 the	 most	 accurate	
structural	models	of	tertiary	structures	from	amino	acid	sequences.	However,	this	can	often	
lead	to	template	bias,	where	structures	are	more	likely	to	take	physiological	properties	from	
the	 homologue	 templates	 used	 in	 model	 formation.	 Refinement	 methods	 to	 improve	
predicted	 structure	 quality	 and	 alleviate	 template	 bias	 have	 seen	 significant	 progress	 in	
recent	years	 in	both	global	whole-structure	accuracy	and	in	 local	regions.	Potential	Energy	
Minimization	 (PEM)	 through	alterations	 to	 the	backbone,	 side	 chain	 rebuilding	 to	 remove	
steric	 clashes	 and	 structural	 relaxation	 can	 lead	 to	 refined	 structural	 targets	 (Heo	 et	 al.,	





Comparing	 oligomeric	 and	 complex	 structures	 can	 be	 performed	 with	 MM-Align,	 which	
provides	an	alignment	for	two	proteins	that	is	independent	of	primary	sequence	(Mukherjee	
and	 Zhang,	 2009).	 TM-Align	 will	 perform	 a	 similar	 function	 for	 comparing	 monomers,	
however	multimer	functionality	is	not	provided	(Zhang	and	Skolnick,	2005).	Chains	for	input	
proteins	 could	 be	 merged	 into	 a	 single	 contrived	 monomer	 and	 used	 with	 TM-Align,	
although	MM-Align	provides	additional	 functionality	 that	prevents	cross-chain	alignments.	














searching	 spatial	 arrangements	 of	 the	 proteins	 involved	 and	 using	 an	 energy-minimizing	
scoring	 function	 to	 isolate	 a	 particular	 configuration	 (Ritchie,	 2008).	 These	 methods	 will	
produce	 a	 list	 of	 potential	 structures,	 including	 the	 correct	 near-native	 solution;	 however	
isolating	this	structure	from	many	is	a	prevalent	challenge	to	bioinformaticians	interested	in	
this	 field.	 Knowledge	 of	 solvent	 accessibility,	 binding	 site	 details	 and	 local	 docking	
approaches	 can	 all	 be	 used	 to	 limit	 the	 number	 of	 potential	models	 available	 and	 obtain	




There	 are	 currently	more	 than	 60	 different	 docking	 tools	 available	 to	 predict	 quaternary	
structure	from	protein	subparts	(Pagadala	et	al.,	2017).	Each	of	these	tools	are	designed	to	
combine	 protein	 subunits	 together	 to	 form	 a	 complex	 or	 oligomer,	 however	 multiple	
different	 methods	 are	 used	 for	 docking,	 providing	 varying	 accuracy	 depending	 on	 the	
methods	and	inputs	used.	HexDock	is	a	fast	Fourier	transform	(FFT)	based	protein	docking	
algorithm	(Ritchie	and	Venkatraman,	2010).	Hex	utilizes	a	‘spherical	polar	Fourier	technique’	
(SPF),	 where	 rotational	 correlations	 have	 been	 used	 as	 a	 replacement	 for	 a	 standard	
Cartesian	grid.	FRODOCK,	a	fast-rotational-docking	approach	has	performed	benchmarking	
tests	 showing	 a	 significant	 performance	 improvement	 using	 this	 method	 (Garzon	 et	 al.,	
2009).	 Multiple	 potential	 configurations	 are	 produced	 by	 Hex,	 which	 are	 ordered	 by	 an	
energy	based	scoring	function	to	provide	an	optimal	docking	solution.		
	
RosettaDock	 is	 a	 tool	which	 can	be	used	 to	perform	 local	docking.	 Local	docking	 requires	
knowledge	of	 the	binding	 locations	of	each	protein.	 Local	docking	 searches	a	 subspace	of	
the	total	possible	spatial	configurations,	requiring	the	user	to	provide	an	approximation	of	
the	 output	 structure	 by	 ensuring	 that	 binding	 sites	 are	 facing	 towards	 each	 other.	 Local	
docking	provides	a	structure	closer	to	the	native,	as	computational	time	spent	searching	for	
the	correct	spatial	conformation	is	significantly	reduced,	allowing	for	a	focus	on	short-range	









The	 binding	 of	 two	molecules	 in	 a	 solvent	 can	 be	 described	 by	 the	 Gibbs	 Free	 Energy,	 a	







entropy	 respectively,	 T	 is	 the	 temperature	 in	 Kelvin	 and	 R	 is	 the	 ideal	 gas	 constant.	 A	 kd	




Studying	 the	 difference	 in	 Gibbs	 free	 energy	 between	 a	 mutation	 and	 its	 wildtype	 can	





The	 study	 of	 electrostatics	 and	 its	 role	 in	 PPI	 has	 been	made	 simpler	 through	 the	 use	 of	
continuum	 solvation	 models.	 To	 perform	 electrostatic	 potential	 calculations,	 commonly	
performed	with	MD	 and	 BD	 simulations,	 full	 all-atom	 structural	 data	 and	 atomic	 charges	















Energy	 Refinement)	 or	 CHARMM	 (Chemistry	 at	 Harvard	 Macromolecular	 Mechanics)	














1	 ADAM17	 TIMP3	 	
2	 CCL2	 CCR2	 	
3	 CCL5	 CCR5	 	
4	 CMA1	 MMP1	 	
5	 CSF1	 CSF1R	 	
6	 CXCL10	 CXCR3	 	
7	 CXCL11	 CXCR3	 	
8	 CXCL9	 CXCR3	 	






11	 IL1B	 IL1R1	 	
12	 IL10	 IL10RA	 	
13	 IL12	 IL12R	 IL12	and	IL12R	are	Heterodimeric	
14	 IL17A	 IL17RA	 	
15	 IL18	 IL18R	 IL18R	is	Heterodimeric	









17	 IL21	 IL21R	 	
18	 IL33	 IL1RL1	 	
19	 IL4	 IL4R	 	
20	 IL5	 IL5R	 IL5	is	Homodimeric	
21	 IL6	 IL6R	 	
22	 PDGFA	 PDGFRA	 	
23	 PDGFB	 PDGFRB	 PDGFB	is	Homodimeric	
24	 PDGFA	 PDGFRB	 	






27	 TIMP1	 MMP1	 	
28	 TIMP1	 MMP2	 	
29	 TIMP1	 MMP3	 	
30	 TIMP1	 MMP9	 	
31	 TIMP1	 MMP13	 	
32	 TIMP2	 MMP1	 	
33	 TIMP2	 MMP2	 	
34	 TIMP2	 MMP3	 	
35	 TIMP2	 MMP9	 	
36	 TIMP2	 MMP13	 	
37	 TIMP3	 MMP1	 	
38	 TIMP3	 MMP2	 	
39	 TIMP3	 MMP3	 	
40	 TIMP3	 MMP9	 	
41	 TIMP3	 MMP13	 	
42	 TIMP4	 MMP1	 	
43	 TIMP4	 MMP2	 	
44	 TIMP4	 MMP3	 	
45	 TIMP4	 MMP9	 	
46	 TNFA	 TNFR	 TNFR	is	Heterodimeric	
	
 Establishing	oligomeric	status	

































































































To	 provide	 a	 complex	 as	 close	 to	 the	 native	 as	 possible,	 a	 local	 docking	 procedure	 was	
undertaken.	A	local	docking	procedure	requires	knowledge	of	the	native	binding	sites,	and	
binding	 simulations	 are	 performed	 on	 a	 subset	 of	 the	 total	 number	 of	 possible	
















To	 allow	 for	 the	 local	 docking	 procedure	 to	 take	 place	 effectively,	 near-binding-sites	 for	
each	model	 isolated	as	previously	described	are	positioned	 to	 face	 the	other	before	 local	
docking	 begins.	 For	 each	 protein	 structure	 within	 the	 dataset	 generated	 in	 Chapter	 4,	 a	













100Å	apart	before	 the	 rotational	matrices	are	calculated,	and	 returned	 to	10Å	apart	after	
rotation	has	been	calculated.	Rotational	and	translational	matrices	are	applied	to	our	PDB	





was	used	to	predict	complex	structure	 for	each	 interaction	defined	 in	Table	5.1,	using	the	
mutation	data	isolated	in	Chapter	4.		
	
Once	 a	 structure	 was	 obtained	 with	 rotational	 near-binding-site-distance	 minimization,	
these	structures	are	relaxed	using	the	Rosetta	‘Relax’	protocol.	Relax	performs	a	simple	all-
atom	refinement	 that	acts	as	a	pre-processing	step	 for	 future	docking,	 through	continued	





























The	Chimera	derived	 structures	 are	detailed	 in	 the	previous	 step	were	provided	as	 input,	
with	an	output	location	for	the	PDB	file	and	the	score	file	specified	using	the	commands	–
in:file:s,	 -out:path:pdb	 and	 –out:path:scorefile	 respectively.	 RosettaRelax	 returns	multiple	








local	 docking	 procedures,	 providing	 complexes	 closer	 to	 the	 native	 than	 global	 docking	
procedures	at	a	reduced	computational	cost.	The	relaxed	structures,	derived	using	the	near-
binding-site	 information	 as	 described	 in	 section	 5.2.4	 and	 the	 Rosetta	 Relax	 protocol	 are	






















based	scoring	 functions,	 the	total	score	and	 interface	score,	as	defined	 in	 (O’Meara	et	al.,	
2015).	The	interface	score	is	calculated	as	the	total	complex	score	minus	the	score	for	each	













our	 input	protein,	 structure-based	 templates	were	utilized	 if	 they	have	a	TM-Score	higher	
than	0.5	when	aligned	 to	 the	 input	protein.	 Failing	 this,	 if	no	appropriate	 templates	were	




web	 servers	 –	 http://galaxy.seoklab.org/refine	 and	 http://galaxy.seoklab.org/homomer.	
Both	web	servers	are	running	on	Linux	clusters	of	2.33GHz	Intel	Xeon	8-core	processors	(4	
















Compute	Device	 CPU	 Hex	 has	 functionality	 to	 perform	 quick	
docking	 simulations	 on	 a	 GPU	 unit,	















SDA7	 and	 TransComp	 were	 both	 considered	 to	 calculate	 association	 rate	 using	 our	
predicted	 protein	 structures.	 To	 compare	 SDA	 and	 TransComp	 results,	 a	 collection	 of	 13	
structures	with	known	kon	were	found	and	used	as	inputs	for	both	methods.	Outputs	were	















While	 TransComp	 is	 an	 excellent	 tool	 providing	 strong	 predictions	 of	 association	 kinetics	
from	 tertiary	 structure,	 some	 minor	 alterations	 were	 required	 to	 be	 made	 from	 the	
downloadable	 version	 of	 TransComp.	 Due	 to	 a	 compatibility	 issue	 with	 version	 16.04	 of	
Ubuntu,	 line	 13	 of	 Sample.sh	 required	 to	 be	 changed	 to	 'nconfOne=100000’	 to	 prevent	
excessive	 rotational	 and	 translational	 space	 sampling.	 In	 addition,	 due	 to	 the	 size	 of	 the	
macromolecules	 returned	by	 RosettaCommons	Docking	 and	Hex,	 coordinates	 in	 PQR	 files	
required	8	digits	to	be	scored,	removing	necessary	whitespace	from	the	input	file.	To	correct	




TransComp	 was	 used	 to	 generate	 association	 rates	 for	 each	 interaction	 subunit.	
Prerequisites	 include	 APBS	 (Adaptive	 Poisson-Boltzmann	 Solver)	 (Baker	 et	 al.,	 2001)	 for	








Occasionally,	 TransComp	would	 be	 unable	 to	 generate	 a	 transient	 complex	 from	 the	 hex	




















PRODIGY	 results	were	combined	with	TransComp	results	 to	predict	a	koff	 value.	 	PRODIGY	





proteins	 are	 considered	 homodimers,	 with	 27	 mutations	 giving	 a	 total	 of	 32	 different	








Interferon-Gamma	 4	 1EKU	 IFNG	
Interleukin	5	 8	 3QT2	 IL5	
















































































































To	 evaluate	 the	 accuracy	 of	 TransComp	 and	 SDA,	 a	 collection	 of	 experimentally	 derived	

























160	 7.4E+05	 5.6E+06	 7.6E+00	 4.21E+7	 1.90E+9	 3/6.0	 5.69E+1	















































100	 1.5E+08	 5.8E+08	 3.9E+00	 9.00E+8	 7.20E+6	 4/6.0	 6.00E+0	
PDB	 –	 PDB	 Code	 for	 experimentally	 derived	 structure;	 C	 –	 Chain	 IDs	 in	 PDB;	 Desc	 –	
Description	of	the	interaction;	IS	–	Ionic	Strength	(in	mM);	Ex	kon	–	Experimentally	derived	kon	
value;	TC	–	TransComp	prediction;	T	Acc	–	TC/(Ex	kon);	 SDA	–	webSDA	prediction;	Range	–	
Upper	 limit	of	SDA	prediction;	SDARC	–	Reaction	criteria	used	 in	SDA	 to	 isolate	best	 result	
(No	of	Contact	Points/Distance	Apart);	SDA	Acc	–	(SDA/(Ex	kon)	
	
Within	 this	 proof-of-concept	 test,	 10	 of	 our	 TransComp	 results	 were	 within	 an	 order	 of	
magnitude	 from	 the	 reported	 results,	 while	 only	 6	 SDA7	 results	 were	 within	 the	 same	
window.	Additionally,	 SDA7	 returns	a	 range	of	 results,	 requiring	 the	definition	of	 reaction	
criteria	which	would	return	a	range	of	results	that	would	need	to	be	arbitrarily	reduced	into	









TransComp	 was	 used	 to	 calculate	 association	 rates	 were	 calculated	 for	 1119	 complexes	
involved	in	atherosclerosis.	Of	these	complexes,	835	returned	an	association	rate.	Failure	in	
calculating	an	association	rate	was	due	to	the	interaction	requiring	an	intermediary	step,	or	
computational	 intensity	 restrictions.	 Association	 rates	 were	 not	 calculated	 when	 an	
individual	 interaction	would	 take	 longer	 than	3	months	 to	process	on	a	single	core	virtual	
machine.	 An	 exhaustive	 list	 of	 association	 rate	 values	 can	 be	 found	 in	 Appendix	 5.	 The	
median	of	the	association	rates	is	1.5	x	105,	with	an	interquartile	range	of	2.142	x	106.	
	
Some	 results	obtained	were	evidently	 erroneous.	 For	example,	 the	binding	of	CSF1R-001-
245	to	CSF1-001	returned	a	kon	value	of	3.81	x	10-188.	Such	issues	however	do	not	seem	to	
be	 an	 issue	 for	 the	 fast-binding	 proteins;	 TransComp	 estimation	 of	 the	 association	 rate	
between	MMP3-001-45	and	TIMP3-001	 is	5.61	x1010,	which	 is	a	value	within	 the	 range	of	












MATLAB’s	 polyfit	 function	 was	 used	 to	 generate	 the	 line	 of	 best	 fit.	 Figure	 5.5	 shows	 a	
comparison	between	the	variance	in	kon	between	a	mutation	and	its	wildtype	alongside	the	
TM-Score	for	an	alignment	between	the	mutated	protein	and	its	wildtype.	The	line	of	best	
fit	 was	 generated	 in	 Matlab	 using	 the	 polyfit	 method.	 Figure	 5.5	 suggests	 a	 correlation,	
albeit	minor,	 between	 increased	 variation	within	 a	 protein	 structure	 leading	 to	 increased	






TM-Score	 is	 shown	 in	 Figure	 5.6.	 The	 mean	 of	 the	 kd	 values	 is		





























while	 assessing	 interaction	 9	 (Appendix	 3,	 Table	 1)	 in	 the	 absence	 of	whole	 protein	 data	
(Ogiso	et	al.,	2002).	
	
Homodimeric	wildtype	 structures	 derived	 from	 amino	 acid	 sequences	 during	 this	 chapter	
have	 a	mean	RMSD	of	 3.015A,	while	our	heterodimeric	 structures	have	 a	mean	RMSD	of	
4.35A.	 The	 sample	 size	 is	 too	 small	 to	make	 sweeping	 conclusions,	 however	 strong	 near-
native	 structures	 have	 been	 established	 for	 our	 wildtype	 data,	 giving	 confidence	 in	 the	
structures	generated	using	mutation	data.		
	






When	 pipelining	 quantitative	 prediction	 methods	 together,	 compound	 error	 can	 quickly	
become	a	problem.	To	get	to	the	stage	where	we	can	predict	association	rates	from	amino	
acid	sequences	 in	 this	 thesis,	we	have	converted	primary	structure	 into	 tertiary	 structure,	
into	 quaternary	 structure	 (potentially	 involving	 oligomers),	 into	 an	 association	 and	
dissociation	 rate	 prediction.	 Each	 of	 these	 stages	 introduces	 a	 degree	 of	 uncertainty,	
decreasing	 confidence	 in	 our	 results.	 In	 addition,	 it	 is	 distinctly	 possible	 that	 a	 minor	
discrepancy	 early	 within	 the	 algorithmic	 pipeline	 can	 propagate	 into	 a	 major	 divergence	
from	the	expected	result	by	the	time	all	aspects	of	the	methodology	have	been	applied.	
	
While	 we	 can	 assess	 accuracy	 for	 individual	 components	 of	 our	 methodology	 such	 as	
aligning	 predicted	 structures	 or	 association	 rates	 to	 experimentally	 validated	 ones,	
calculating	how	a	variation	in	an	uncertain	area	of	a	protein	structure	prediction	will	affect	
our	kon	prediction	is	a	significantly	more	challenging	task.	However,	as	confidence	grows	in	
the	 predictive	 power	 of	 each	 of	 the	 subsections	 of	 our	 pipeline,	 confidence	 grows	 in	 the	
complete	 methodology.	 Protein	 structure	 prediction	 methods	 and	 docking	 methods	 are	






and	 force-fields	 and	 continuum	 solvation	methods	used	 in	 association	 rate	prediction	 are	







result	with	 the	addition	of	 reaction	criteria	 (i.e.	 the	distance	between	proteins	where	 the	
short-range	 interactions	begin	 to	occur	 and	 the	number	of	 contact	 points	 involved	 in	 the	





used	 to	 calculate	 equilibrium	 states	 and	 to	 estimate	 how	quickly	 the	 system	 responds	 to	
external	 stimuli,	 such	 as	 a	 drug	 or	 another	 competitor.	 Within	 the	 context	 of	 systems	
biology,	binding	kinetics	can	be	used	to	parameterize	a	mathematical	model	to	provide	an	
increased	 level	 of	 biological	 relevance.	 Currently,	 having	 ascertained	 a	 collection	 of	




While	 sections	 of	 the	 described	 pipeline	 are	 state-of-the-art	 and	 utilize	 the	 strongest	
publically	 available	 algorithms	 developed	 by	 the	 computational	 biology	 community,	
improvements	could	be	made	to	the	procedure	if	computational	intensity	constraints	were	
removed.	Increasing	the	amount	of	time	I-TASSER	spends	on	refinement	on	structural	areas	
with	 insufficient	 homologous	 data	 could	 lead	 to	 an	 increase	 in	 the	 quality	 of	 the	 input	
structures,	 and	 subsequently	 the	 output	 binding	 kinetics.	 Not	 all	 of	 the	 computationally-
calculated	 docked	 structures	 were	 used	 as	 TransComp	 inputs.	 Due	 to	 computational	










of	 computational	 constraints	would	 have	 allowed	 for	 the	 calculation	of	 these	 values.	 The	
quality	 of	 our	 quaternary	 structure	 is	 highly	 dependent	 on	 the	 availability	 of	 structural	
information	 leading	 to	 an	 informed	 docking	 simulation.	 Increasing	 the	 number	 of	 docks	
produced	 by	 both	 Rosetta	 and	 Hex	 to	 be	 slimmed	 down	 using	 their	 respective	 scoring	
functions	would	 increase	 the	 possibility	 of	 a	 near-native	 structure	 being	 isolated.	 Rosetta	
global	 docking	 algorithms	 could	 also	 have	 been	 used	 instead	 of	 Hex	 if	 not	 for	 the	 great	








complex	 significantly	 faster	 and	more	 often	 than	 it	 unbinds	 into	 its	 constituent	 parts	 (or	
‘diffusion-limited’)	 can	 be	 estimated	 more	 accurately	 with	 the	 TransComp	 methodology.	
















amino	 acid	 sequence	 has	 the	 potential	 to	 benefit	 mathematical	 modelling	 and	
computational	 drug	 design	 communities.	 Kinetic	 parameter	 availability	 is	 sparse	 for	most	
known	 PPIs,	 and	 the	 ability	 to	 initially	 parameterize	 a	 pathway	 in	 the	 absence	 of	





























Computational	 models	 are	 a	 means	 of	 solving	 a	 problem,	 not	 the	 end	 result.	 Without	
relating	 model	 results	 back	 to	 pathway	 dynamics	 to	 study	 the	 underlying	 biology	 and	




all	 others	 included	 within	 the	 model.	 Networks	 of	 biological	 processes	 which	 utilize	
experimentally	 derived	 data	 to	 maximize	 biological	 relevance	 have	 led	 to	 remarkable	




proteomic,	 metabolomic	 and	 transcriptomic	 data	 being	 generated	 within	 the	 last	 two	
decades.	 Placing	 this	 data	 in	 the	 public	 domain	 or	 facilitating	 methods	 for	 data	 sharing	
allows	for	the	wider	scientific	community	to	benefit	and	utilize	these	data	as	part	of	a	wide	
range	 of	 experiments	 (Chervitz	 et	 al.,	 2011).	 Similar	 to	 mathematical	 modelling,	 the	








Reparameterising	mathematical	models	 as	 part	 of	 a	 program	of	 personalized	or	 stratified	
medicine	is	a	fledgling	field,	however	important	work	has	been	undertaken	to	demonstrate	
the	 possibilities.	 The	 core	 concept	 relies	 upon	 calculating	 a	 set	 of	 quantitative	
measurements	of	biological	activity	to	stratify	patient	groups	that	can	be	applied	to	a	stable	







models	 have	 been	 developed	 which	 suggest	 a	 stratification	 method	 for	 patients	 with	
chronic	 myeloid	 leukemia	 (Brehme	 et	 al.,	 2016).	 Models	 for	 dopamine	 metabolism	 and	
folate-mediated	one	carbon	metabolism	have	been	developed	and	reparametrized	based	on	
experimentally-derived	 enzyme	 activity	 data,	 which	 has	 been	 connected	 to	 population	
genetics	 to	 provide	 a	 potential	 stratification	 methodology	 (Nijhout	 et	 al.,	 2015).	 Patient	
stratification	 has	 previously	 been	 achieved	 through	 reparameterisation	 of	 mathematical	
models,	however	gene	expression	levels	were	used	rather	than	binding	kinetics	(Björnson	et	
al.,	 2015).	 Combining	 enzyme	 kinetics	 and	 population	 genetics	 as	 part	 of	 a	mathematical	
model	 reparameterisation	 program	 could	 lead	 to	 the	 discovery	 of	 different	 disease	




Computational	 models	 can	 provide	 a	 series	 of	 benefits	 regarding	 the	 elucidation	 of	
biological	 processes.	 Two-state	 discrete	 Boolean	 models	 have	 been	 used	 to	 represent	
biological	processes	such	as	apoptosis	(Schlatter	et	al.,	2009)	and	circadian	rhythms	(Akman	
et	 al.,	 2012).	 Fully	 quantitative	 models,	 such	 as	 ODE	 models,	 can	 generate	 therapeutic	
hypotheses	 such	 as	 the	 identification	 of	 predictive	 biomarkers	 and	 the	 generation	 of	
potential	 multi-drug	 therapies.	 Stratifying	 patient	 groups	 based	 on	 biomarker	 data	 and	
subsequent	 therapeutic	 selection	 have	 seen	 an	 increase	 in	 the	 success	 of	 breast	 cancer	
treatment	 (Yeo	 et	 al.,	 2014).	 Through	 the	 development	 of	mathematical	models	 of	 small	
sections	of	biological	systems,	and	combining	them	once	the	underlying	dynamics	are	well	
understood,	 larger	 models	 are	 being	 created	 by	 the	 systems	 biology	 community	 to	
represent	whole	biological	systems.	A	whole	cell	model	of	Mycoplasma	genitalium	has	been	
produced	 (Karr	 et	 al.,	 2012a).	 Ideally,	 if	 computational	 models	 can	 be	 developed	 to	
accurately	represent	the	underlying	physiology	while	representing	whole	biological	systems,	
an	 in	 silico	 clinical	 trial	 could	 be	 developed	 before	 patient	 trials,	 giving	 insight	 into	 drug	









Mathematical	 modelling	 has	 led	 to	 optimization	 of	 multi-drug	 therapeutics	 in	 multiple	
diseases.	 Models	 have	 been	 developed	 of	 breast	 cancer	 signaling	 networks	 where	 an	
optimal	 therapeutic	blockade	was	hypothesized	 to	bypass	compensatory	circuits	and	 limit	
tumor	 growth,	 a	 hypothesis	 which	 was	 subsequently	 validated	 on	 mice	 (Kirouac	 et	 al.,	
2013).	 Systems	 pharmacology	 methods	 have	 been	 used	 to	 suggest	 drug	 targets	 for	 the	
treatment	 of	 Alzheimer’s	 disease	 (Nicholas	 et	 al.,	 2013).	 Using	 systems	 pharmacology	
methods	 to	 study	 the	 effects	 of	 common	 drugs	 on	 atherosclerosis	 progression	 has	 been	





















Connecting	 the	 relationship	 between	 the	 quantities	 of	 reactants	 and	 products	 in	 this	
manner	 allows	 for	 the	 development	 of	 models	 of	 whole	 biological	 systems;	 however	 a	
collection	 of	 assumptions	 are	 required	 in	 the	 development	 of	 a	model	 of	 this	 type.	 This	






would	differ	 in	 a	 system	with	an	 increased	number	of	 transitory	 structures.	 It	 is	 assumed	
that	protein	A	is	not	altered	by	binding	and	is	freely	available	to	bind	to	other	entities	once	
this	interaction	is	complete,	and	that	the	transitory	state	binding	can	be	reversed.	Finally,	it	

























can	 lead	 to	 a	 reduction	 in	 reaction	 velocity.	 These	 substances	 can	 be	 a	 natural	 part	 of	 a	
homeostatic	 biological	 system,	 such	 as	 epidermal	 growth	 factor	 (EGF)	 inhibiting	 SMC	
production	 of	 elastin	 (Ichiro	 et	 al.,	 1990),	 or	 as	 an	 external	 source	 like	 a	 targeted	 drug.	
Modelling	 the	 introduction	 of	 a	 drug	 into	 a	 biological	 system	 designed	 to	 compete	 with	
other	 reactants	 for	 a	 particular	 receptor	 can	 be	 completed	 with	 an	 extension	 to	 the	
Michaelis-Menten	methodology:		








































true	 global	 minimum	 of	 the	 problem	 requires	 some	 nuance.	 Simulated	 annealing	 is	 an	
optimization	 technique	 relying	 on	 probabilistic	methods	 to	 find	 a	 global	minimum	where	
multiple	local	minima	exist.	Genetic	algorithms	are	a	technique	which	imitates	the	biological	








produce	 a	 solution	 for	 the	 next	 generation.	 As	 the	 number	 of	 generations	 increases,	






Ascertaining	 genetic	 differences	 between	 population	 subgroups	 can	 be	 beneficial	 during	
computational	 analyses	 relating	 to	 stratified	 medicine.	 Quantification	 of	 changes	 in	
molecular	interactions	due	to	genetic	variance	can	be	used	to	reparameterize	mathematical	
models,	 potentially	 leading	 to	 population	 specific	 insights	 into	 disease	 pathogenesis.	
Changes	 in	 binding	 kinetics	 in	 one	 specific	 interaction	 can	 cause	 unforeseen	 downstream	
effects,	seemingly	unrelated	to	the	initial	interaction.	Through	systems	biology	methods	and	
mathematical	modelling,	downstream	effects	can	be	predicted	and	therapeutic	hypotheses	


















































avoid	 reporting	on	subtleties	hidden	within	 the	model.	Atheroma	size	could	be	 related	 to	
the	 lesion	 content	 of	macrophages,	 foam	 cells	 and	 smooth	muscle	 cells.	 Collagen,	 elastin	
and	 other	 ECM	 elements	 are	 vital	 when	 considering	 plaque	 volume	 and	 lesion	 stability.	
Concentrations	 of	MMPs	 and	 their	 inhibitors	 are	 key	when	 considering	 chance	 of	 plaque	
rupture.	 Plasma	 concentrations	 of	 biological	 entities	 have	 the	 potential	 to	 be	 useful	















Kinetic	 parameters	 kM	 and	 kcat	will	 be	 altered	 by	 the	 changes	 in	 kon	 and	 koff	 calculated	 in	
Chapter	5.	Equation	6-2	(section	6.1.4)	has	been	used	to	calculate	how	this	mutation	data	
will	 alter	 kcat	 and	 kM,	 to	 allow	 for	 per-mutation	 reparameterisation	 of	 the	 mathematical	
model.	 However,	 due	 to	 compound	 error	 in	 the	 derivation	 of	 binding	 kinetics	 from	
predicted	structure	and	the	estimation	of	certain	kinetic	parameters	used	in	the	model,	the	















kon	 and	 koff	 have	 been	 calculated	 as	 described	 in	 Chapter	 5,	 and	 kcat	 and	 kM	 have	 been	














R = 	, ∗ C ∗ D	
	
Where	 k	 =	 kcat	 /	 kM;	 v	 =	 reaction	 velocity;	 A	 and	 R	 are	 reactants	 within	 the	 interaction.	
Through	rearrangement	of	Equation	6-3,	kcat	is	calculated	by:	
Equation	6-4	





























, ∗ . ∗ 	0W ∗ 	0X …









To	 provide	 a	 quick	 insight	 into	 the	 disease	 altering	 dynamics	 of	 a	 mutation,	 a	 scoring	
function	 has	 been	 developed	 to	 provide	 a	 scalar	 value	 representing	 a	 combination	 of	
atheroma	size,	cell	density,	protein	content	and	collagen	content.	To	assess	the	quality	of	a	
simulation,	a	cell	count	and	the	collagen	content	of	total	 intimal	protein	(as	a	percentage)	
are	 calculated.	 The	 cell	 count	 includes	 total	 abundances	 of	 smooth	 muscle	 cells,	





























mutation	 kcat	 values	 were	 paired	 with	 the	 interaction	 kcorr	 as	 defined	 in	 section	 6.2.1.	
Wildtype	values	were	 successfully	 calculated	 for	all	 interactions	excluding	MMP1→TIMP3,	
MMP1→TIMP4	 and	 PDGF→	 PDGFR,	 and	 as	 such	 mutations	 involving	 these	 interactions	












wildtypes	 for	 each	 model	 protein.	 Population	 genetics	 data	 was	 isolated	 from	 the	 1000	
Genome	Project	using	the	EnsEMBL	API	as	described	in	Section	4.2.1.	For	each	population,	a	
search	was	 undertaken	 to	 isolate	mutations	within	 phase	 3	 of	 the	 1000	 Genome	 Project	
with	 a	 >	 50%	 variant	 allele	 frequency	 (VAF).	 If	 such	 an	 allele	 exists	 for	 a	 population	









































































Where	 the	 AScore	 is	 as	 defined	 in	 section	 6.2.2,	 D	 is	 the	 number	 of	 drugs	 applied	 to	 the	
system,	 and	 C(n)	 is	 the	 concentration	 of	 drug	 n.	 Drug	 concentrations	 were	 set	 to	 be	
between	0	 and	1000	mM,	 and	 all	 ki	 values	were	 assumed	 to	be	1	mM.	 Simulations	were	













In	 order	 to	 develop	 a	 description	 of	 mutations	 that	 are	 representative	 of	 a	 population,	
genetic	profiles	were	developed	as	described	in	section	6.2.4.	 In	situations	where	multiple	
mutations	 exist	 for	 the	 same	 gene,	 and	 ultimately	 the	 same	 protein,	 the	 most	 common	











































































































CSF1R-001-362	 7.32E+4	 0.32838	 0.0994	 MA	 5.31E-6	 22	














IL12RB1-001-214	 4.15E+03	 1.43E-18	 8.0970	 100000	 21.4029	 39	
CSF1-001-408	 5.13E+04	 0.063048	 0.0994	 MA	 0.1567	 22	











Ascore	 Top	 10	 Atherogenic	
Variants	
Ascore	
CCR2-001-355	 0.0147	 CXCR3-002	 90.0790	
CCR2-002-64	 0.0171	 CXCL11-003-29	 46.2952	
CCL2-001-69	 0.0207	 CXCL11-001-73	 18.5207	
CSF1-002-461	 0.0228	 CXCL11-003	 12.4330	
CXCL10-001-58	 0.0592	 CXCL9-001-101	 6.1296	
CCL5-001-68	 0.0625	 CCL5-002-5	 4.3096	
CCL5-002-68	 0.0625	 CCL5-001-5	 4.3096	
IL4-201-134	 0.0675	 MMP9-001-279	 1.7972	
CCL5-001-40	 0.0679	 TIMP2-008-92	 1.7972	
CCL5-002-40	 0.0679	 TIMP1-002-10	 1.7971	
	
 Population	subgroup	specific	results	












from	 these	 populations	within	 the	 1000	Genome	 Project	 dataset.	MMP9	 is	 a	 collagenase	
involved	in	the	degradation	of	collagen	and	elastin.	EGF	is	a	key	player	in	the	regulation	of	
elastin	 synthesis.	 Variation	within	 rates	 of	 extra-cellular	matrix	 synthesis	 and	degradation	












001-64	 has	 caused	 a	 severe	 reduction	 in	 the	 rate	 of	 monocyte	 recruitment,	 and	
subsequently	atheroma	size.	Quantitatively,	it	is	clear	that	this	result	is	not	representative	of	



















MMP9	 and	 CSF1R	 mutations	 were	 found	 to	 be	 prevalent	 in	 Southern	 Han	 Chinese	
populations.	 Alongside	 the	 lesion	 stability	 consequences	 caused	 by	MMP9,	 a	mutation	 in	
CSF1R	 alters	 the	 rate	 by	 which	 monocytes	 will	 differentiate	 into	 macrophages.	 This	
mutation	has	caused	a	slowing	in	the	rate	of	differentiation,	reducing	the	relevant	kcat	value	















2016),	 however	 to	 reduce	 the	 computational	 difficulty	 of	 calculating	 association	 rates	 for	
this	interaction	we	only	considered	one	alpha	chain	of	the	receptor.	Within	our	model,	this	














known	 to	 be	 experimentally	 heterodimeric,	 however	 to	 reduce	 computational	 costs	 in	
estimating	association	rates	then	the	chain	IL12RB1	was	exclusively	used.	Interleukin	12	is	a	








Our	 Finnish	 genetic	 profile	 contains	 the	 same	 mutation	 in	 IL12RB1	 as	 our	 Toscani	
population,	 alongside	 a	 mutation	 in	 macrophage	 colony	 stimulating	 factor.	 This	 CSF1	
mutation	causes	a	very	minor	pro-atherogenic	effect,	however	the	effect	is	so	small	that	it	is	























EGFR	 is	 an	 important	 component	of	elastin	 synthesis.	 EGFR-001-521	 is	 the	mutation	 (also	
common	within	Han	Chinese,	Chinese	Dai	and	Kinh	populations)	that	is	the	sole	constituent	


















described	 in	 section	 6.2.4.	 Using	 each	 of	 our	 population	 subgroup	 models,	 a	 genetic	
algorithm	was	applied	to	calculate	the	multi-drug	combination	designed	to	minimize	plaque	










































































Returning	 a	 final	 MDscore	 of	 0.3268.	 Wildtype	 therapeutics	 give	 an	 MDscore	 of	 0.3713,	




























































CXCL10-001-58,	 CCL5-001-68,	 CCL5-002-68,	 CCL5-001-40	 and	 CCL5-002-40	 all	 cause	 a	
significant	reduction	in	atheroma	size	due	to	the	reduction	of	immune	cells	recruited	to	the	
lesion.	 Another	 mutation	 in	 the	 top	 10	 is	 IL4-201-134,	 causing	 a	 severe	 change	 in	 the	






recruitment	and	disrupting	 the	Th1/Th2	balance	are	 two	potential	areas	of	 investigation	 in	






pathway	 dynamics	 when	 reparameterisation	 has	 taken	 place	 to	 consider	 the	 effect	 of	
mutations	commonly	found	within	these	populations.	Within	genetic	profile	1	(Han	Chinese	
from	China,	 Chinese	Dai	 from	China	 and	 Kinh	 from	Vietnam),	 a	 decrease	 in	 extra-cellular	
matrix	 remodelling	 has	 led	 to	 a	 total	 increase	 in	 concentrations	 of	 elastin	 and	 collagen.	
Increased	 collagen	 within	 an	 atheroma	 can	 lead	 to	 an	 increase	 in	 lesion	 size,	 however	
collagen	can	also	be	beneficial	to	plaque	stability,	reducing	the	likelihood	of	a	cardiovascular	
event.	While	studies	exist	providing	statistics	related	to	CVD	for	each	of	these	populations,	
none	 of	 them	provide	 sufficient	 histological	 detail	 to	 use	 as	 validation	 for	 the	 conclusion	





Japanese	 individuals	 within	 Japan	 present	 fewer	 symptoms	 of	 subclinical	 atherosclerosis	
than	 other	 populations.	 Indeed,	 Japan	 has	 a	 significantly	 fewer	 CVD	 related	 deaths	 than	
reported	 in	 other	 countries	 (Nojiri	 and	Daida,	 2017).	 Despite	 the	 stability	 issues	with	 our	
Japanese	genetic	profile,	 the	atheroprotective	nature	of	 the	variation	common	within	 this	
genetic	 profile	 mirrors	 the	 reduction	 in	 subclinical	 atherosclerosis	 manifestation	 and	
subsequent	CVD	risk.	There	are	multiple	potential	reasons	for	the	reduced	CVD	risk	in	Japan,	
including	 a	 low-fat	 diet	 and	 significantly	 reduced	 obesity	 within	 the	 country.	 However,	











shows	 a	 minor	 change	 in	 this	 balance	 due	 to	 an	 IL12RB1	 mutation.	 The	 effect	 of	 these	
mutations	 is	 very	 minor	 and	 would	 likely	 have	 an	 almost	 insignificant	 effect	 on	
cardiovascular	risk.	Studies	into	European	American	populations	are	limited	(Johnson	et	al.,	
2011),	 however	 it	 has	 been	 shown	 that	 cardiovascular	 disease	 related	 morbidity	 and	
mortality	 in	 Italy	 is	 reduced	when	compared	to	other	European	countries,	although	this	 is	
likely	to	be	primarily	due	to	dietary	factors	(Palmieri	et	al.,	2010).		
	




reduction	 in	 numbers	 of	 smokers	 and	 healthier	 diet	 leading	 to	 average	 lower	 serum	
cholesterol	and	blood	pressure	(Jousilahti	et	al.,	2016;	Vartiainen	et	al.,	1999).	
	
Genetic	profile	 7	 (Yorubi	 from	Nigeria,	 Luhya	 from	Kenya,	Gambian	 from	Gambia,	Mende	
from	 Sierra	 Leone,	 Esan	 from	 Nigeria	 and	 African	 Caribbeans	 from	 Barbados)	 show	 an	
alteration	to	the	Th1-	Th2	balance	due	to	a	mutation	in	IL4R.	This	mutation	is	expected	to	be	
atheroprotective.	 Europeans	 have	 a	 higher	 risk	 of	 cardiovascular	 disease	 than	 an	 African	
Caribbean	population	 (Chaturvedi,	2003).	Studies	have	been	performed	to	assess	CVD	risk	
within	Yoruba	Nigerians	and	individuals	in	western	Kenya,	however	these	studies	solely	look	





mutation	 in	 EGFR,	 leading	 to	 an	 increase	 in	 elastin	 concentration	 within	 the	 artery	 wall.	









and	 South	 Asian	 individuals	 (Gupta	 and	 Brister,	 2006;	 Lloyd-Jones	 et	 al.,	 2010).	




IL18R1-001-232	(rs148457935)	 is	a	mutation	which	 leads	to	an	 increase	 in	kon	to	1.26x106.	
Within	the	mathematical	model,	this	has	given	a	kcat	value	of	2.4525	x105	to	represent	this	
mutation.	Studies	have	shown	that	an	increase	in	IL-18	concentration	and	activity	leads	to	a	
reduction	 in	collagen	within	the	 intima	 in	apolipoprotein	E	deficient	mice,	creating	plaque	
instability	 (De	 Nooijer	 et	 al.,	 2004).	 Increasing	 the	 activity	 of	 IL18	 through	
reparameterisation	 will	 lead	 to	 similar	 behavior	 as	 incorporating	 overexpression	 into	 the	
model,	suggesting	that	this	behavior	will	be	seen	in	an	individual	with	the	mutation	IL18R1-

















expected	 to	 stop	 increasing	 and	 stabilize	 to	 approximately	 5x106	 pg/ml,	 even	 with	 small	
variations	 in	 protein	 activity.	 With	 a	 large	 increase	 in	 IL18	 activity	 represented	 by	 the	






The	 mechanism	 of	 action	 of	 both	 statins	 and	 PCSK9	 inhibitors	 involve	 the	 reduction	 of	
plasma	LDL	levels	through	the	modification	of	the	cholesterol	metabolism	pathway	and	the	
lipoprotein	 metabolism	 pathway	 respectively.	 Their	 therapeutic	 properties	 could	 be	
indirectly	added	to	the	model	through	a	forced	reduction	of	plasma	LDL	levels,	however	it	










The	 introduction	of	 fifteen	different	drugs	was	simulated	 for	each	genetic	profile.	Each	of	
the	multi-drug	therapeutics	simulations	described	in	section	6.3.5	suggested	a	combination	
of	three	different	drugs,	while	five	genetic	profiles	suggest	the	introduction	of	a	new	drug	
targeting	 the	 interaction	 IL18	 →	 IL18R	 to	 disrupt	 the	 Th1/Th2	 balance.	 The	 nine	 genetic	
profiles	 outlined	 in	 section	 6.3.1	 suggest	 a	 collection	 of	 different	 drug	 combinations	 and	
concentrations	to	treat	stratified	patient	groups.	
	
 Can	 we	 identify	 biomarkers	 in	 plasma	 from	 high	 concentrations	 within	 the	
atheroma?	








Identification	 of	 biomarkers	 within	 population	 subgroups	 is	 a	 cornerstone	 of	 stratified	
medicine	 approaches.	 Within	 our	 mathematical	 model,	 concentrations	 are	 modelled	 for	
proteins	 found	within	 the	 blood,	 the	 plaque,	 or	 both.	 The	 benefit	 of	 a	 biomarker	 within	






disease	 progression.	 Any	 potential	 biomarkers	 identified	 would	 be	 significantly	 less	
beneficial	 in	practice	 if	providing	measurements	proved	challenging	–	 i.e.	 if	 the	biomarker	
was	found	within	the	plaque	rather	than	within	blood.	In	the	case	of	IL-4,	is	it	possible	that	
we	will	see	similar	results	within	the	plasma?	The	answer	depends	on	the	dynamics	of	the	




Particular	 results	 are	obvious	outliers.	 For	 example,	 TransComp	estimated	 the	association	
rate	of	CSF1R-001-245	with	CSF1-001	to	be	3.81x10-188	M-1	s-1.	Additionally,	IL12RB1-001-214	












Mutations	 shown	 to	 be	 atherogenic	 or	 atheroprotective	 could	 have	opposite	 effects	with	
other	diseases.	Asthma	is	an	inflammation	driven	disease	affecting	the	lungs,	which	shares	
inflammatory	mechanisms	with	atherosclerosis	(Lambrecht	and	Hammad,	2015).	Asthma	is	
a	 Th2	 driven	 disorder	 where	 T	 cell	 activation	 leads	 to	 mucus	 production,	 oedema	 and	
inflammation	 of	 the	 airways.	 Tipping	 the	 Th1/Th2	 balance	 towards	 Th2	 cells	 is	 likely	 to	
increase	the	severity	of	the	disorder	(Bosnjak	et	al.,	2011).	Genetic	profile	7	contains	IL4R-
001-576,	a	mutation	which	promotes	Th2	differentiation,	altering	the	Th1/Th2	balance	within	












The	 creation	 of	 genetic	 profiles	 to	 represent	 individual	 populations	 allows	 for	 the	
reparameterisation	 of	 the	 model	 for	 these	 genetic	 profiles	 and	 the	 study	 of	 theoretical	
multi-drug	 interventions	 to	optimize	plaque	reduction.	Systems	biology	methods	have	 the	
potential	to	be	a	strong	predictor	of	how	a	perturbation	will	affect	disease	dynamics	when	
the	 mathematical	 model	 of	 the	 disease	 and	 the	 disruption	 are	 both	 well-defined.	 The	
quantity	 and	 quality	 of	 publically	 available	 biological	 data	 relating	 to	 PPIs	 and	 of	
mathematical	 models	 relating	 to	 disease	 processes	 has	 significantly	 increased	 in	 recent	
years.	Combining	powerful	models	with	vast	datasets	has	the	potential	to	lead	to	advances	

























has	 been	 considered,	 discussed	 and	 debated	 amongst	 healthcare	 professionals	 for	 years	
(Gonzalez-garay,	 2015;	 Kalow,	 2002;	 Nijhout	 et	 al.,	 2015).	 However,	 many	 significant	
advances	in	computational	modelling	are	required	before	this	becomes	a	reality.	Improving	
methods	to	analyse	how	genetic	variation	affects	the	dynamics	of	particular	diseases	is	an	
important	 step	on	 the	 journey	 to	 idealized	personalized	medicine.	 	Within	 this	 thesis,	we	
have	 developed	 a	 computational	 model	 of	 atherosclerosis	 containing	 significantly	 more	
biological	 entities	 than	 any	 other	 available	model	 of	 plaque	 formation.	 Validating	model	
results	 through	 comparison	 with	 experimentally	 derived	 results	 has	 been	 performed	
extensively	 to	 ensure	 biological	 relevance.	Multi-drug	 systems	 pharmacology	 approaches	
have	been	utilized	to	suggest	drug	combinations	to	minimize	plaque	growth,	and	an	overall	
in	silico	platform	for	the	study	of	atherosclerosis	dynamics	has	been	created.	
Utilizing	 sequence	 data	 taken	 from	 phase	 3	 of	 the	 1000	Genome	 Project,	 a	 collection	 of	
mutations	relating	to	atherosclerosis	were	isolated.	A	protein-forming	amino	acid	sequence	
was	constructed	for	each	of	these	sequences,	and	state-of-the-art	protein	folding	methods	
were	 used	 to	 predict	 tertiary	 structures	 for	 each	 of	 these	mutations.	 Comparative	 steps	
were	 taken	 to	 demonstrate	 the	 validity	 and	 accuracy	 of	 each	 of	 these	 predicted	 protein	
structures	through	alignment	to	experimental	proteins	found	in	the	Protein	Data	Bank,	and	
these	mutations	were	 heatmapped	 to	 show	 regions	 of	 proteins	with	 increased	 structural	
variability.	Docking	methods	were	utilized	to	derive	a	quaternary	structure,	and	to	study	the	
complexes	formed	during	atherogenesis.	Binding	kinetics	were	calculated	in	the	form	of	kon	











mathematical	 model,	 to	 predict	 population	 specific	 changes	 in	 plaque	 development.	











of	 this	 thesis	 includes	 aspects	 of	 atherosclerosis	 that	 have	 not	 been	 modelled	 by	 other	
groups	and	models	the	concentrations	of	more	biological	entities	than	other	models	within	
this	 field	 (Parton	 et	 al.,	 2015).	 Extensive	 validation	 has	 been	 performed	 to	 ensure	 the	
biological	relevance	of	the	model.	
 Aim	2	–	Study	the	variation	in	structure	for	proteins	related	to	atherosclerosis	
A	 collection	 of	 protein	 structures	 detailed	 in	 Chapter	 4	 were	 obtained	 using	 protein	
structure	 prediction	 methods	 that	 CASP	 experiments	 have	 proven	 to	 be	 highly	 reliable.	
Alignments	to	experimentally	derived	wildtypes	were	performed	to	ensure	accuracy	of	our	





model	 detailed	 in	 Chapter	 3	 was	 reparametrized	 according	 to	 this	 binding	 kinetics	 data.	






Project	population	genetics	data	 to	allow	 for	 the	prediction	of	how	population	 subgroup-
specific	structural	variance	will	alter	atherosclerosis	progression,	as	shown	in	Chapter	6.	
Each	 of	 these	 aims	 have	 been	 achieved	 and	 comprehensively	 detailed	within	 this	 thesis,	
assisting	 in	 the	 overall	 objective	 of	 studying	 the	 dynamics	 of	 atherosclerosis	 across	
population	subgroups.	
7.3 The	need	for	collaboration	
While	 the	 mathematical	 model	 developed	 shows	 extensive	 depth	 and	 complexity	 in	 the	
study	of	atherosclerosis,	numerous	biological	processes	and	pathways	significant	to	plaque	
formation	are	not	included	as	part	of	this	study.	LDL	concentration	within	the	blood,	one	of	
the	primary	 risk	 factors	 for	 cardiovascular	disease,	 is	 considered	as	a	 constant	within	 the	
mathematical	 model.	 This	 prevents	 the	 consideration	 of	 short-term	 fluctuations	 in	
concentrations,	 dietary	 changes,	 the	 process	 of	 cholesterol	 metabolism,	 the	 process	 of	









cell	 model	 was	 developed,	 representing	Mycoplasma	 genitalium	 	 (Karr	 et	 al.,	 2012a),	 in	
what	 is	 still	 one	 of	 the	 largest	 computational	 models	 currently	 available	 to	 represent	











In	 the	 pursuit	 of	 true	 personalized	 medicine,	 interconnected	 models	 representing	 large	
biological	systems	are	more	likely	to	be	able	to	predict	side	effects	of	model	perturbations.	
Of	 course,	 the	 study	 of	 subsections	 and	 pathways	 can	 bring	 key	 insight	 into	 disease	
dynamics;	however,	larger	and	more	comprehensive	models	of	biological	systems	have	the	
potential	to	bring	new,	stronger	results.	Gaps	in	our	knowledge	can	be	bridged	through	the	
introduction	 of	 systems	 biology	 approaches	 to	 biological	 systems,	 yet	 the	 systems	
concerned	are	 so	 complex	 that	 it	 requires	 vast	 resources	 spanning	multiple	disciplines	 to	
bring	 computational	 biology	 results	 into	 clinical	 healthcare	 benefits.	 Developing	 a	 strong	
computational	 model	 of	 a	 disease	 process	 requires	 skills	 in	 areas	 such	 as	 mathematics,	
informatics	and	biochemistry.	To	provide	expertise	in	individual	disease	areas	and	guidance	
on	clinically	beneficial	results,	input	from	domain	experts	and	clinicians	can	be	a	significant	






this	 thesis.	 The	 model	 has	 been	 developed	 to	 SBGN	 (Le	 Novere	 et	 al.,	 2009)	 and	 SBML	
(Hucka	et	al.,	2003)	open	standards	and	the	SBML	version	has	been	deposited	in	BioModels,	
a	 public	 domain	 computational	 model	 database,	 to	 encourage	 collaboration	 and	 reuse	
(Novère,	 2006).	 Results	 have	 shown	 the	 biological	 relevance	 of	 the	mathematical	model	
through	 reproduction	 of	 results	 from	 other	 biological	 studies,	 as	 detailed	 in	 section	 3.3.	
Considering	the	concentration	of	each	protein	and	cell	type	within	the	model	using	an	ODE	
allows	 for	 the	 pharmacological	 modelling	 of	 drug	 interventions	 using	 hypothetical	 drugs	
acting	on	specific	targets	as	well	as	known	drugs.		
However,	despite	the	considerable	detail	included	in	the	multi-scale	model,	it	can	in	no	way	
be	 considered	 a	 complete	 representation	 of	 atherosclerosis.	 Some	 cell	 subtypes,	 such	 as	
anti-inflammatory	macrophages,	 have	 not	 been	 included	within	 the	mathematical	model	









spatial	 factors	are	not	considered	within	 this	model.	This	 removes	 factors	such	as	arterial	
remodelling	 and	 wall	 shear	 stress,	 which	 has	 been	 shown	 to	 be	 linked	 to	 atheroma	
development	 (Cunningham	and	Gotlieb,	2005).	The	 removal	of	 spatial	 considerations	also	
limits	 study	 of	 atheroma	 location,	 and	 any	 considerations	 of	 atheroma	 size	 have	 to	 be	
linked	to	the	morphological	content	of	the	artery	wall.		
Model	outputs	have	been	compared	to	experimental	results	 to	express	the	validity	of	 the	
model.	 Experimental	 data	 have	 been	 found	 describing	 concentrations	 for	 a	 collection	 of	
proteins	and	cell	types	included	within	the	model,	and	model	simulations	are	compared	to	
these	data	to	ensure	biological	relevance.	Perturbations	in	concentrations	and	activity	of	a	
selection	of	 cytokines	 and	 chemokines	within	 the	model	were	 introduced	 to	predict	 how	
these	 changes	 influence	 atherogenesis.	 Variations	 in	 concentrations	 of	 IL-12	 and	 IL-18	 in	
mice	have	been	shown	to	disrupt	the	Th1/Th2	balance	and	alter	the	cellular	composition	of	
the	 plaque	 (Elhage	 et	 al.,	 2003;	 Hauer	 et	 al.,	 2005).	 Reductions	 in	 proteoglycan	
concentrations	and	PLA2	activity	lower	plaque	levels	of	oxidized	LDL,	leading	to	a	reduction	
in	atheroma	size	due	to	fewer	foam	cells	being	created	(Delgado-Roche	et	al.,	2015;	Vickers	
et	 al.,	 2009).	 An	 increase	 in	 PDGF	 concentration	 boosts	 smooth	 muscle	 cell	 abundance,	
affecting	 plaque	 stability	 (Loppnow	 and	 Libby,	 1990).	 Collagen	 concentrations	 are	 more	
challenging	to	predict	when	considering	perturbations	to	the	system.	As	plaque	size	grows	
and	 time	 progresses,	 collagen	 synthesis	 grows	 due	 to	 increased	 abundance	 of	 smooth	
muscle	 cells,	 while	 collagen	 remodelling	 increases	 at	 the	 same	 time	 due	 to	 increased	
production	of	MMPs	 (Newby,	2005;	Rekhter,	1999).	More	severe	 lesions	 left	 long	enough	
will	 have	 decreasing	 levels	 of	 collagen	 due	 to	 higher	 levels	 of	MMPs	within	 the	 system,	
increasing	the	likelihood	of	plaque	rupture	and	a	subsequent	cardiac	event	(Adiguzel	et	al.,	
2009).	Each	of	 these	 studies	have	been	 reproduced	 in	 silico	within	 the	model.	Multi-drug	








While	 the	 development	 of	 this	 model	 of	 atherosclerosis	 and	 the	 subsequent	
pharmacological	 study	 of	 potential	 multi-drug	 interventions	 provides	 insight	 into	
atherosclerosis	 pathogenesis,	 some	 common	 therapeutics	 used	 to	 treat	 CVD	 and	
atherosclerosis	 are	 not	 represented	 within	 this	 model.	 Statins	 inhibit	 the	 synthesis	 of	
cholesterol	by	 inhibition	of	HMG-CoA	 reductase,	 leading	 to	a	 reduction	of	 LDL	within	 the	
blood	(Stancu	and	Sima,	2001),	and	as	such	the	effects	of	statin	therapy	can	be	considered	
within	 the	model,	 albeit	 indirectly.	 Similarly,	 PCSK9	 inhibitors	 prevent	 the	 degradation	 of	
LDL	 receptors	 in	 the	 liver,	 increasing	 the	 rate	 of	 LDL-C	 removal	 (Page	 and	Watts,	 2016).	
PCSK9	inhibitors	lead	to	significant	reduction	of	LDL	concentrations	within	the	liver,	which	
could	be	indirectly	included	within	the	model	similarly	to	statins.	Creation	of	a	‘supermodel’	
that	 includes	 atherosclerosis,	 cholesterol	 metabolism	 and	 the	 removal	 of	 plasma	 LDL	 by	
hepatocytes	 would	 allow	 for	 the	 study	 of	 multi-drug	 interventions	 that	 includes	 the	
subtleties	 involved	with	 statin	 therapy	 and	 PCSK9	 inhibition.	 Cholesterol	metabolism	 has	
been	 successfully	 modelled	 previously	 using	 the	 SBML	 format	 (Mazein	 et	 al.,	 2013;	 Mc	
Auley	et	al.,	2012)	and	more	recently	the	role	of	aging	in	this	process	has	been	considered	
(Morgan	et	al.,	2016).	The	connection	between	PCSK9	and	LDL	cholesterol	levels	have	been	
modelled	 within	 specific	 mammalian	 systems	 (Hansen	 et	 al.,	 2017),	 and	 the	
pharmacological	 results	of	PCSK9	 inhibition	on	plasma	LDL	has	been	modelled	 (Gadkar	et	








homologues	 and	 folds	 for	 use	 in	 structure	 formation.	 Due	 to	 computational	 intensity	
restrictions,	only	a	subset	of	all	mutations	contained	within	phase	3	of	the	1000	Genomes	
Project	were	chosen	for	subsequent	analysis	in	this	study.	The	subset	chosen	was	weighted	






chosen	 affecting	 larger	 structures	 like	 receptors.	 This	 gave	 a	 broad	 spread	 of	 mutations	
across	 all	 proteins	 selected	 to	 represent	 atherosclerosis,	 allowing	 for	 further	 study	 of	
protein	 structure,	 binding	 kinetics	 and	 function.	 Comparison	 of	 predicted	 structures	 to	




be	 useful	 in	 the	 recognition	 of	 the	 severity	 of	 a	 group	 of	mutations.	When	 clinical	 data	
exists	 linking	a	mutation	 to	a	particular	disease,	our	dataset	 can	be	 searched	 for	 variants	
with	a	strong	alignment	to	either	 the	wildtype	or	 the	disease-causing	mutation	to	predict	
the	 likelihood	 of	 a	mutation	 being	 disease-causing.	 The	 dataset	 generated	was	 large	 and	
varied,	benefiting	later	stratification	exercises.	
Improvements	could	still	be	made	to	our	predicting	protein	structure	procedures,	however.	
Expanding	 our	 dataset	 beyond	 the	 1000	 Genome	 Project	 to	 similar	 sequencing	 projects	





and	 freeing	 up	 such	 time	 for	 additional	mutations,	 albeit	with	 a	minor	 drop	 in	 accuracy.	
Heatmaps	could	have	been	more	informative	if	weighted	with	population	genetics	data.	In	
general,	 our	 intentions	 to	 produce	 the	 most	 accurate	 predictions	 possible	 within	 our	




residue	 RMSD	 as	 calculated	 by	 ResQ,	 are	 generally	 valuable	 yet	 are	 not	 100%	 accurate	
(Yang	et	al.,	2016).	The	collection	of	graphs	shown	in	Figure	4.6	to	study	local	accuracy	of	
structural	predictions	demonstrate	that	while	limits	provided	to	variation	from	wildtype	are	






protein	 to	 represent	 this	 local	 accuracy	 to	 allow	 for	 quick	 visualization	 of	 protein	 areas	
where	we	are	more	confident	of	accurate	structure.	An	additional	heatmap	was	created	to	
show	 the	 variance	 in	protein	 structure	 across	 the	 collection	of	mutations	 included	 in	our	
dataset.	 Mutations	 linked	 to	 disease	 in	 IL4R	 and	 ABCA1	 were	 identified	 and	 structural	
similarity	with	wildtype	and	other	mutations	was	considered,	suggesting	protein	structures	
that	 are	 structurally	 similar	 to	 disease	 causing	 mutations	 that	 may	 benefit	 from	 further	
investigation.	
 Future	Improvements	
As	protein	 structure	prediction	methods	become	more	accurate	and	 less	 computationally	
intensive,	 large	 structural	 datasets	 can	 be	 developed	 which	 could	 be	 used	 as	 part	 of	 a	
multitude	 of	 studies.	With	 the	 existence	 of	 repositories	 such	 as	 ClinVar	 (Landrum	 et	 al.,	
2014)	 detailing	 links	 between	 mutations	 and	 phenotypes,	 including	 mutations	 linked	 to	
disease,	 structural	 datasets	 could	 be	 compared	 to	 known	 disease-linked	 mutations	 to	
predict	mutation	severity	 (in	 the	context	of	disease).	CASP	and	CAMEO	experiments	have	
excellently	 constructed	 a	 competitive	 and	 rewarding	 atmosphere	 to	 drive	 progress	 with	
protein	 structure	 prediction	methods,	with	 the	 number	 of	 entrants	 growing	 year-on-year	
and	increasing	accuracy	and	speed	being	demonstrated	by	the	winning	entries	consistently	
between	competitions	(Haas	et	al.,	2013;	Moult	et	al.,	2016).	The	Protein	Data	Bank	is	the	
world-leading	 repository	 for	 experimentally	 derived	 protein	 structures,	 with	 9,990	 X-Ray	
structures	and	455	NMR	structures	uploaded	in	2016	(PDB,	2016).	With	the	improvement	of	
structural	 prediction	 methods,	 a	 separate	 repository	 containing	 predicted	 protein	
structures	 has	 the	 potential	 to	 be	 beneficial	 to	 the	 bioinformatics	 community	 at	 large.	
Caution	would	need	to	be	taken	to	ensure	a	minimum	level	of	predicted-structure	quality;	
however,	 it	has	been	demonstrated	that	even	I-TASSER	results	returning	a	relatively	weak	
prediction	 will	 still	 represent	 the	 correct	 model	 topology.	 As	 such,	 a	 predicted-structure	
repository	 could	 benefit	 the	 research	 community,	 particularly	 for	 larger	 proteins	 where	
performing	structural	prediction	methods	is	a	computationally	intensive	task.		
7.6 Calculation	of	Binding	Kinetics	
Alterations	 in	 the	 velocity	 of	 binding	 and	 unbinding	 within	 a	 protein-protein	 interaction	










while	 electrostatics	 can	 also	 influence	 steering	 to	 ensure	 that	 reactants	 interact	 at	 their	
respective	binding	 sites	 (Wade	et	 al.,	 1998).	As	 such,	 focusing	on	electrostatics	 alongside	
protein	 shape	 is	 a	 reasonable	 method	 of	 computationally	 studying	 and	 prediction	
association	rates	for	a	PPI.	TransComp	has	many	benefits	for	use	as	part	of	a	study	of	PPI	
association	 rates,	 including	 access	 to	 a	 publically	 available	web	 server	 for	 testing	 and	 to	
return	 computationally	 intensive	 results	 in	 a	 short	 period	 of	 time,	 and	 internal	
determination	of	reaction	criteria	leading	to	a	single	scalar	result	being	returned;	removing	
an	additional	assumption	or	computational	 step	which	would	have	been	required	 if	SDA7	
results	were	 used	 (Martinez	 et	 al.,	 2015;	Qin	 et	 al.,	 2011).	Using	 TransComp	 to	 calculate	
association	 rates	 for	 1119	 interactions	 required	 significant	 computational	 resources,	 in	
contrast	 to	 PRODIGY	 which	 was	 able	 to	 estimate	 kd	 vales.	 Approximately	 500,000	 core	




magnitude	 of	 experimentally	 derived	 association	 rate	 values.	 While	 this	 is	 still	 a	 large	
margin	 of	 error	 to	 work	with,	 it	 does	 provide	 sufficient	 accuracy	 for	 us	 to	 progress	 into	
reparameterisation	 experiments.	 TransComp	 has	 shown	 increased	 accuracy	 for	 proteins	
with	 association	 rates	 in	 the	 range	 of	 105	 -	 1010	 M-1s-1,	 due	 to	 the	 transient	 complex	
approximation	 utilized	 as	 part	 of	 its	methodology	 (Qin	 et	 al.,	 2011).	 As	 such,	 association	
rates	in	the	lower	half	of	the	results	spectrum	with	a	value	of	100	-	104	M-1s-1	are	less	likely	
to	be	accurate.		
A	 collection	of	TransComp	 results	with	 low	kon	 values	were	obvious	outliers.	 For	example	
CSF1R-001-245	 binding	 to	 CSF-001	 returns	 an	 association	 rate	 of	 3.81	 x10-188.	 This	
breakdown	 in	kinetics	prediction	 is	caused	by	a	very	 large	electrostatic	potential	between	








transitory	 state,	which	was	 common	 for	 some	proteins	within	 our	 dataset.	 PRODIGY	was	
generally	more	 reliable;	however,	 issues	were	had	with	 some	complexes	 (primarily	 IL5	→	




6.3.1,	 allowing	 for	 successful	 reparameterisation	 experiments	 despite	 our	 reduction	 in	
dataset	size.	
Derivation	 of	 binding	 kinetics	 are	 the	 product	 of	 a	 collection	 of	 bioinformatics	 tools.	
GalaxyHomomer	(Baek	et	al.,	2017),	RosettaDock	(Davis	and	Baker,	2009),	Hex	(Macindoe	
et	 al.,	 2010),	 TransComp	 (Qin	 et	 al.,	 2011),	 PRODIGY	 (Xue	 et	 al.,	 2016)	 and	 PDB2PQR	
(Dolinsky	 et	 al.,	 2007)	 were	 all	 used	 to	 provide	 a	 collection	 of	 association	 rates.	
Homodimeric	structures,	predicted	using	GalaxyHomomer,	gave	dimeric	structures	similarly	
close	 to	 the	 native	 as	 local	 docking	 results	 provided	 by	 local	 docking	 despite	
GalaxyHomomer	 not	 requiring	 contact	 points	 as	 an	 input.	 Benchmarking	 results	 showed	




Improving	 dataset	 coverage	 and	 improving	 association	 and	dissociation	 rate	 accuracy	 are	
two	obvious	improvements	that	could	be	made	to	our	methodology.	Predicting	whether	a	
complex	 is	 likely	 to	 fail	 TransComp	 analysis	 before	 spending	 considerable	 computational	
resources	on	 the	 run	 itself	 could	 allow	 for	 the	 reduction	of	 computational	 time,	 allowing	
resources	to	be	put	to	better	use.	Utilising	similar	methods	to	calculate	kon	and	koff,	rather	
than	 combining	 the	 Brownian	 Dynamics	 simulation	 style	 of	 TransComp	 and	 the	 contact-
based	methods	of	PRODIGY	could	reduce	bias	introduced	by	both	methods.	New	methods	













learning	 platform	 for	 patient	 stratification	 and	 the	 study	 of	 atherogenesis	 dynamics.	
Utilizing	binding	kinetics	data	for	a	collection	of	mutations	to	investigate	disease	dynamics	
and	 predict	 pathogenesis	 differences	 for	 each	 mutation	 has	 provided	 a	 platform	 for	
evaluation	 of	 its	 downstream	 effects.	 Experimental	 data	 has	 shown	 encouraging	
corroborative	 results	when	 compared	 to	 disease	 dynamics	 of	 our	 genetic	 profiles.	Multi-
drug	therapeutics	designed	for	the	minimization	of	plaque	size	when	inhibitors	are	added	to	
the	 system	 suggests	 different	 therapeutics	 were	 optimized	 for	 different	 population	
subgroups.	 The	 generation	 of	 746	 models	 of	 atherosclerosis	 representing	 individual	
mutations	with	effects	on	disease	dynamics	provides	a	demonstration	of	model	robustness	
and	 a	 proof	 of	 concept	 that	 reparameterisation	 can	 provide	 prediction	 on	 therapeutic	
effects	and	‘-omics’	data	driven	disease	dynamics	as	part	of	an	in	silico	testing	system.	
Increased	 accuracy	 in	 binding	 kinetics	 data	 would	 have	 improved	 the	 quality	 of	 our	
reparameterisation	 experiments.	 Experimental	 derivation	 of	 binding	 kinetics	 or	 protein	
structure	would	have	led	to	a	reparameterisation	that	was	closer	to	the	native,	underlying	
biology.	 The	 genetic	 profiles	 developed	 in	 chapter	 6	 are	 designed	 to	 represent	 individual	
population	 subgroups;	 however,	 due	 to	 the	 limited	number	of	mutations	 included	within	
the	dataset	isolated	in	chapter	4,	these	genetic	profiles	contained	a	relatively	small	number	
of	variations.	The	Ascore,	designed	to	provide	a	scalar	value	to	represent	atheroma	size	and	
severity,	 could	 have	 been	 calculated	 in	 a	 multitude	 of	 ways.	 The	 MDscore,	 studying	 the	
efficacy	 of	 the	multi-drug	 interventions,	 could	 similarly	 have	 been	 altered	 by	 varying	 the	








particular	 population	 subgroups	 to	 investigate	 the	 potential	 of	 altering	 atherosclerosis	
dynamics	and	therapeutic	optimization	for	each	of	these	subgroups.	Unfortunately,	due	to	
limitations	 placed	 on	 our	 dataset,	 only	 8	 unique	 genetic	 profiles	were	 created.	However,	
interesting	 results	were	 obtained	 for	 each	 of	 these	 genetic	 profiles.	 The	mutation	 CCR2-
001-64	 (rs1799864),	 found	 in	 50.96%	of	 Japanese	 individuals	within	 phase	 3	 of	 the	 1000	
Genome	 Project,	 reduces	 the	 rate	 of	 monocyte	 recruitment	 to	 the	 site	 of	 endothelial	
damage,	a	potential	 influencing	 factor	 for	 the	 reduced	 rate	of	 cardiovascular	disease	 in	a	
Japanese	 population.	 Similarly,	 IL12RB1-001-214	 (rs11575934)	 is	 commonly	 found	 in	
Toscani	and	Finnish	populations	(58.87%	and	55.55%	respectively),	a	mutation	which	alters	
the	T	cell	constituency	of	the	lesion	while	only	making	a	minor	change	to	atheroma	severity,	
giving	 an	 opportunity	 for	 alternative	 therapeutics	 for	 these	 population	 subgroups.	






Project	 (Auton	et	al.,	2015),	or	 similar	projects	 like	UK10K	 (Consortium,	2016)	 could	have	
provided	a	reparameterisation	more	representative	of	the	population.	Starting	from	these	
improved	 genetic	 profiles	 and	 utilising	 the	 entire	 computational	 pathway	 outlined	 in	 this	
thesis	 for	 mutations,	 by	 predicting	 a	 tertiary	 structure,	 binding	 kinetics	 and	
reparameterisation,	would	have	given	credence	 to	 the	biological	 relevance	of	each	of	 the	
genetic	 profiles.	 Creation	 of	 a	 ‘supermodel’	 as	 postulated	 in	 section	 7.4.1	 would	 have	
allowed	for	the	introduction	of	other	common	CVD	related	drugs	into	the	system,	such	as	
PCSK9	inhibitors	and	statins.	Additionally,	a	‘supermodel’	could	provide	insights	into	multi-
drug	 therapeutic	dynamics	 and	provide	a	 collection	of	other	mechanisms	which	 could	be	
responsible	for	population	subgroup	specific	differences	in	atherosclerosis	dynamics.	Using	
commonly	known	drugs	with	known	inhibitory	constant	(ki)	values	could	have	allowed	for	








All	 of	 the	 work	 undertaken	 within	 this	 thesis	 can	 be	 considered	 as	 part	 of	 the	 same	
methodology,	 an	 algorithmic	 road	 with	 the	 final	 goal	 of	 atherosclerosis	 patient	
stratification.	 From	 the	 development	 of	 the	 mathematical	 model,	 to	 tertiary	 structure	
prediction,	to	binding	kinetics	derivation,	and	finally	reparameterisation,	each	chapter	 is	a	
key	part	of	 the	methodology	with	which	 following	 chapters	 require	 to	 correctly	 function.	
Chaining	 together	 algorithmic	 sections	 with	 predictive	 elements	 requires	 awareness	 and	
handling	 of	 compound	 error.	 Minor	 errors	 in	 results	 in	 the	 earlier	 part	 of	 the	 overall	
methodology	 combine	with	minor	errors	 in	other	 subsections	 leading	 to	an	overall	 larger	
error	 in	 the	 end.	 Reduction	 of	 error	 in	 individual	 subsections	where	 possible	 can	 lead	 to	
larger	improvements	in	the	quality	of	our	final	results,	leading	to	general	improvements	as	
technologies	develop	and	knowledge	grows.	Improvements	and	additions	to	the	publically	
available	 model	 of	 atherosclerosis	 through	 parameterization	 updates	 or	 network	
optimization	 can	 reduce	 the	 error	 and	 improve	 the	 quality	 of	 our	 final	 multi-drug	
therapeutics.	 Improvements	 in	 the	 prediction	 algorithms	 for	 obtaining	 tertiary	 structures	











from	 each	 of	 these	 technologies	 into	 an	 overlying	 vision	 of	 disease	 dynamics.	 Potential	
molecular	targets	for	drugs	have	been	described	for	an	overall	population	and	additionally	
for	subgroups	of	these	populations	as	part	of	a	program	of	stratified	medicine,	and	overall	






convert	 therapeutic	 hypotheses	 generated	 by	mathematical	models	 into	 clinical	 benefits,	






The	work	 included	 in	 this	 thesis	 utilizes	 state-of-the-art	 technologies	 in	 protein	 structure	
prediction,	docking	and	prediction	of	binding	kinetics	to	develop	therapeutic	hypotheses	of	
atherosclerosis.	The	natural	progression	of	this	work	is	to	expand	the	size	and	scope	of	the	
model	 of	 atherosclerosis	 to	 include	 lipoprotein	 metabolism	 and	 cholesterol	 metabolism.	
Once	a	 successful	model	has	been	developed	 to	 include	 these	biological	processes,	other	
models	could	be	combined	on	the	way	to	the	ultimate	goal	of	developing	a	‘virtual	human.’	
In	 the	more	 immediate	 future,	 it	would	be	beneficial	 to	use	 the	 same	methodology	on	a	
different	 network	 of	 disease	 or	 biological	 function.	 Many	 of	 the	 protein	 structures	 and	
binding	kinetics	data	generated	as	part	of	this	project	are	important	parts	of	inflammatory	
disease,	 allowing	 for	 cross-use	 in	 a	 similar	 study	 looking	 at	 a	 disease	 with	 a	 core	
inflammatory	 element,	 such	 as	 rheumatoid	 arthritis	 or	 asthma.	 An	 interesting	 ‘wet-lab’	








endarterectomy	 samples	 could	 be	 obtained,	 quantification	 of	 concentrations	 of	 proteins	
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al.,	 2014;	Wixon	and	Kell,	 2000)	and	a	 collection	of	 review	articles	of	 atherosclerosis	 (see	
Supplementary	table	4).	For	each	of	these	cell	types,	PubMed	and	Google	Scholar	searches	
were	 undertaken	 with	 the	 query	 ‘CELLNAME	 atherosclerosis	 review’.	 The	 results	 were	
sorted	by	 ‘Best	Match’/’relevance’,	 and	 the	 top	25	 results	were	selected.	Each	article	was	
searched	for	references	to	extracellular	proteins	and	other	biological	entities	connected	to	
these	cells.	Each	entity	found	in	this	way	was	listed	as	a	provisional	candidate	for	our	model.	
Another	 combined	 PubMed	 and	 Google	 Scholar	 search	 was	 undertaken	 with	 the	 query	
‘ENTITYNAME	atherosclerosis’,	to	identify	experimental	data	to	show	its	source	or	presence	
within	an	atheroma	(or	another	compartment	contained	within	the	model)	and	its	influence	
(however	 minor)	 on	 atherogenesis.	 If	 it	 the	 entity	 met	 this	 criteria,	 it	 was	 included.		








curation	 unrealistic.	 Once	 our	 initial	 network	 had	 been	 developed	 it	 was	 split	 into	 the	
collection	 of	 sub-processes	 shown	 in	 Appendix	 3	 -	 Supplementary	 Table	 7.	 	 A	 PubMed	
search	 was	 performed	 for	 a	 collection	 of	 keywords	 related	 to	 these	 sub-processes,	
improving	the	completeness	of	the	model.	
The	 model	 was	 assembled	 using	 CellDesigner	 (Funahashi	 et	 al.,	 2003,	 2008)	 to	 facilitate	
exporting	 files	 into	 Systems	 Biology	 Markup	 Language	 (SBML)	 (Hucka	 et	 al.,	 2003)	 and	






2009).	 All	 proteins	 were	 given	 their	 unique	 name	 from	 the	 HGNC	 (HUGO	 Gene	
Nomenclature	Committee)	(Gray	et	al.,	2015)	to	prevent	ambiguity.		
	
For	 mathematical	 expediency,	 it	 is	 assumed	 that	 all	 entities	 within	 each	 compartment	
occupy	 the	 same	 space,	 negating	 the	 need	 for	 diffusion	 coefficients.	 Interactions	 were	
described	mathematically	with	either	the	Law	of	Mass	Action	(LOMA)	(Voit	et	al.,	2015)	or	
Michaelis-Menten	 kinetics	 (Johnson	 and	 Goody,	 2012;	 Michaelis	 and	 Menten,	 1913).		
Degradation	and	cell	death	are	modelled	using	LOMA.	Lipoprotein	delipidation,	transfer	and	
formation	 is	modelled	using	LOMA.	 	Cytokine	production,	excluding	TNF-Alpha,	within	 the	
tunica	 intima	 is	 modeled	 using	 LOMA.	 	 Cytokine	 production	 within	 the	 artery	 lumen	 is	
modeled	 using	Michaelis-Menten	 kinetics.	 	 Oxidation	 of	 lipoproteins,	 foam	 cell	 formation	
and	 SMC	migration	 are	modelled	 using	 a	modified	 form	of	Michaelis-Menten	 kinetics.	 All	
other	interactions	are	modelled	using	LOMA.		A	Hill	coefficient	has	been	added	to	equations	
regarding	 lipoprotein	 transfer	 to	 ensure	 accuracy	 in	 downstream	 oxidised	 LDL	
concentrations	 for	 different	 LDL	 concentrations.	 A	 list	 of	 the	 specific	 equations	 for	 each	
species	can	be	found	in	Appendix	3	-	Supplementary	Table	1.		
	
In	 order	 to	 find	 biologically	 relevant	 parameter	 values,	 a	 literature	 mining	 process	 was	
undertaken.	Enzyme	 rate	parameters	were	 included	 in	 the	model	were	either	 taken	 from	
studies	which	calculated	them	directly,	determined	through	fitting	species	concentrations	to	
experimental	 data	 or	made	 an	 estimation	 where	 appropriate	 experimental	 data	 was	 not	













the	 SBML	 version	 of	 the	model	was	 also	 simulated	 using	 the	 SBML	ODE	 Solver	 built	 into	
CellDesigner	(Funahashi	et	al.,	2003;	Machné	et	al.,	2006).		Initial	conditions	for	each	entity	
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ABCA1	 ABCG1	 CCL2	in	Intima	 CCL2	in	Lumen	 CXCL9	
CXCL10	 CXCL11	 Chymase	 Collagen	 EGF	
Elastin	
Interferon	
Gamma	 IL-1B	in	Intima	 IL-10	 IL-12	
IL-17	 IL-18	 IL-1B	in	Lumen	 IL-2	 IL-21	
IL-33	 IL-4	 IL-5	 IL-6	 MCSF	
MMP1	 MMP2	 MMP3	 MMP9	 MMP13	
PDGF	 PLA2	 Proteoglycans	 SMAse	 TGF-Beta	
TIMP1	 TIMP2	 TIMP3	 TIMP4	 TNF-Alpha	





























































































































The	 mathematical	 model	 detailed	 above	 has	 been	 implemented	 in	 MATLAB,	 using	 the	
method	 ‘ode23t’.	Ode23t	 is	 a	MATLAB	 function	 designed	 to	 solve	 systems	 of	moderately	


























Receptor	Name	 Ligand	Name	 kon	 kd	 koff	
CCR2-001	 CCL2-001	 1.86E+06	 3.77E-08	 7.01E-02	
CCR2-001	 CCL2-001-69	 5.52E+04	 3.92E-09	 2.16E-04	
CCR2-001	 CCL2-001-71	 2.54E+05	 4.89E-10	 1.24E-04	
CCR2-001	 CCL2-004	 2.02E+05	 1.77E-06	 3.57E-01	
CCR2-001-355	 CCL2-001	 2.73E+04	 4.03E-10	 1.10E-05	
CCR2-001-64	 CCL2-001	 2.87E+05	 1.17E-11	 3.34E-06	
CCR2-002	 CCL2-001	 1.87E+05	 4.52E-08	 8.45E-03	
CCR2-002-64	 CCL2-001	 3.92E+04	 2.97E-09	 1.16E-04	
CCR2-201	 CCL2-001	 8.37E+05	 3.41E-08	 2.85E-02	
CCR2-201-355	 CCL2-001	 7.05E+05	 1.66E-09	 1.17E-03	
CCR2-201-64	 CCL2-001	 3.47E+05	 7.10E-11	 2.46E-05	
CCR5-001	 CCL5-001	 5.94E+03	 9.67E-11	 5.74E-07	
CCR5-001	 CCL5-001-40	 1.07E+01	 3.55E-11	 3.80E-10	
CCR5-001	 CCL5-001-5	 4.25E+05	 4.08E-09	 1.73E-03	
CCR5-001	 CCL5-001-56	 1.98E+03	 8.70E-11	 1.72E-07	
CCR5-001	 CCL5-001-67	 1.08E+04	 1.18E-10	 1.27E-06	
CCR5-001	 CCL5-001-68	 5.64E+00	 4.79E-10	 2.70E-09	
CCR5-001	 CCL5-002	 5.94E+03	 9.67E-11	 5.74E-07	
CCR5-001	 CCL5-002-40	 1.07E+01	 3.55E-11	 3.80E-10	
CCR5-001	 CCL5-002-5	 4.25E+05	 4.08E-09	 1.73E-03	
CCR5-001	 CCL5-002-56	 1.98E+03	 8.70E-11	 1.72E-07	
CCR5-001	 CCL5-002-67	 1.08E+04	 1.18E-10	 1.27E-06	
CCR5-001	 CCL5-002-68	 5.64E+00	 4.79E-10	 2.70E-09	
CCR5-001-223	 CCL5-001	 1.71E+04	 9.76E-10	 1.67E-05	
CCR5-001-335	 CCL5-001	 3.43E+03	 7.37E-08	 2.53E-04	
CCR5-001-55	 CCL5-001	 5.29E+03	 1.19E-10	 6.29E-07	
CSF1R-001	 CSF1-001	 1.37E+09	 4.08E-06	 5.59E+03	
CSF1R-001	 CSF1-001-292	 1.67E+10	 1.73E-05	 2.88E+05	
CSF1R-001	 CSF1-001-408	 2.16E+09	 1.65E-06	 3.55E+03	
CSF1R-001	 CSF1-001-438	 1.34E+04	 1.36E-06	 1.82E-02	
CSF1R-001	 CSF1-001-489	 8.55E+05	 4.66E-05	 3.99E+01	
CSF1R-001	 CSF1-002-292	 3.18E+09	 3.33E-06	 1.06E+04	
CSF1R-001	 CSF1-002-408	 5.13E+04	 1.23E-06	 6.30E-02	
CSF1R-001	 CSF1-002-461	 2.01E+00	 7.81E-05	 1.57E-04	
CSF1R-001	 CSF1-002-489	 7.68E+09	 9.52E-08	 7.31E+02	
CSF1R-001	 CSF1-002-523	 1.35E+02	 1.63E-07	 2.20E-05	
CSF1R-001	 CSF1-003	 1.68E+04	 1.08E-06	 1.82E-02	
CSF1R-001	 CSF1-003-292	 1.63E+09	 5.52E-05	 8.99E+04	






CSF1R-001	 CSF1-004	 1.65E+04	 2.81E-07	 4.64E-03	
CSF1R-001-245	 CSF1-001	 3.81E-188	 3.82E-06	 1.45E-193	
CSF1R-001-362	 CSF1-001	 7.32E+04	 4.49E-06	 3.28E-01	
CSF1R-201	 CSF1-001	 1.86E+05	 7.56E-06	 1.41E+00	
CSF1R-201-153	 CSF1-001	 9.29E+09	 2.44E-05	 2.26E+05	
CSF1R-201-241	 CSF1-001	 3.19E+05	 4.41E-06	 1.41E+00	
CSF1R-201-245	 CSF1-001	 4.95E+09	 2.54E-05	 1.26E+05	
CSF1R-201-268	 CSF1-001	 1.85E+07	 2.69E-04	 4.98E+03	
CSF1R-201-279	 CSF1-001	 4.99E-140	 5.20E-06	 2.59E-145	
CSF1R-201-298	 CSF1-001	 1.91E+05	 1.00E-06	 1.92E-01	
CSF1R-201-32	 CSF1-001	 2.57E+04	 5.19E-06	 1.33E-01	
CSF1R-201-60	 CSF1-001	 7.69E+03	 5.51E-05	 4.24E-01	
CXCR3-001	 CXCL10-001	 3.50E+06	 1.97E-07	 6.91E-01	
CXCR3-001	 CXCL10-001-18	 6.91E+06	 6.57E-10	 4.54E-03	
CXCR3-001	 CXCL10-001-29	 1.52E+06	 1.75E-08	 2.66E-02	
CXCR3-001	 CXCL10-001-33	 6.93E+04	 3.63E-09	 2.52E-04	
CXCR3-001	 CXCL10-001-58	 1.29E+02	 2.28E-09	 2.94E-07	
CXCR3-001	 CXCL10-001-66	 6.43E-02	 3.03E-07	 1.95E-08	
CXCR3-001	 CXCL10-001-68	 7.13E+03	 2.95E-05	 2.10E-01	
CXCR3-001	 CXCL10-001-80	 4.92E+06	 1.30E-06	 6.37E+00	
CXCR3-001	 CXCL10-001-96	 1.39E+05	 1.65E-10	 2.29E-05	
CXCR3-001	 CXCL11-001	 3.38E+03	 1.71E-10	 5.77E-07	
CXCR3-001	 CXCL11-001-29	 6.04E+02	 1.38E-07	 8.35E-05	
CXCR3-001	 CXCL11-001-72	 5.50E+04	 7.25E-08	 3.99E-03	
CXCR3-001	 CXCL11-001-73	 1.12E+06	 7.63E-05	 8.54E+01	
CXCR3-001	 CXCL11-003	 7.55E+05	 6.76E-08	 5.10E-02	
CXCR3-001	 CXCL11-003-29	 2.73E+06	 2.61E-05	 7.12E+01	
CXCR3-001	 CXCL11-003-72	 5.27E+04	 1.38E-07	 7.25E-03	
CXCR3-001	 CXCL11-003-73	 4.22E+02	 4.88E-07	 2.06E-04	
CXCR3-001	 CXCL9-001	 1.82E+05	 3.56E-06	 6.48E-01	
CXCR3-001	 CXCL9-001-1	 3.31E+05	 9.08E-08	 3.00E-02	
CXCR3-001	 CXCL9-001-101	 1.95E+07	 6.51E-08	 1.27E+00	
CXCR3-001	 CXCL9-001-125	 4.24E+05	 4.56E-07	 1.93E-01	
CXCR3-001	 CXCL9-001-40	 2.76E+06	 7.99E-07	 2.21E+00	
CXCR3-001	 CXCL9-001-71	 1.69E+05	 3.11E-09	 5.26E-04	
CXCR3-002	 CXCL10-001	 1.02E+06	 6.45E-06	 6.58E+00	
CXCR3-002	 CXCL11-001	 1.81E+04	 3.88E-05	 7.02E-01	
CXCR3-002	 CXCL9-001	 2.81E+08	 6.31E-08	 1.77E+01	
EGFR-001	 EGF-001	 1.28E+04	 1.29E-06	 1.66E-02	
EGFR-001	 EGF-001-151	 2.31E+09	 3.05E-07	 7.03E+02	
EGFR-001	 EGF-002-389	 8.14E+04	 2.43E-05	 1.98E+00	
EGFR-001-521	 EGF-001	 2.07E+05	 9.84E-06	 2.04E+00	
EGFR-002	 EGF-001	 1.36E+05	 1.91E-06	 2.59E-01	






EGFR-002-640	 EGF-001	 3.11E+04	 4.39E-08	 1.37E-03	
EGFR-002-703	 EGF-001	 5.12E+04	 1.91E-07	 9.76E-03	
EGFR-003	 EGF-001	 7.60E+04	 3.36E-07	 2.56E-02	
EGFR-003-521	 EGF-001	 1.28E+04	 6.60E-08	 8.45E-04	
EGFR-004-476	 EGF-001	 3.43E+08	 6.70E-07	 2.30E+02	
EGFR-005	 EGF-001	 7.45E-144	 4.60E-08	 3.43E-151	
EGFR-201	 EGF-001	 9.34E+04	 5.30E-05	 4.95E+00	
EGFR-201-521	 EGF-001	 2.21E+03	 6.29E-08	 1.39E-04	
EGFR-202	 EGF-001	 5.16E+04	 1.03E-05	 5.33E-01	
IFNGR1-001	 IFNG-001	 7.34E+06	 4.10E-08	 3.01E-01	
IFNGR1-001	 IFNG-001-160	 3.31E+09	 6.39E-08	 2.12E+02	
IFNGR1-001	 IFNG-001-162	 1.09E+09	 1.00E-08	 1.09E+01	
IFNGR1-001	 IFNG-001-72	 4.60E+07	 2.44E-09	 1.12E-01	
IFNGR1-001-14	 IFNG-001	 1.08E+07	 7.12E-09	 7.69E-02	
IFNGR1-001-180	 IFNG-001	 7.55E+03	 2.36E-11	 1.78E-07	
IFNGR1-001-335	 IFNG-001	 3.68E+08	 7.16E-10	 2.64E-01	
IFNGR1-001-467	 IFNG-001	 1.01E+07	 2.77E-08	 2.80E-01	
IFNGR1-201	 IFNG-001	 3.60E+08	 1.05E-08	 3.77E+00	
IFNGR1-201-14	 IFNG-001	 3.65E+08	 1.47E-06	 5.37E+02	
IFNGR1-201-180	 IFNG-001	 3.34E+07	 1.17E-09	 3.91E-02	
IFNGR1-201-46	 IFNG-001	 8.43E+02	 3.78E-11	 3.18E-08	
IFNGR1-201-61	 IFNG-001	 1.47E+02	 3.70E-12	 5.44E-10	
IFNGR2-001	 IFNG-001	 3.29E+01	 6.33E-09	 2.08E-07	
IFNGR2-001	 IFNG-001-160	 2.44E+03	 3.89E-10	 9.48E-07	
IFNGR2-001	 IFNG-001-162	 5.83E+06	 1.80E-09	 1.05E-02	
IFNGR2-001	 IFNG-001-72	 3.68E+02	 8.74E-12	 3.21E-09	
IFNGR2-001-64	 IFNG-001	 4.69E+03	 9.63E-12	 4.52E-08	
IL10RA-001	 IL10-001	 9.89E+04	 4.07E-04	 4.02E+01	
IL10RA-001	 IL10-001-15	 1.07E+06	 2.16E-06	 2.31E+00	
IL10RA-001	 IL10-001-169	 8.11E+04	 4.72E-09	 3.82E-04	
IL10RA-001	 IL10-001-19	 2.09E+05	 1.43E-10	 2.99E-05	
IL10RA-001	 IL10-001-20	 5.75E+05	 6.08E-08	 3.49E-02	
IL10RA-001	 IL10-001-45	 8.12E+03	 8.67E-06	 7.04E-02	
IL10RA-001	 IL10-001-71	 1.05E+05	 2.38E-05	 2.50E+00	
IL10RA-001	 IL10-001-72	 1.50E+05	 3.71E-05	 5.56E+00	
IL10RA-001-159	 IL10-001	 3.88E+05	 4.56E-05	 1.77E+01	
IL10RA-001-224	 IL10-001	 4.60E+04	 8.04E-05	 3.70E+00	
IL10RA-001-233	 IL10-001	 1.75E-01	 1.21E-13	 2.12E-14	
IL10RA-001-351	 IL10-001	 9.10E+04	 3.41E-21	 3.10E-16	
IL10RA-001-420	 IL10-001	 1.45E-16	 6.79E-26	 9.84E-42	
IL12RB1-001	 IL12A-001	 1.57E+03	 1.18E-29	 1.85E-26	
IL12RB1-001	 IL12A-001-211	 5.24E+05	 7.36E-07	 3.86E-01	
IL12RB1-001	 IL12A-001-82	 2.36E+04	 4.92E-10	 1.16E-05	






IL12RB1-001	 IL12A-005-115	 3.74E+04	 4.69E-11	 1.75E-06	
IL12RB1-001	 IL12A-005-153	 1.56E+06	 8.55E-11	 1.33E-04	
IL12RB1-001	 IL12A-005-164	 4.57E+04	 1.48E-09	 6.77E-05	
IL12RB1-001	 IL12A-005-200	 4.49E+07	 1.14E-09	 5.14E-02	
IL12RB1-001	 IL12A-005-3	 6.81E+05	 1.45E-18	 9.87E-13	
IL12RB1-001	 IL12A-005-81	 5.39E+07	 1.06E-05	 5.71E+02	
IL12RB1-001	 IL12A-006	 9.19E+02	 9.06E-11	 8.33E-08	
IL12RB1-001	 IL12A-006-139	 8.94E+06	 3.62E-12	 3.23E-05	
IL12RB1-001	 IL12A-006-157	 1.50E+06	 2.32E-06	 3.48E+00	
IL12RB1-001	 IL12A-006-177	 1.42E+05	 8.60E-07	 1.22E-01	
IL12RB1-001	 IL12A-006-224	 4.11E+04	 1.17E-09	 4.82E-05	
IL12RB1-001	 IL12A-006-28	 3.49E-05	 2.17E-14	 7.58E-19	
IL12RB1-001	 IL12A-006-3	 7.19E+04	 6.78E-07	 4.88E-02	
IL12RB1-001	 IL12A-006-81	 1.44E+05	 2.88E-07	 4.14E-02	
IL12RB1-001-156	 IL12A-001	 5.08E+01	 3.63E-07	 1.85E-05	
IL12RB1-001-214	 IL12A-001	 4.15E+03	 3.45E-22	 1.43E-18	
IL12RB1-001-352	 IL12A-001	 8.56E-35	 1.08E-21	 9.24E-56	
IL12RB1-001-365	 IL12A-001	 7.64E-09	 1.09E-18	 8.33E-27	
IL12RB1-001-378	 IL12A-001	 3.08E+03	 1.45E-06	 4.47E-03	
IL12RB1-001-91	 IL12A-001	 8.55E-15	 8.17E-27	 6.98E-41	
IL12RB1-002-156	 IL12A-001	 5.08E+01	 3.63E-07	 1.85E-05	
IL12RB1-002-214	 IL12A-001	 1.14E-15	 3.45E-22	 3.93E-37	
IL12RB1-002-378	 IL12A-001	 3.08E+03	 1.45E-06	 4.47E-03	
IL12RB1-002-47	 IL12A-001	 3.53E-22	 2.62E-19	 9.24E-41	
IL12RB1-002-91	 IL12A-001	 8.55E-15	 8.17E-27	 6.98E-41	
IL12RB1-003-201	 IL12A-001	 9.05E+06	 7.78E-06	 7.04E+01	
IL17RA-001	 IL17A-001	 4.45E-02	 4.61E-13	 2.05E-14	
IL17RA-001	 IL17A-001-134	 7.48E+00	 2.60E-05	 1.94E-04	
IL17RA-001	 IL17A-001-43	 1.47E-13	 4.60E-06	 6.77E-19	
IL17RA-001	 IL17A-001-69	 2.43E+03	 9.95E-05	 2.42E-01	
IL17RA-001	 IL17A-001-71	 5.42E+08	 3.29E-06	 1.78E+03	
IL17RA-001	 IL17A-001-74	 3.18E-03	 5.07E-06	 1.61E-08	
IL17RA-001	 IL17A-001-95	 1.79E-84	 5.83E-07	 1.04E-90	
IL17RA-001-367	 IL17A-001	 1.80E-03	 1.73E-11	 3.11E-14	
IL17RA-001-607	 IL17A-001	 4.46E+03	 5.29E-07	 2.36E-03	
IL17RA-001-691	 IL17A-001	 6.96E+00	 4.40E-07	 3.06E-06	
IL18R1-001	 IL18-001	 4.16E+01	 6.93E-11	 2.88E-09	
IL18R1-001	 IL18-001-127	 1.37E-04	 7.21E-11	 9.88E-15	
IL18R1-001	 IL18-001-164	 1.49E-01	 9.41E-13	 1.40E-13	
IL18R1-001	 IL18-001-22	 3.26E+03	 1.96E-10	 6.40E-07	
IL18R1-001	 IL18-001-47	 4.57E+01	 1.16E-09	 5.29E-08	
IL18R1-001	 IL18-001-63	 2.89E+03	 1.03E-07	 2.98E-04	
IL18R1-001	 IL18-003	 5.86E+03	 7.81E-10	 4.58E-06	






IL18R1-001	 IL18-003-160	 8.74E+01	 2.26E-10	 1.97E-08	
IL18R1-001	 IL18-003-22	 2.06E+00	 2.05E-11	 4.21E-11	
IL18R1-001	 IL18-003-43	 5.12E+01	 3.60E-11	 1.84E-09	
IL18R1-001	 IL18-003-59	 1.50E+04	 2.79E-10	 4.19E-06	
IL18R1-001	 IL18-006	 4.16E+01	 6.93E-11	 2.88E-09	
IL18R1-001	 IL18-006-127	 1.37E-04	 7.21E-11	 9.88E-15	
IL18R1-001	 IL18-006-164	 1.49E-01	 9.41E-13	 1.40E-13	
IL18R1-001	 IL18-006-22	 3.26E+03	 1.96E-10	 6.40E-07	
IL18R1-001	 IL18-006-47	 4.57E+01	 1.16E-09	 5.29E-08	
IL18R1-001	 IL18-006-63	 2.89E+03	 1.03E-07	 2.98E-04	
IL18R1-001-170	 IL18-001	 3.81E+03	 7.25E-09	 2.76E-05	
IL18R1-001-232	 IL18-001	 1.26E+06	 2.27E-08	 2.86E-02	
IL18R1-001-423	 IL18-001	 1.05E+03	 9.98E-11	 1.05E-07	
IL18R1-201	 IL18-001	 4.16E+01	 6.93E-11	 2.88E-09	
IL18R1-201-170	 IL18-001	 3.81E+03	 7.25E-09	 2.76E-05	
IL18R1-201-232	 IL18-001	 1.26E+06	 2.27E-08	 2.86E-02	
IL18R1-201-423	 IL18-001	 1.05E+03	 9.98E-11	 1.05E-07	
IL18R1-202	 IL18-001	 5.78E+04	 2.11E-11	 1.22E-06	
IL18R1-202-100	 IL18-001	 3.05E-02	 2.52E-10	 7.67E-12	
IL18R1-202-117	 IL18-001	 5.63E+05	 4.04E-09	 2.27E-03	
IL18R1-202-139	 IL18-001	 3.42E+04	 2.47E-09	 8.46E-05	
IL18R1-202-162	 IL18-001	 1.45E+05	 3.95E-10	 5.72E-05	
IL18R1-202-53	 IL18-001	 4.32E+04	 1.76E-10	 7.59E-06	
IL18R1-202-84	 IL18-001	 2.00E+04	 3.11E-10	 6.21E-06	
IL1R1-001	 IL1B-001	 4.41E-29	 2.41E-20	 1.06E-48	
IL1R1-001	 IL33-001-124	 1.56E+07	 4.11E-05	 6.40E+02	
IL1R1-001	 IL33-001-153	 5.44E-01	 4.23E-06	 2.30E-06	
IL1R1-001	 IL33-001-201	 1.48E+04	 1.08E-05	 1.60E-01	
IL1R1-001	 IL33-001-263	 1.05E+07	 1.84E-06	 1.93E+01	
IL1R1-001	 IL33-001-83	 5.05E+06	 2.96E-07	 1.50E+00	
IL1R1-001	 IL33-201-31	 2.11E+05	 2.08E-06	 4.40E-01	
IL1R1-001	 IL33-201-4	 2.43E+10	 6.68E-06	 1.62E+05	
IL1R1-001	 IL33-201-75	 4.26E+04	 7.48E-07	 3.19E-02	
IL1R1-001	 IL33-201-96	 3.19E+07	 1.18E-04	 3.76E+03	
IL1R1-001	 IL33-202-108	 2.46E+00	 1.24E-05	 3.05E-05	
IL1R1-001	 IL33-202-180	 6.98E+10	 4.26E-05	 2.97E+06	
IL1R1-001	 IL33-202-39	 2.06E+11	 1.08E-04	 2.22E+07	
IL1R1-001	 IL33-202-55	 4.28E+10	 6.31E-05	 2.70E+06	
IL1R1-001	 IL33-202-57	 1.57E-22	 9.83E-21	 1.54E-42	
IL1R1-001	 IL33-203	 8.31E+06	 2.48E-05	 2.06E+02	
IL1R1-001	 IL33-203-31	 1.13E+09	 5.75E-07	 6.50E+02	
IL1R1-001	 IL33-203-39	 2.56E+09	 1.86E-04	 4.77E+05	
IL1R1-001	 IL33-203-4	 3.80E+04	 1.05E-05	 3.99E-01	






IL1R1-001-510	 IL33-001	 2.74E-01	 7.30E-07	 2.00E-07	
IL1R1-006-344	 IL33-001	 6.87E+08	 2.97E-06	 2.04E+03	
IL1R1-006-425	 IL33-001	 2.00E+09	 4.42E-08	 8.85E+01	
IL1R1-013	 IL33-001	 2.18E+05	 1.91E-11	 4.16E-06	
IL1R1-013-124	 IL33-001	 4.09E+07	 2.99E-11	 1.22E-03	
IL1R1-013-344	 IL33-001	 1.91E+09	 2.74E-11	 5.23E-02	
IL1RL1-001	 IL33-201-96	 9.25E+06	 3.41E-06	 3.16E+01	
IL1RL1-001	 IL33-202-108	 2.32E-37	 9.75E-29	 2.26E-65	
IL1RL1-001-176	 IL33-001	 4.22E+04	 9.91E-12	 4.18E-07	
IL1RL1-002-216	 IL33-001	 4.10E+02	 1.23E-14	 5.04E-12	
IL1RL1-008-180	 IL33-001	 7.79E+00	 1.30E-13	 1.01E-12	
IL1RL1-201-127	 IL33-001	 2.62E+09	 2.01E-05	 5.26E+04	
IL21R-001	 IL21-001	 2.46E+05	 3.53E-09	 8.69E-04	
IL21R-001	 IL21-001-135	 3.18E+08	 4.69E-08	 1.49E+01	
IL21R-001	 IL21-001-40	 1.25E+10	 4.26E-08	 5.33E+02	
IL21R-001	 IL21-201	 1.22E+05	 3.55E-10	 4.33E-05	
IL21R-001	 IL21-201-135	 1.34E+09	 3.79E-07	 5.08E+02	
IL21R-001	 IL21-201-40	 2.19E+05	 1.82E-09	 3.97E-04	
IL21R-001-318	 IL21-001	 1.31E+05	 2.67E-05	 3.50E+00	
IL21R-001-484	 IL21-001	 1.77E+00	 4.50E-11	 7.96E-11	
IL21R-003	 IL21-001	 2.46E+05	 3.53E-09	 8.69E-04	
IL21R-003-318	 IL21-001	 1.31E+05	 2.67E-05	 3.50E+00	
IL21R-003-484	 IL21-001	 1.54E+06	 2.03E-07	 3.13E-01	
IL21R-006	 IL21-001	 2.46E+05	 3.53E-09	 8.69E-04	
IL21R-006-318	 IL21-001	 2.28E+05	 1.26E-05	 2.87E+00	
IL21R-006-484	 IL21-001	 1.54E+06	 2.03E-07	 3.13E-01	
IL2RA-001	 IL2-001	 7.02E+01	 3.27E-12	 2.29E-10	
IL2RA-001	 IL2-001-140	 3.07E+02	 3.46E-12	 1.06E-09	
IL2RA-001	 IL2-001-21	 4.84E-01	 1.75E-12	 8.48E-13	
IL2RA-001	 IL2-001-43	 1.64E+04	 4.35E-11	 7.14E-07	
IL2RA-001	 IL2-001-54	 4.15E-04	 1.26E-12	 5.21E-16	
IL2RA-001-153	 IL2-001	 1.52E+03	 2.75E-10	 4.18E-07	
IL2RA-002	 IL2-001	 1.10E+02	 3.64E-12	 4.01E-10	
IL2RA-002-111	 IL2-001	 2.30E+05	 6.95E-12	 1.60E-06	
IL2RA-002-148	 IL2-001	 3.77E+03	 1.57E-09	 5.91E-06	
IL2RA-002-159	 IL2-001	 2.14E+03	 1.14E-11	 2.44E-08	
IL2RA-002-161	 IL2-001	 3.73E+05	 1.74E-10	 6.50E-05	
IL2RA-002-181	 IL2-001	 3.02E+00	 1.32E-09	 4.00E-09	
IL2RA-002-191	 IL2-001	 3.54E+05	 3.82E-09	 1.35E-03	
IL2RA-002-200	 IL2-001	 8.43E+02	 2.33E-12	 1.96E-09	
IL2RA-002-25	 IL2-001	 9.34E+06	 1.29E-06	 1.21E+01	
IL2RA-002-39	 IL2-001	 1.62E+08	 2.00E-07	 3.25E+01	
IL2RA-002-42	 IL2-001	 3.53E+06	 9.38E-08	 3.31E-01	






IL2RA-002-91	 IL2-001	 1.53E+00	 8.57E-09	 1.31E-08	
IL2RA-004	 IL2-001	 8.24E+04	 4.31E-12	 3.55E-07	
IL2RA-004-111	 IL2-001	 1.24E+05	 2.46E-07	 3.05E-02	
IL2RA-004-153	 IL2-001	 4.44E+05	 1.06E-05	 4.69E+00	
IL2RA-004-244	 IL2-001	 5.21E+05	 9.32E-08	 4.85E-02	
IL2RA-004-91	 IL2-001	 1.05E-04	 4.94E-12	 5.19E-16	
IL4R-001	 IL4-001	 1.17E+04	 4.37E-05	 5.12E-01	
IL4R-001	 IL4-001-100	 3.49E-37	 6.22E-26	 2.17E-62	
IL4R-001	 IL4-001-105	 2.33E+09	 1.56E-05	 3.64E+04	
IL4R-001	 IL4-001-109	 3.35E+03	 1.21E-09	 4.05E-06	
IL4R-001	 IL4-001-152	 1.30E+05	 9.35E-06	 1.21E+00	
IL4R-001	 IL4-001-22	 4.25E-21	 3.16E-35	 1.34E-55	
IL4R-001	 IL4-001-26	 2.49E+06	 1.74E-06	 4.34E+00	
IL4R-001	 IL4-001-30	 1.84E+09	 2.76E-06	 5.08E+03	
IL4R-001	 IL4-001-53	 1.34E+07	 2.73E-06	 3.66E+01	
IL4R-001	 IL4-001-98	 3.01E+07	 9.04E-07	 2.72E+01	
IL4R-001	 IL4-002	 5.40E+03	 1.03E-06	 5.54E-03	
IL4R-001	 IL4-002-102	 1.18E-16	 9.57E-14	 1.13E-29	
IL4R-001	 IL4-002-136	 2.66E+06	 6.21E-07	 1.65E+00	
IL4R-001	 IL4-002-22	 2.10E+06	 6.57E-05	 1.38E+02	
IL4R-001	 IL4-002-26	 1.20E+07	 3.55E-07	 4.26E+00	
IL4R-001	 IL4-002-30	 1.49E+03	 1.14E-11	 1.70E-08	
IL4R-001	 IL4-002-82	 1.71E+06	 1.54E-06	 2.62E+00	
IL4R-001	 IL4-002-84	 5.39E+04	 6.01E-06	 3.24E-01	
IL4R-001	 IL4-002-89	 1.60E+05	 3.59E-09	 5.75E-04	
IL4R-001	 IL4-002-93	 7.67E+07	 5.26E-08	 4.04E+00	
IL4R-001	 IL4-201	 6.87E-08	 7.57E-06	 5.20E-13	
IL4R-001	 IL4-201-134	 2.46E+10	 1.09E-04	 2.68E+06	
IL4R-001	 IL4-201-22	 2.45E+08	 2.43E-06	 5.96E+02	
IL4R-001	 IL4-201-26	 1.77E+04	 1.72E-06	 3.04E-02	
IL4R-001	 IL4-201-30	 6.18E-03	 6.09E-06	 3.76E-08	
IL4R-001	 IL4-201-67	 7.50E+08	 1.41E-06	 1.06E+03	
IL4R-001	 IL4-201-82	 1.07E+06	 4.96E-06	 5.30E+00	
IL4R-001-185	 IL4-001	 1.67E+08	 5.75E-06	 9.61E+02	
IL4R-001-400	 IL4-001	 5.41E+03	 3.30E-05	 1.78E-01	
IL4R-001-436	 IL4-001	 1.29E+07	 1.54E-06	 1.99E+01	
IL4R-001-503	 IL4-001	 1.56E+03	 1.76E-05	 2.75E-02	
IL4R-001-576	 IL4-001	 4.12E+05	 1.27E-04	 5.24E+01	
IL4R-001-579	 IL4-001	 8.56E+05	 1.42E-06	 1.22E+00	
IL4R-001-75	 IL4-001	 5.93E+02	 3.23E-05	 1.92E-02	
IL4R-001-752	 IL4-001	 1.85E+05	 2.13E-06	 3.94E-01	
IL4R-001-82	 IL4-001	 3.08E+09	 6.24E-06	 1.92E+04	
IL4R-001-97	 IL4-001	 2.15E-09	 1.29E-05	 2.77E-14	






IL4R-004-185	 IL4-001	 2.15E+06	 5.01E-07	 1.08E+00	
IL4R-004-400	 IL4-001	 5.58E+04	 2.14E-07	 1.19E-02	
IL4R-004-431	 IL4-001	 1.30E+06	 3.68E-07	 4.78E-01	
IL4R-004-436	 IL4-001	 2.86E-33	 5.20E-06	 1.49E-38	
IL4R-004-503	 IL4-001	 1.74E+04	 7.41E-06	 1.29E-01	
IL4R-004-576	 IL4-001	 1.82E+02	 8.95E-11	 1.63E-08	
IL4R-004-579	 IL4-001	 1.59E+04	 7.38E-06	 1.17E-01	
IL4R-004-75	 IL4-001	 1.95E+05	 4.45E-05	 8.67E+00	
IL4R-004-752	 IL4-001	 2.67E+04	 8.03E-07	 2.14E-02	
IL4R-004-786	 IL4-001	 1.88E+04	 8.69E-06	 1.63E-01	
IL4R-004-82	 IL4-001	 8.68E+07	 8.04E-06	 6.98E+02	
IL4R-004-97	 IL4-001	 4.89E+05	 8.34E-06	 4.08E+00	
IL4R-201	 IL4-001	 2.97E-08	 1.90E-14	 5.64E-22	
IL4R-201-170	 IL4-001	 4.99E+00	 6.00E-06	 2.99E-05	
IL4R-201-385	 IL4-001	 1.05E+06	 2.05E-05	 2.15E+01	
IL4R-201-416	 IL4-001	 6.07E+07	 1.28E-05	 7.76E+02	
IL4R-201-421	 IL4-001	 2.95E+05	 1.33E-04	 3.91E+01	
IL4R-201-488	 IL4-001	 8.17E+07	 7.70E-07	 6.29E+01	
IL4R-201-561	 IL4-001	 5.62E+05	 5.79E-07	 3.25E-01	
IL4R-201-564	 IL4-001	 3.34E-06	 7.13E-12	 2.38E-17	
IL4R-201-60	 IL4-001	 1.26E+05	 2.15E-06	 2.71E-01	
IL4R-201-660	 IL4-001	 2.16E+06	 1.51E-05	 3.26E+01	
IL4R-201-67	 IL4-001	 1.63E+04	 1.37E-06	 2.24E-02	
IL4R-201-737	 IL4-001	 9.11E+05	 1.11E-05	 1.01E+01	
IL4R-201-771	 IL4-001	 4.36E-178	 3.84E-06	 1.67E-183	
IL4R-201-82	 IL4-001	 7.78E+06	 8.21E-07	 6.38E+00	
IL5RA-001	 IL5-001	 8.21E+04	 2.88E-05	 2.36E+00	
IL5RA-001	 IL5-001-104	 3.30E+05	 0.00E+00	 0.00E+00	
IL5RA-001	 IL5-001-17	 5.88E+04	 1.15E-05	 6.76E-01	
IL5RA-001	 IL5-001-40	 1.91E+07	 1.07E-05	 2.03E+02	
IL5RA-001	 IL5-001-45	 2.26E+04	 1.32E-05	 2.98E-01	
IL5RA-001	 IL5-001-49	 8.75E+05	 3.56E-05	 3.12E+01	
IL5RA-001	 IL5-001-6	 4.51E+05	 1.30E-05	 5.85E+00	
IL5RA-001	 IL5-001-93	 4.41E+04	 1.21E-05	 5.35E-01	
IL5RA-001-129	 IL5-001	 3.95E+06	 1.01E-04	 3.99E+02	
IL5RA-001-359	 IL5-001	 5.71E+05	 7.39E-05	 4.22E+01	
IL5RA-001-59	 IL5-001	 6.35E+05	 4.87E-05	 3.09E+01	
IL5RA-002	 IL5-001	 4.01E+05	 2.89E-05	 1.16E+01	
IL5RA-002-129	 IL5-001	 3.00E+05	 0.00E+00	 0.00E+00	
IL5RA-002-262	 IL5-001	 6.36E+04	 0.00E+00	 0.00E+00	
IL5RA-002-59	 IL5-001	 1.88E+06	 0.00E+00	 0.00E+00	
IL5RA-003	 IL5-001	 8.18E+05	 0.00E+00	 0.00E+00	
IL5RA-003-129	 IL5-001	 1.94E+05	 0.00E+00	 0.00E+00	






IL5RA-003-59	 IL5-001	 1.95E+05	 5.06E-05	 9.86E+00	
IL5RA-004	 IL5-001	 3.32E+04	 3.06E-05	 1.02E+00	
IL5RA-004-129	 IL5-001	 8.37E+06	 1.99E-04	 1.66E+03	
IL5RA-004-359	 IL5-001	 4.30E+05	 1.61E-07	 6.91E-02	
IL5RA-004-59	 IL5-001	 1.75E+05	 5.98E-05	 1.05E+01	
IL5RA-005	 IL5-001	 1.61E+05	 8.21E-05	 1.32E+01	
IL5RA-005-129	 IL5-001	 4.63E+03	 3.75E-06	 1.74E-02	
IL5RA-005-262	 IL5-001	 1.18E+06	 3.35E-04	 3.96E+02	
IL5RA-005-59	 IL5-001	 8.29E+05	 7.75E-05	 6.42E+01	
IL5RA-006	 IL5-001	 2.47E+05	 2.15E-05	 5.30E+00	
IL5RA-006-129	 IL5-001	 1.90E+05	 1.08E-04	 2.05E+01	
IL5RA-006-262	 IL5-001	 8.65E+05	 0.00E+00	 0.00E+00	
IL5RA-006-59	 IL5-001	 2.64E+05	 3.57E-06	 9.42E-01	
IL5RA-007	 IL5-001	 6.87E+04	 0.00E+00	 0.00E+00	
IL5RA-007-129	 IL5-001	 5.85E+05	 0.00E+00	 0.00E+00	
IL5RA-007-359	 IL5-001	 1.25E+05	 1.64E-05	 2.05E+00	
IL5RA-007-59	 IL5-001	 2.17E+05	 0.00E+00	 0.00E+00	
IL5RA-201	 IL5-001	 7.17E+04	 1.53E-06	 1.10E-01	
IL5RA-201-129	 IL5-001	 6.12E+05	 0.00E+00	 0.00E+00	
IL5RA-201-264	 IL5-001	 2.75E+03	 1.52E-07	 4.17E-04	
IL5RA-201-287	 IL5-001	 4.95E+05	 0.00E+00	 0.00E+00	
IL5RA-201-59	 IL5-001	 7.49E+04	 1.14E-07	 8.51E-03	
IL6R-001	 IL6-001	 1.30E+05	 3.79E-05	 4.93E+00	
IL6R-001	 IL6-001-104	 2.76E+06	 1.03E-06	 2.85E+00	
IL6R-001	 IL6-001-116	 2.31E+04	 4.53E-08	 1.05E-03	
IL6R-001	 IL6-001-152	 7.44E+04	 1.40E-07	 1.04E-02	
IL6R-001	 IL6-001-162	 2.68E+04	 1.59E-06	 4.26E-02	
IL6R-001	 IL6-001-2	 5.50E+05	 1.41E-06	 7.73E-01	
IL6R-001	 IL6-001-31	 6.57E+03	 4.11E-07	 2.70E-03	
IL6R-001	 IL6-001-32	 3.32E+05	 4.87E-06	 1.62E+00	
IL6R-001	 IL6-001-55	 2.35E+05	 2.71E-06	 6.37E-01	
IL6R-001	 IL6-001-6	 6.27E+05	 2.34E-07	 1.46E-01	
IL6R-001	 IL6-001-7	 1.73E+05	 2.19E-06	 3.78E-01	
IL6R-001	 IL6-001-79	 1.48E+06	 9.33E-07	 1.38E+00	
IL6R-001	 IL6-003	 7.14E+05	 9.62E-06	 6.87E+00	
IL6R-001	 IL6-003-110	 3.78E+05	 3.26E-08	 1.23E-02	
IL6R-001	 IL6-003-28	 4.97E+04	 2.58E-08	 1.28E-03	
IL6R-001	 IL6-003-3	 2.11E+05	 4.87E-06	 1.03E+00	
IL6R-001	 IL6-003-40	 6.21E+06	 5.72E-06	 3.55E+01	
IL6R-001	 IL6-003-76	 2.60E+04	 3.53E-06	 9.17E-02	
IL6R-001	 IL6-003-89	 1.60E+05	 3.31E-05	 5.30E+00	
IL6R-001	 IL6-003-92	 9.60E+05	 1.26E-05	 1.20E+01	
IL6R-001	 IL6-004	 1.96E+05	 3.59E-06	 7.03E-01	






IL6R-001	 IL6-004-3	 9.90E+05	 3.92E-06	 3.88E+00	
IL6R-001	 IL6-004-40	 2.42E+05	 1.77E-04	 4.28E+01	
IL6R-001	 IL6-004-76	 4.13E+03	 7.67E-09	 3.17E-05	
IL6R-001	 IL6-004-86	 2.78E+03	 3.06E-09	 8.51E-06	
IL6R-001	 IL6-005	 1.63E+04	 1.18E-06	 1.93E-02	
IL6R-001	 IL6-005-129	 7.10E+04	 7.14E-06	 5.07E-01	
IL6R-001	 IL6-005-139	 7.26E+04	 1.49E-07	 1.08E-02	
IL6R-001	 IL6-005-2	 7.70E+04	 8.62E-07	 6.64E-02	
IL6R-001	 IL6-005-32	 9.82E+04	 6.00E-07	 5.89E-02	
IL6R-001	 IL6-005-56	 2.12E+05	 2.92E-06	 6.19E-01	
IL6R-001	 IL6-005-6	 4.91E+04	 1.82E-08	 8.92E-04	
IL6R-001	 IL6-005-8	 3.26E+05	 8.33E-07	 2.72E-01	
IL6R-001	 IL6-005-81	 6.95E+04	 4.49E-06	 3.12E-01	
IL6R-001	 IL6-005-9	 1.56E+05	 6.48E-08	 1.01E-02	
IL6R-001	 IL6-005-93	 2.61E+02	 2.31E-07	 6.02E-05	
IL6R-001	 IL6-006	 1.13E+04	 4.68E-06	 5.29E-02	
IL6R-001	 IL6-006-104	 1.68E+05	 2.36E-06	 3.96E-01	
IL6R-001	 IL6-006-116	 2.29E+05	 3.57E-06	 8.17E-01	
IL6R-001	 IL6-006-152	 2.12E+04	 8.65E-07	 1.83E-02	
IL6R-001	 IL6-006-165	 1.38E+03	 7.30E-08	 1.01E-04	
IL6R-001	 IL6-006-168	 1.34E+04	 1.23E-05	 1.65E-01	
IL6R-001	 IL6-006-186	 2.28E+04	 2.47E-06	 5.63E-02	
IL6R-001	 IL6-006-2	 3.55E+03	 1.93E-07	 6.84E-04	
IL6R-001	 IL6-006-31	 4.69E+06	 9.42E-06	 4.42E+01	
IL6R-001	 IL6-006-32	 1.10E+06	 1.59E-05	 1.74E+01	
IL6R-001	 IL6-006-55	 2.24E+06	 1.50E-05	 3.36E+01	
IL6R-001	 IL6-006-6	 6.54E+05	 2.14E-05	 1.40E+01	
IL6R-001	 IL6-006-7	 1.99E+06	 6.36E-08	 1.27E-01	
IL6R-001	 IL6-006-79	 3.72E+05	 3.68E-07	 1.37E-01	
IL6R-001	 IL6-201	 1.12E+05	 6.15E-07	 6.89E-02	
IL6R-001	 IL6-201-104	 1.81E+04	 6.09E-09	 1.10E-04	
IL6R-001	 IL6-201-116	 7.90E+04	 2.99E-06	 2.36E-01	
IL6R-001	 IL6-201-152	 6.06E+03	 4.42E-09	 2.68E-05	
IL6R-001	 IL6-201-162	 9.62E+04	 2.27E-08	 2.18E-03	
IL6R-001	 IL6-201-2	 5.76E+05	 4.87E-06	 2.80E+00	
IL6R-001	 IL6-201-31	 1.46E+03	 8.87E-08	 1.29E-04	
IL6R-001	 IL6-201-32	 1.19E+06	 5.09E-06	 6.06E+00	
IL6R-001	 IL6-201-55	 9.18E-03	 6.02E-10	 5.52E-12	
IL6R-001	 IL6-201-6	 1.43E+07	 2.85E-05	 4.08E+02	
IL6R-001	 IL6-201-7	 6.29E+03	 1.68E-08	 1.06E-04	
IL6R-001	 IL6-201-79	 5.67E+05	 6.72E-07	 3.81E-01	
IL6R-001-358	 IL6-001	 1.99E+04	 6.38E-08	 1.27E-03	
IL6R-001-385	 IL6-001	 1.85E+05	 1.19E-05	 2.20E+00	






IL6R-003	 IL6-001	 2.10E+05	 4.98E-05	 1.05E+01	
IL6R-003-65	 IL6-001	 1.85E+05	 5.16E-07	 9.55E-02	
IL6R-201	 IL6-001	 1.38E+05	 2.87E-05	 3.97E+00	
IL6R-201-65	 IL6-001	 8.88E+04	 4.89E-08	 4.34E-03	
MMP1-001	 CMA1-001	 5.05E+06	 4.19E-10	 2.12E-03	
MMP1-001	 CMA1-001-151	 3.02E+06	 4.06E-09	 1.23E-02	
MMP1-001	 CMA1-001-157	 2.58E+07	 2.26E-07	 5.84E+00	
MMP1-001	 CMA1-001-183	 1.00E+04	 7.32E-10	 7.32E-06	
MMP1-001	 CMA1-001-221	 1.82E+07	 1.51E-07	 2.74E+00	
MMP1-001	 CMA1-001-226	 1.96E+05	 1.04E-08	 2.05E-03	
MMP1-001	 CMA1-001-33	 7.91E+05	 8.43E-10	 6.67E-04	
MMP1-001	 CMA1-001-38	 1.19E-01	 1.46E-09	 1.74E-10	
MMP1-001	 CMA1-001-46	 7.19E+05	 6.88E-07	 4.95E-01	
MMP1-001	 CMA1-001-48	 6.72E+04	 9.26E-07	 6.23E-02	
MMP1-001	 CMA1-001-63	 1.21E+06	 7.55E-08	 9.14E-02	
MMP1-001	 CMA1-001-66	 3.64E+06	 2.16E-08	 7.85E-02	
MMP1-001	 CMA1-001-69	 4.79E+08	 2.74E-08	 1.31E+01	
MMP1-001	 CMA1-001-98	 3.26E+02	 4.52E-11	 1.47E-08	
MMP1-001	 CMA1-002	 2.47E+05	 8.35E-09	 2.06E-03	
MMP1-001	 CMA1-002-1	 3.93E+01	 8.47E-12	 3.33E-10	
MMP1-001	 CMA1-002-106	 4.74E+03	 6.82E-09	 3.23E-05	
MMP1-001	 CMA1-002-110	 7.73E-01	 4.97E-14	 3.84E-14	
MMP1-001	 CMA1-002-115	 1.28E+08	 4.10E-05	 5.25E+03	
MMP1-001	 CMA1-002-124	 5.75E+07	 4.65E-07	 2.68E+01	
MMP1-001	 CMA1-002-126	 3.90E+07	 4.72E-05	 1.84E+03	
MMP1-001	 CMA1-002-40	 1.82E+07	 1.40E-07	 2.55E+00	
MMP1-001	 CMA1-002-46	 1.67E+06	 1.14E-07	 1.90E-01	
MMP1-001	 CMA1-002-48	 3.22E+03	 6.47E-09	 2.08E-05	
MMP1-001	 CMA1-002-59	 2.21E+04	 6.16E-06	 1.36E-01	
MMP1-001	 CMA1-002-72	 1.57E+07	 2.07E-08	 3.25E-01	
MMP1-001	 CMA1-002-75	 5.09E+06	 1.60E-09	 8.12E-03	
MMP1-001	 CMA1-002-77	 3.92E+07	 2.07E-06	 8.12E+01	
MMP1-001	 CMA1-002-93	 1.25E+07	 5.15E-10	 6.43E-03	
MMP1-001	 CMA1-002-95	 5.53E+07	 1.20E-08	 6.61E-01	
MMP1-001	 TIMP1-001	 1.40E+06	 5.02E-06	 7.02E+00	
MMP1-001	 TIMP1-001-10	 8.70E+04	 2.00E-07	 1.74E-02	
MMP1-001	 TIMP1-001-102	 5.75E+05	 4.01E-07	 2.31E-01	
MMP1-001	 TIMP1-001-105	 4.84E+04	 2.04E-06	 9.89E-02	
MMP1-001	 TIMP1-001-136	 4.38E+05	 5.98E-07	 2.62E-01	
MMP1-001	 TIMP1-001-171	 1.53E+00	 1.93E-11	 2.95E-11	
MMP1-001	 TIMP1-001-185	 1.69E+06	 9.80E-06	 1.66E+01	
MMP1-001	 TIMP1-001-192	 1.97E+05	 5.62E-07	 1.11E-01	
MMP1-001	 TIMP1-001-203	 3.85E-02	 3.73E-11	 1.43E-12	






MMP1-001	 TIMP1-001-50	 1.74E+03	 1.27E-11	 2.20E-08	
MMP1-001	 TIMP1-001-51	 1.92E+05	 4.95E-09	 9.49E-04	
MMP1-001	 TIMP1-001-76	 1.40E+01	 2.34E-10	 3.27E-09	
MMP1-001	 TIMP1-001-77	 2.71E+02	 1.61E-06	 4.37E-04	
MMP1-001	 TIMP1-002	 2.19E+05	 1.57E-05	 3.44E+00	
MMP1-001	 TIMP1-002-10	 9.59E+03	 2.70E-06	 2.59E-02	
MMP1-001	 TIMP1-002-102	 1.59E+05	 1.52E-05	 2.41E+00	
MMP1-001	 TIMP1-002-105	 3.73E+04	 4.45E-06	 1.66E-01	
MMP1-001	 TIMP1-002-115	 7.68E+04	 1.12E-05	 8.62E-01	
MMP1-001	 TIMP1-002-116	 5.66E+05	 1.80E-06	 1.02E+00	
MMP1-001	 TIMP1-002-33	 4.09E+00	 2.22E-12	 9.08E-12	
MMP1-001	 TIMP1-002-50	 6.70E-07	 1.16E-12	 7.76E-19	
MMP1-001	 TIMP1-002-51	 2.59E+02	 5.46E-12	 1.42E-09	
MMP1-001	 TIMP1-002-76	 4.52E+06	 1.42E-05	 6.40E+01	
MMP1-001	 TIMP1-002-77	 5.65E+03	 5.74E-06	 3.24E-02	
MMP1-001	 TIMP1-003	 6.87E+01	 4.02E-12	 2.76E-10	
MMP1-001	 TIMP1-003-107	 1.68E+05	 7.50E-05	 1.26E+01	
MMP1-001	 TIMP1-003-12	 3.36E+05	 2.46E-06	 8.27E-01	
MMP1-001	 TIMP1-003-121	 2.02E+04	 6.49E-09	 1.31E-04	
MMP1-001	 TIMP1-003-128	 2.48E+04	 6.30E-07	 1.56E-02	
MMP1-001	 TIMP1-003-13	 7.56E+05	 1.58E-05	 1.19E+01	
MMP1-001	 TIMP1-003-139	 5.11E+02	 1.87E-11	 9.56E-09	
MMP1-001	 TIMP1-003-38	 1.92E+05	 1.57E-05	 3.00E+00	
MMP1-001	 TIMP1-003-41	 3.02E+06	 5.96E-07	 1.80E+00	
MMP1-001	 TIMP1-003-72	 4.09E+01	 1.78E-12	 7.29E-11	
MMP1-001	 TIMP2-001	 8.87E+01	 1.55E-13	 1.37E-11	
MMP1-001	 TIMP2-003	 1.75E+00	 3.72E-15	 6.51E-15	
MMP1-001	 TIMP2-003-130	 2.50E+01	 6.91E-08	 1.73E-06	
MMP1-001	 TIMP2-003-139	 4.36E+06	 2.68E-11	 1.17E-04	
MMP1-001	 TIMP2-008	 1.75E+00	 3.72E-15	 6.51E-15	
MMP1-001	 TIMP2-008-130	 8.49E+06	 6.37E-11	 5.41E-04	
MMP1-001	 TIMP2-008-139	 3.00E+05	 1.39E-11	 4.16E-06	
MMP1-001	 TIMP2-008-42	 1.07E+04	 7.70E-07	 8.24E-03	
MMP1-001	 TIMP2-008-54	 7.49E+00	 5.96E-11	 4.46E-10	
MMP1-001	 TIMP2-008-69	 3.91E+03	 4.71E-10	 1.84E-06	
MMP1-001	 TIMP3-001-142	 7.42E+07	 5.36E-05	 3.98E+03	
MMP1-001	 TIMP3-001-186	 4.17E+06	 8.76E-05	 3.65E+02	
MMP1-001	 TIMP3-001-22	 1.21E+08	 5.46E-05	 6.60E+03	
MMP1-001	 TIMP4-001-109	 1.65E+05	 1.41E-06	 2.33E-01	
MMP1-001	 TIMP4-001-141	 4.89E+03	 8.14E-07	 3.98E-03	
MMP1-001	 TIMP4-001-19	 1.68E+07	 4.20E-05	 7.05E+02	
MMP1-001	 TIMP4-001-206	 3.57E+07	 1.43E-04	 5.09E+03	
MMP1-001	 TIMP4-001-214	 2.28E+05	 5.58E-12	 1.27E-06	






MMP1-001-374	 TIMP1-001	 4.78E+05	 5.32E-07	 2.54E-01	
MMP1-001-374	 TIMP4-001	 8.72E+04	 1.02E-04	 8.93E+00	
MMP1-001-406	 CMA1-001	 9.47E+06	 8.30E-09	 7.86E-02	
MMP1-001-406	 TIMP1-001	 8.68E+01	 6.05E-15	 5.25E-13	
MMP1-001-406	 TIMP3-001	 1.73E+07	 4.87E-06	 8.42E+01	
MMP13-001	 TIMP1-001	 2.56E+08	 1.23E-08	 3.14E+00	
MMP13-001	 TIMP1-001-10	 3.47E+09	 4.64E-07	 1.61E+03	
MMP13-001	 TIMP1-001-102	 1.87E+07	 1.63E-06	 3.04E+01	
MMP13-001	 TIMP1-001-105	 5.05E+08	 1.43E-07	 7.21E+01	
MMP13-001	 TIMP1-001-136	 4.42E+05	 2.20E-08	 9.74E-03	
MMP13-001	 TIMP1-001-171	 1.35E+08	 5.54E-12	 7.48E-04	
MMP13-001	 TIMP1-001-185	 1.55E+08	 4.29E-07	 6.65E+01	
MMP13-001	 TIMP1-001-192	 6.14E+08	 1.51E-05	 9.30E+03	
MMP13-001	 TIMP1-001-203	 5.64E+07	 2.21E-04	 1.25E+04	
MMP13-001	 TIMP1-001-33	 3.29E+08	 1.33E-06	 4.36E+02	
MMP13-001	 TIMP1-001-50	 1.18E+08	 5.50E-07	 6.49E+01	
MMP13-001	 TIMP1-001-51	 7.48E+05	 1.03E-06	 7.73E-01	
MMP13-001	 TIMP1-001-76	 6.02E+02	 4.69E-13	 2.83E-10	
MMP13-001	 TIMP1-001-77	 6.97E+08	 5.18E-08	 3.61E+01	
MMP13-001	 TIMP1-002	 7.65E+04	 6.59E-08	 5.04E-03	
MMP13-001	 TIMP1-002-10	 1.23E+04	 4.32E-10	 5.31E-06	
MMP13-001	 TIMP1-002-102	 6.71E+06	 6.00E-09	 4.03E-02	
MMP13-001	 TIMP1-002-105	 1.08E+05	 1.32E-09	 1.42E-04	
MMP13-001	 TIMP1-002-115	 1.50E+06	 9.39E-10	 1.41E-03	
MMP13-001	 TIMP1-002-116	 6.17E+04	 3.02E-08	 1.86E-03	
MMP13-001	 TIMP1-002-33	 4.10E+04	 6.23E-08	 2.55E-03	
MMP13-001	 TIMP1-002-50	 4.14E+01	 2.10E-08	 8.71E-07	
MMP13-001	 TIMP1-002-51	 3.22E+01	 1.10E-11	 3.55E-10	
MMP13-001	 TIMP1-002-76	 2.17E+05	 5.81E-08	 1.26E-02	
MMP13-001	 TIMP1-002-77	 6.25E+05	 6.00E-08	 3.75E-02	
MMP13-001	 TIMP1-003	 1.41E+06	 5.46E-09	 7.70E-03	
MMP13-001	 TIMP1-003-107	 5.40E+05	 7.24E-08	 3.91E-02	
MMP13-001	 TIMP1-003-12	 4.92E+06	 4.78E-05	 2.35E+02	
MMP13-001	 TIMP1-003-121	 2.13E+06	 2.92E-06	 6.22E+00	
MMP13-001	 TIMP1-003-128	 1.45E+07	 1.23E-08	 1.79E-01	
MMP13-001	 TIMP1-003-13	 2.95E+06	 2.62E-08	 7.73E-02	
MMP13-001	 TIMP1-003-139	 3.26E+05	 3.29E-05	 1.07E+01	
MMP13-001	 TIMP1-003-38	 1.52E+06	 4.29E-05	 6.52E+01	
MMP13-001	 TIMP1-003-41	 3.06E+00	 5.95E-13	 1.82E-12	
MMP13-001	 TIMP1-003-72	 1.84E+03	 1.69E-11	 3.11E-08	
MMP13-001	 TIMP2-001	 1.29E+06	 7.49E-09	 9.66E-03	
MMP13-001	 TIMP2-001-119	 3.72E+07	 1.17E-09	 4.35E-02	
MMP13-001	 TIMP2-003	 2.53E+05	 3.27E-07	 8.27E-02	






MMP13-001	 TIMP2-003-139	 4.33E-06	 2.71E-11	 1.17E-16	
MMP13-001	 TIMP2-008	 1.19E+05	 4.37E-06	 5.20E-01	
MMP13-001	 TIMP2-008-130	 7.51E+05	 2.24E-05	 1.68E+01	
MMP13-001	 TIMP2-008-139	 4.33E-06	 2.71E-11	 1.17E-16	
MMP13-001	 TIMP2-008-42	 4.41E+06	 2.24E-05	 9.86E+01	
MMP13-001	 TIMP2-008-54	 1.13E+05	 2.87E-07	 3.24E-02	
MMP13-001	 TIMP2-008-69	 9.28E+03	 2.49E-06	 2.31E-02	
MMP13-001	 TIMP3-001	 5.51E+06	 1.79E-04	 9.86E+02	
MMP13-001	 TIMP3-001-142	 1.63E+05	 1.16E-05	 1.89E+00	
MMP13-001	 TIMP3-001-201	 3.02E+04	 1.21E-05	 3.66E-01	
MMP13-001	 TIMP3-001-22	 1.27E+07	 8.85E-05	 1.12E+03	
MMP13-001	 TIMP3-001-37	 3.09E+07	 1.67E-04	 5.17E+03	
MMP13-001-158	 TIMP1-001	 3.99E+08	 3.00E-06	 1.20E+03	
MMP13-001-158	 TIMP2-001	 1.93E+05	 1.99E-05	 3.85E+00	
MMP13-001-158	 TIMP3-001	 1.52E+07	 3.41E-05	 5.18E+02	
MMP13-002	 TIMP1-001	 1.43E+05	 1.96E-09	 2.80E-04	
MMP13-002	 TIMP2-001	 2.85E+06	 1.36E-05	 3.88E+01	
MMP13-002	 TIMP3-001	 1.06E+06	 4.53E-05	 4.80E+01	
MMP13-002-158	 TIMP1-001	 1.09E+08	 2.02E-07	 2.20E+01	
MMP13-002-158	 TIMP2-001	 2.16E+05	 5.08E-06	 1.10E+00	
MMP13-201	 TIMP1-001	 1.30E+08	 1.18E-11	 1.54E-03	
MMP13-201	 TIMP2-001	 8.82E+04	 5.50E-06	 4.85E-01	
MMP13-201	 TIMP3-001	 1.32E+09	 1.04E-07	 1.38E+02	
MMP13-201-158	 TIMP1-001	 1.42E+06	 1.92E-08	 2.73E-02	
MMP13-201-158	 TIMP2-001	 1.12E+05	 2.76E-05	 3.09E+00	
MMP13-201-158	 TIMP3-001	 4.42E+09	 3.31E-09	 1.46E+01	
MMP2-001	 TIMP1-001	 1.38E+07	 1.20E-08	 1.65E-01	
MMP2-001	 TIMP1-001-10	 5.72E+07	 9.86E-11	 5.64E-03	
MMP2-001	 TIMP1-001-102	 7.20E+06	 1.17E-12	 8.39E-06	
MMP2-001	 TIMP1-001-105	 1.17E+06	 1.36E-09	 1.59E-03	
MMP2-001	 TIMP1-001-136	 4.18E+03	 2.95E-13	 1.23E-09	
MMP2-001	 TIMP1-001-171	 1.92E+00	 3.11E-17	 5.98E-17	
MMP2-001	 TIMP1-001-185	 6.82E+05	 4.86E-14	 3.32E-08	
MMP2-001	 TIMP1-001-192	 5.02E+07	 1.74E-09	 8.74E-02	
MMP2-001	 TIMP1-001-203	 1.64E+05	 5.21E-14	 8.55E-09	
MMP2-001	 TIMP1-001-33	 1.49E+07	 6.19E-10	 9.22E-03	
MMP2-001	 TIMP1-001-50	 1.92E+05	 1.38E-14	 2.65E-09	
MMP2-001	 TIMP1-001-51	 9.59E+06	 4.38E-12	 4.20E-05	
MMP2-001	 TIMP1-001-76	 1.99E+05	 3.01E-12	 5.99E-07	
MMP2-001	 TIMP1-001-77	 2.55E+07	 4.20E-08	 1.07E+00	
MMP2-001	 TIMP1-002	 2.39E+05	 5.93E-06	 1.42E+00	
MMP2-001	 TIMP1-002-10	 3.00E+03	 7.34E-11	 2.20E-07	
MMP2-001	 TIMP1-002-102	 9.45E+05	 3.79E-07	 3.58E-01	






MMP2-001	 TIMP1-002-115	 1.94E+00	 2.33E-11	 4.51E-11	
MMP2-001	 TIMP1-002-116	 1.93E+03	 1.58E-10	 3.04E-07	
MMP2-001	 TIMP1-002-33	 4.96E+05	 9.64E-07	 4.78E-01	
MMP2-001	 TIMP1-002-50	 5.45E+06	 7.73E-09	 4.21E-02	
MMP2-001	 TIMP1-002-51	 5.20E+05	 3.68E-10	 1.91E-04	
MMP2-001	 TIMP1-002-76	 2.48E+04	 4.88E-09	 1.21E-04	
MMP2-001	 TIMP1-002-77	 1.96E+05	 9.69E-08	 1.90E-02	
MMP2-001	 TIMP1-003	 1.47E+00	 5.12E-11	 7.53E-11	
MMP2-001	 TIMP1-003-107	 7.17E+05	 6.64E-09	 4.76E-03	
MMP2-001	 TIMP1-003-12	 3.84E+05	 1.40E-08	 5.36E-03	
MMP2-001	 TIMP1-003-121	 9.91E+05	 4.07E-10	 4.03E-04	
MMP2-001	 TIMP1-003-128	 2.41E+04	 1.67E-09	 4.02E-05	
MMP2-001	 TIMP1-003-13	 2.91E-01	 1.86E-11	 5.42E-12	
MMP2-001	 TIMP1-003-139	 5.82E+04	 8.31E-11	 4.84E-06	
MMP2-001	 TIMP1-003-38	 3.81E+04	 8.01E-09	 3.05E-04	
MMP2-001	 TIMP1-003-41	 6.71E+05	 2.99E-09	 2.01E-03	
MMP2-001	 TIMP1-003-72	 6.10E+00	 1.34E-12	 8.19E-12	
MMP2-001	 TIMP2-001	 5.45E+00	 8.20E-15	 4.47E-14	
MMP2-001	 TIMP2-001-119	 3.77E+05	 1.20E-05	 4.53E+00	
MMP2-001	 TIMP2-001-146	 4.75E+05	 4.96E-06	 2.36E+00	
MMP2-001	 TIMP2-003	 2.42E+06	 3.94E-05	 9.54E+01	
MMP2-001	 TIMP2-003-130	 6.14E+06	 3.93E-06	 2.41E+01	
MMP2-001	 TIMP2-003-139	 9.41E+04	 7.78E-05	 7.32E+00	
MMP2-001	 TIMP2-008	 2.09E+04	 6.51E-05	 1.36E+00	
MMP2-001	 TIMP2-008-130	 7.27E+04	 8.58E-06	 6.24E-01	
MMP2-001	 TIMP2-008-42	 5.92E+04	 1.22E-04	 7.24E+00	
MMP2-001	 TIMP2-008-54	 2.55E+06	 4.85E-05	 1.24E+02	
MMP2-001	 TIMP2-008-69	 1.41E+04	 5.90E-06	 8.32E-02	
MMP2-001	 TIMP3-001	 8.47E-01	 3.31E-07	 2.81E-07	
MMP2-001	 TIMP3-001-121	 8.33E+07	 4.61E-06	 3.84E+02	
MMP2-001	 TIMP3-001-186	 3.11E+00	 3.46E-06	 1.07E-05	
MMP2-001	 TIMP4-001	 4.28E+06	 9.00E-05	 3.85E+02	
MMP2-001	 TIMP4-001-103	 1.78E+04	 4.20E-06	 7.47E-02	
MMP2-001	 TIMP4-001-109	 4.55E+05	 2.52E-07	 1.15E-01	
MMP2-001	 TIMP4-001-141	 5.81E+05	 2.44E-09	 1.42E-03	
MMP2-001	 TIMP4-001-143	 1.23E+05	 4.95E-07	 6.08E-02	
MMP2-001	 TIMP4-001-19	 7.12E+04	 7.06E-06	 5.03E-01	
MMP2-001	 TIMP4-001-206	 5.15E+04	 7.77E-06	 4.00E-01	
MMP2-001	 TIMP4-001-214	 7.34E+05	 9.06E-09	 6.65E-03	
MMP2-001	 TIMP4-001-24	 6.64E+05	 1.06E-04	 7.01E+01	
MMP2-001-447	 TIMP1-001	 9.50E+07	 7.92E-08	 7.52E+00	
MMP2-001-447	 TIMP2-001	 4.01E+03	 7.67E-06	 3.08E-02	
MMP2-001-447	 TIMP3-001	 1.40E+05	 7.34E-06	 1.03E+00	






MMP2-008	 TIMP2-001	 1.96E+06	 7.11E-06	 1.39E+01	
MMP2-008-333	 TIMP1-001	 7.59E+08	 1.43E-08	 1.08E+01	
MMP2-008-333	 TIMP2-001	 1.11E+05	 8.76E-07	 9.72E-02	
MMP2-008-333	 TIMP3-001	 2.20E+02	 3.14E-06	 6.91E-04	
MMP2-008-371	 TIMP1-001	 2.25E+07	 1.67E-09	 3.76E-02	
MMP2-008-371	 TIMP2-001	 1.20E+05	 1.06E-06	 1.28E-01	
MMP2-008-371	 TIMP3-001	 8.31E+01	 1.90E-06	 1.58E-04	
MMP2-008-545	 TIMP1-001	 1.79E+06	 1.15E-10	 2.06E-04	
MMP2-008-545	 TIMP2-001	 1.11E+07	 1.74E-06	 1.93E+01	
MMP3-001	 TIMP1-001	 7.79E+04	 2.82E-06	 2.20E-01	
MMP3-001	 TIMP1-001-10	 9.99E+03	 4.62E-08	 4.62E-04	
MMP3-001	 TIMP1-001-102	 7.00E-04	 1.00E-09	 7.02E-13	
MMP3-001	 TIMP1-001-105	 5.61E+01	 2.60E-12	 1.46E-10	
MMP3-001	 TIMP1-001-136	 2.82E+05	 7.60E-05	 2.14E+01	
MMP3-001	 TIMP1-001-171	 2.37E+06	 5.39E-06	 1.28E+01	
MMP3-001	 TIMP1-001-185	 5.41E+05	 3.49E-06	 1.89E+00	
MMP3-001	 TIMP1-001-192	 6.66E+04	 3.08E-06	 2.05E-01	
MMP3-001	 TIMP1-001-203	 4.33E-03	 6.37E-14	 2.76E-16	
MMP3-001	 TIMP1-001-33	 5.51E+05	 5.11E-06	 2.82E+00	
MMP3-001	 TIMP1-001-50	 3.06E+04	 2.12E-06	 6.50E-02	
MMP3-001	 TIMP1-001-51	 3.67E+02	 1.96E-14	 7.19E-12	
MMP3-001	 TIMP1-001-76	 3.36E+05	 2.32E-05	 7.80E+00	
MMP3-001	 TIMP1-001-77	 2.51E+04	 4.19E-06	 1.05E-01	
MMP3-001	 TIMP1-002	 3.58E+06	 3.37E-05	 1.20E+02	
MMP3-001	 TIMP1-002-10	 2.79E+05	 4.05E-06	 1.13E+00	
MMP3-001	 TIMP1-002-102	 8.70E+04	 1.35E-07	 1.18E-02	
MMP3-001	 TIMP1-002-105	 2.95E+05	 2.17E-05	 6.40E+00	
MMP3-001	 TIMP1-002-115	 1.40E+06	 4.00E-05	 5.60E+01	
MMP3-001	 TIMP1-002-116	 7.70E+03	 8.32E-12	 6.41E-08	
MMP3-001	 TIMP1-002-33	 1.61E+05	 2.17E-05	 3.49E+00	
MMP3-001	 TIMP1-002-50	 1.46E+05	 2.56E-06	 3.74E-01	
MMP3-001	 TIMP1-002-51	 5.20E+05	 7.33E-05	 3.81E+01	
MMP3-001	 TIMP1-002-76	 4.13E+04	 2.49E-05	 1.03E+00	
MMP3-001	 TIMP1-002-77	 1.78E+05	 1.11E-05	 1.97E+00	
MMP3-001	 TIMP1-003	 2.43E+07	 1.95E-06	 4.74E+01	
MMP3-001	 TIMP1-003-107	 8.66E+05	 7.66E-06	 6.64E+00	
MMP3-001	 TIMP1-003-12	 1.18E+05	 1.40E-05	 1.65E+00	
MMP3-001	 TIMP1-003-121	 1.47E+05	 4.55E-05	 6.69E+00	
MMP3-001	 TIMP1-003-128	 7.65E+05	 2.27E-07	 1.74E-01	
MMP3-001	 TIMP1-003-13	 1.93E+07	 1.43E-05	 2.75E+02	
MMP3-001	 TIMP1-003-139	 8.99E+04	 5.47E-07	 4.92E-02	
MMP3-001	 TIMP1-003-38	 8.45E+06	 2.94E-07	 2.49E+00	
MMP3-001	 TIMP1-003-41	 3.20E+05	 3.02E-05	 9.65E+00	






MMP3-001	 TIMP2-001	 2.00E+04	 1.36E-10	 2.72E-06	
MMP3-001	 TIMP2-003	 1.49E+04	 3.52E-06	 5.25E-02	
MMP3-001	 TIMP2-003-130	 5.11E+05	 9.96E-07	 5.09E-01	
MMP3-001	 TIMP2-003-139	 4.82E+06	 2.69E-07	 1.29E+00	
MMP3-001	 TIMP2-008	 7.70E+06	 1.30E-05	 1.00E+02	
MMP3-001	 TIMP2-008-130	 2.10E+05	 1.05E-06	 2.20E-01	
MMP3-001	 TIMP2-008-139	 1.07E+06	 6.13E-08	 6.56E-02	
MMP3-001	 TIMP2-008-42	 2.33E+06	 8.33E-09	 1.94E-02	
MMP3-001	 TIMP2-008-54	 1.51E+06	 3.30E-10	 4.99E-04	
MMP3-001	 TIMP2-008-69	 3.18E+05	 4.56E-08	 1.45E-02	
MMP3-001	 TIMP3-001	 8.89E+05	 2.11E-04	 1.87E+02	
MMP3-001	 TIMP3-001-121	 1.28E+07	 4.82E-05	 6.17E+02	
MMP3-001	 TIMP3-001-142	 1.24E+05	 1.50E-04	 1.86E+01	
MMP3-001	 TIMP3-001-186	 3.05E+05	 1.03E-04	 3.14E+01	
MMP3-001	 TIMP3-001-196	 8.54E+09	 1.90E-04	 1.62E+06	
MMP3-001	 TIMP3-001-22	 7.21E+06	 3.03E-05	 2.18E+02	
MMP3-001	 TIMP3-001-37	 9.50E+06	 2.02E-05	 1.91E+02	
MMP3-001	 TIMP4-001	 4.97E+04	 2.02E-05	 1.00E+00	
MMP3-001	 TIMP4-001-141	 1.19E+03	 1.43E-11	 1.70E-08	
MMP3-001	 TIMP4-001-214	 2.15E-08	 1.99E-15	 4.27E-23	
MMP3-001	 TIMP4-001-24	 1.07E+07	 3.01E-04	 3.22E+03	
MMP3-001	 TIMP4-001-28	 7.71E+08	 1.21E-04	 9.33E+04	
MMP3-001-45	 TIMP1-001	 6.05E+07	 3.58E-08	 2.16E+00	
MMP3-001-45	 TIMP3-001	 5.61E+10	 3.41E-04	 1.91E+07	
MMP3-001-45	 TIMP4-001	 2.20E+07	 2.19E-04	 4.82E+03	
MMP3-001-96	 TIMP1-001	 2.41E+05	 1.91E-06	 4.61E-01	
MMP9-001	 TIMP1-001	 7.20E+01	 6.14E-12	 4.42E-10	
MMP9-001	 TIMP1-001-10	 7.49E+02	 7.56E-11	 5.66E-08	
MMP9-001	 TIMP1-001-102	 8.52E+05	 1.77E-04	 1.50E+02	
MMP9-001	 TIMP1-001-105	 2.81E+06	 4.72E-06	 1.33E+01	
MMP9-001	 TIMP1-001-136	 1.25E+06	 1.16E-06	 1.45E+00	
MMP9-001	 TIMP1-001-171	 4.17E+00	 8.05E-12	 3.36E-11	
MMP9-001	 TIMP1-001-185	 1.45E+05	 2.41E-09	 3.49E-04	
MMP9-001	 TIMP1-001-192	 5.34E+05	 1.82E-05	 9.74E+00	
MMP9-001	 TIMP1-001-203	 1.89E+00	 1.92E-14	 3.62E-14	
MMP9-001	 TIMP1-001-33	 2.72E+00	 9.20E-12	 2.50E-11	
MMP9-001	 TIMP1-001-50	 1.26E+04	 8.38E-12	 1.06E-07	
MMP9-001	 TIMP1-001-51	 2.07E+03	 5.37E-11	 1.11E-07	
MMP9-001	 TIMP1-001-76	 1.84E+05	 1.24E-07	 2.28E-02	
MMP9-001	 TIMP1-001-77	 2.27E+05	 3.87E-05	 8.78E+00	
MMP9-001	 TIMP1-002	 6.56E+05	 7.85E-08	 5.15E-02	
MMP9-001	 TIMP1-002-10	 5.25E+06	 1.07E-07	 5.63E-01	
MMP9-001	 TIMP1-002-102	 3.00E+04	 3.54E-05	 1.06E+00	






MMP9-001	 TIMP1-002-115	 1.21E+04	 6.00E-05	 7.26E-01	
MMP9-001	 TIMP1-002-116	 1.14E+06	 1.30E-04	 1.48E+02	
MMP9-001	 TIMP1-002-33	 3.41E+03	 2.59E-09	 8.83E-06	
MMP9-001	 TIMP1-002-50	 1.08E+06	 1.21E-04	 1.30E+02	
MMP9-001	 TIMP1-002-51	 2.37E+01	 5.28E-11	 1.25E-09	
MMP9-001	 TIMP1-002-76	 2.35E+03	 1.07E-07	 2.50E-04	
MMP9-001	 TIMP1-002-77	 4.51E+03	 5.13E-09	 2.31E-05	
MMP9-001	 TIMP1-003	 1.16E+06	 2.18E-05	 2.52E+01	
MMP9-001	 TIMP1-003-107	 5.63E+03	 4.54E-12	 2.55E-08	
MMP9-001	 TIMP1-003-12	 3.88E+04	 4.87E-08	 1.89E-03	
MMP9-001	 TIMP1-003-121	 1.08E+03	 4.68E-12	 5.06E-09	
MMP9-001	 TIMP1-003-128	 7.04E+03	 8.05E-09	 5.66E-05	
MMP9-001	 TIMP1-003-13	 3.88E+01	 1.80E-09	 6.97E-08	
MMP9-001	 TIMP1-003-139	 1.46E+03	 1.68E-09	 2.45E-06	
MMP9-001	 TIMP1-003-38	 1.64E+05	 9.73E-10	 1.60E-04	
MMP9-001	 TIMP1-003-41	 2.69E+04	 1.77E-07	 4.77E-03	
MMP9-001	 TIMP1-003-72	 1.97E+02	 1.09E-08	 2.15E-06	
MMP9-001	 TIMP2-001	 3.74E+01	 0.00E+00	 0.00E+00	
MMP9-001	 TIMP2-003	 4.45E+03	 3.35E-10	 1.49E-06	
MMP9-001	 TIMP2-003-130	 6.09E+04	 1.40E-08	 8.55E-04	
MMP9-001	 TIMP2-003-139	 8.54E+04	 2.97E-10	 2.54E-05	
MMP9-001	 TIMP2-008	 4.45E+03	 3.35E-10	 1.49E-06	
MMP9-001	 TIMP2-008-130	 1.78E-04	 2.97E-15	 5.28E-19	
MMP9-001	 TIMP2-008-139	 8.54E+04	 2.97E-10	 2.54E-05	
MMP9-001	 TIMP2-008-42	 1.59E+07	 1.32E-05	 2.10E+02	
MMP9-001	 TIMP2-008-54	 1.81E+05	 1.27E-06	 2.30E-01	
MMP9-001	 TIMP2-008-69	 4.20E+04	 1.30E-09	 5.45E-05	
MMP9-001	 TIMP3-001	 1.10E+02	 5.35E-11	 5.89E-09	
MMP9-001	 TIMP3-001-121	 3.02E+05	 1.44E-09	 4.33E-04	
MMP9-001	 TIMP3-001-142	 5.30E+01	 1.32E-07	 7.01E-06	
MMP9-001	 TIMP3-001-186	 3.49E+05	 8.31E-09	 2.90E-03	
MMP9-001	 TIMP3-001-196	 4.91E+05	 1.45E-08	 7.11E-03	
MMP9-001	 TIMP3-001-201	 1.66E+05	 2.19E-12	 3.63E-07	
MMP9-001	 TIMP3-001-22	 3.18E+04	 3.06E-09	 9.72E-05	
MMP9-001	 TIMP3-001-37	 1.95E+04	 3.35E-09	 6.52E-05	
MMP9-001	 TIMP4-001	 3.84E+06	 4.62E-04	 1.77E+03	
MMP9-001	 TIMP4-001-103	 2.20E+05	 8.19E-12	 1.80E-06	
MMP9-001	 TIMP4-001-109	 2.30E+05	 2.46E-07	 5.67E-02	
MMP9-001	 TIMP4-001-112	 2.32E+03	 1.35E-08	 3.13E-05	
MMP9-001	 TIMP4-001-141	 2.37E+03	 2.71E-13	 6.43E-10	
MMP9-001	 TIMP4-001-143	 1.54E+04	 1.32E-09	 2.03E-05	
MMP9-001	 TIMP4-001-19	 1.07E+06	 2.92E-05	 3.12E+01	
MMP9-001	 TIMP4-001-206	 3.74E+03	 1.11E-07	 4.14E-04	






MMP9-001	 TIMP4-001-24	 3.02E+03	 3.98E-08	 1.20E-04	
MMP9-001	 TIMP4-001-28	 8.71E+03	 1.91E-08	 1.67E-04	
MMP9-001-20	 TIMP1-001	 2.34E+01	 6.67E-12	 1.56E-10	
MMP9-001-20	 TIMP3-001	 2.74E+01	 2.68E-10	 7.35E-09	
MMP9-001-20	 TIMP4-001	 7.86E+02	 2.08E-09	 1.64E-06	
MMP9-001-239	 TIMP1-001	 2.42E+03	 2.71E-13	 6.55E-10	
MMP9-001-239	 TIMP3-001	 9.20E+03	 3.40E-09	 3.13E-05	
MMP9-001-239	 TIMP4-001	 8.42E+01	 6.09E-10	 5.12E-08	
MMP9-001-279	 TIMP1-001	 5.95E+05	 1.84E-04	 1.10E+02	
MMP9-001-279	 TIMP2-001	 3.98E+01	 0.00E+00	 0.00E+00	
MMP9-001-279	 TIMP3-001	 8.88E+07	 8.70E-08	 7.72E+00	
MMP9-001-279	 TIMP4-001	 8.55E+02	 4.94E-09	 4.22E-06	
MMP9-001-38	 TIMP1-001	 1.92E+06	 1.32E-05	 2.53E+01	
MMP9-001-38	 TIMP3-001	 1.80E+06	 6.26E-07	 1.13E+00	
MMP9-001-38	 TIMP4-001	 3.62E+02	 3.70E-09	 1.34E-06	
MMP9-001-574	 TIMP1-001	 5.32E+02	 1.19E-08	 6.30E-06	
MMP9-001-574	 TIMP3-001	 2.25E+03	 2.15E-08	 4.83E-05	
MMP9-001-574	 TIMP4-001	 2.25E-03	 1.12E-10	 2.52E-13	
MMP9-001-668	 TIMP1-001	 1.05E+06	 5.86E-05	 6.15E+01	
MMP9-001-668	 TIMP3-001	 5.16E-05	 3.34E-10	 1.72E-14	
MMP9-001-668	 TIMP4-001	 2.68E-04	 2.95E-12	 7.91E-16	
PDGFRA-001-761	 PDGFA-001	 3.99E+04	 1.23E-14	 4.91E-10	
PDGFRA-002	 PDGFA-001	 1.83E+07	 7.28E-07	 1.33E+01	
PDGFRB-001	 PDGFB-002-204	 7.23E+08	 6.75E-07	 4.88E+02	
TGFBR1-001	 TGFB1-001	 5.89E+04	 1.62E-10	 9.51E-06	
TGFBR1-001	 TGFB1-001-10	 1.81E+04	 1.13E-08	 2.05E-04	
TGFBR1-001	 TGFB1-001-25	 8.20E-02	 8.51E-12	 6.98E-13	
TGFBR1-001	 TGFB1-001-263	 2.14E+03	 2.90E-10	 6.20E-07	
TGFBR1-001-17	 TGFB1-001	 5.01E+04	 1.62E-10	 8.09E-06	
TGFBR1-001-19	 TGFB1-001	 9.31E+04	 1.62E-10	 1.50E-05	
TGFBR1-003	 TGFB1-001	 1.81E+05	 8.27E-10	 1.50E-04	
TGFBR2-001	 TGFB1-001	 2.21E+03	 2.20E-08	 4.87E-05	
TGFBR2-001	 TGFB1-001-10	 2.17E+05	 7.39E-08	 1.60E-02	
TIMP3-001	 ADAM17-001	 5.97E+05	 2.59E-06	 1.54E+00	
TIMP3-001	 ADAM17-001-202	 5.85E-105	 3.47E-06	 2.03E-110	
TIMP3-001-121	 ADAM17-001	 2.53E+03	 5.07E-06	 1.28E-02	
TIMP3-001-142	 ADAM17-001	 8.63E+03	 1.17E-07	 1.01E-03	
TIMP3-001-186	 ADAM17-001	 4.82E+06	 3.02E-07	 1.46E+00	
TIMP3-001-196	 ADAM17-001	 1.51E+05	 1.47E-07	 2.21E-02	
TIMP3-001-201	 ADAM17-001	 3.15E+05	 5.18E-09	 1.63E-03	
TIMP3-001-22	 ADAM17-001	 1.96E+08	 6.92E-07	 1.36E+02	
TIMP3-001-37	 ADAM17-001	 2.47E+05	 5.78E-07	 1.43E-01	
TNFSFR1B-001	 TNF-001	 8.94E+04	 2.76E-08	 2.46E-03	






TNFSFR1B-001-187	 TNF-001	 5.19E+02	 6.97E-09	 3.62E-06	
TNFSFR1B-001-203	 TNF-001	 4.44E+06	 2.92E-05	 1.30E+02	
TNFSFR1B-001-232	 TNF-001	 1.47E+06	 3.21E-05	 4.72E+01	











































CCR5-001	 CCL5-001	 1000	 1000	 1.00	
CCR5-001	 CCL5-001-40	 1000	 1.8013	 0.10	
CCR5-001	 CCL5-001-5	 1000	 71548.8215	 5.93	
CCR5-001	 CCL5-001-56	 1000	 333.3333	 0.72	
CCR5-001	 CCL5-001-67	 1000	 1818.1818	 1.11	
CCR5-001	 CCL5-001-68	 1000	 0.94949	 0.09	
CCR5-001	 CCL5-002	 1000	 1000	 1.00	
CCR5-001	 CCL5-002-40	 1000	 1.8013	 0.10	
CCR5-001	 CCL5-002-5	 1000	 71548.8215	 5.93	
CCR5-001	 CCL5-002-56	 1000	 333.3333	 0.72	
CCR5-001	 CCL5-002-67	 1000	 1818.1818	 1.11	
CCR5-001	 CCL5-002-68	 1000	 0.94949	 0.09	
CCR5-001-223	 CCL5-001	 1000	 2878.7879	 1.20	
CCR5-001-335	 CCL5-001	 1000	 577.4411	 0.86	
CCR5-001-55	 CCL5-001	 1000	 890.5724	 0.97	
CSF1R-001	 CSF1-001	 9.94E-02	 9.94E-02	 	
CSF1R-001	 CSF1-001-292	 9.94E-02	 1.21E+00	 1.00	






CSF1R-001	 CSF1-001-438	 9.94E-02	 9.72E-07	 1.00	
CSF1R-001	 CSF1-001-489	 9.94E-02	 6.20E-05	 1.00	
CSF1R-001	 CSF1-002-292	 9.94E-02	 2.31E-01	 1.00	
CSF1R-001	 CSF1-002-408	 9.94E-02	 3.72E-06	 1.00	
CSF1R-001	 CSF1-002-461	 9.94E-02	 1.46E-10	 0.03	
CSF1R-001	 CSF1-002-489	 9.94E-02	 5.57E-01	 1.00	
CSF1R-001	 CSF1-002-523	 9.94E-02	 9.79E-09	 1.00	
CSF1R-001	 CSF1-003	 9.94E-02	 1.22E-06	 1.00	
CSF1R-001	 CSF1-003-292	 9.94E-02	 1.18E-01	 1.00	
CSF1R-001	 CSF1-003-373	 9.94E-02	 2.04E-38	 0.03	
CSF1R-001	 CSF1-004	 9.94E-02	 1.20E-06	 1.00	
CSF1R-001-245	 CSF1-001	 9.94E-02	 2.76E-198	 0.03	
CSF1R-001-362	 CSF1-001	 9.94E-02	 5.31E-06	 1.00	
CSF1R-201	 CSF1-001	 9.94E-02	 1.35E-05	 1.00	
CSF1R-201-153	 CSF1-001	 9.94E-02	 6.74E-01	 1.00	
CSF1R-201-241	 CSF1-001	 9.94E-02	 2.31E-05	 1.00	
CSF1R-201-245	 CSF1-001	 9.94E-02	 3.59E-01	 1.00	
CSF1R-201-268	 CSF1-001	 9.94E-02	 1.34E-03	 1.00	
CSF1R-201-279	 CSF1-001	 9.94E-02	 3.62E-150	 0.03	
CSF1R-201-298	 CSF1-001	 9.94E-02	 1.39E-05	 1.00	
CSF1R-201-32	 CSF1-001	 9.94E-02	 1.86E-06	 1.00	
CSF1R-201-60	 CSF1-001	 9.94E-02	 5.58E-07	 1.00	
CXCR3-001	 CXCL10-001	 1000	 1000	 	
CXCR3-001	 CXCL10-001-18	 1000	 1974.2857	 1.13	
CXCR3-001	 CXCL10-001-29	 1000	 434.2857	 0.78	
CXCR3-001	 CXCL10-001-33	 1000	 19.8	 0.21	
CXCR3-001	 CXCL10-001-58	 1000	 0.036857	 0.09	
CXCR3-001	 CXCL10-001-66	 1000	 1.84E-05	 0.09	
CXCR3-001	 CXCL10-001-68	 1000	 2.0371	 0.10	
CXCR3-001	 CXCL10-001-80	 1000	 1405.7143	 1.06	
CXCR3-001	 CXCL10-001-96	 1000	 39.7143	 0.30	
CXCR3-002	 CXCL10-001	 1000	 291.4286	 0.68	
CXCR3-001	 CXCL11-001	 1000	 1000	 	
CXCR3-001	 CXCL11-001-29	 1000	 178.6982	 0.58	
CXCR3-001	 CXCL11-001-72	 1000	 16272.1893	 2.03	
CXCR3-001	 CXCL11-001-73	 1000	 331360.9465	 27.27	
CXCR3-001	 CXCL11-003	 1000	 223372.7811	 18.13	
CXCR3-001	 CXCL11-003-29	 1000	 807692.3075	 68.95	
CXCR3-001	 CXCL11-003-72	 1000	 15591.716	 1.99	
CXCR3-001	 CXCL11-003-73	 1000	 124.8521	 0.51	
CXCR3-002	 CXCL11-001	 1000	 5355.0296	 1.32	
CXCR3-001	 CXCL9-001	 1000	 1000	 1.00	
CXCR3-001	 CXCL9-001-1	 1000	 1818.6813	 1.11	






CXCR3-001	 CXCL9-001-125	 1000	 2329.6703	 1.18	
CXCR3-001	 CXCL9-001-40	 1000	 15164.8352	 1.96	
CXCR3-001	 CXCL9-001-71	 1000	 928.5714	 0.98	
CXCR3-002	 CXCL9-001	 1000	 1543956.044	 134.63	
EGFR-001	 EGF-001	 1938	 1938	 	
EGFR-001	 EGF-001-151	 1938	 349748437.5	 0.50	
EGFR-001	 EGF-002-389	 1938	 12324.4687	 0.70	
EGFR-001-521	 EGF-001	 1938	 31341.0937	 0.60	
EGFR-002	 EGF-001	 1938	 20591.25	 0.64	
EGFR-002-521	 EGF-001	 1938	 3.23E-75	 1.19	
EGFR-002-640	 EGF-001	 1938	 4708.7344	 0.86	
EGFR-002-703	 EGF-001	 1938	 7752	 0.77	
EGFR-003	 EGF-001	 1938	 11506.875	 0.71	
EGFR-003-521	 EGF-001	 1938	 1938	 1.00	
EGFR-004-476	 EGF-001	 1938	 51932343.75	 0.50	
EGFR-005	 EGF-001	 1938	 1.13E-144	 1.19	
EGFR-201	 EGF-001	 1938	 14141.3437	 0.68	
EGFR-201-521	 EGF-001	 1938	 334.6078	 1.15	






































































































































































































































































































IL12RB1-001	 IL12A-001	 8.10E+00	 8.10E+00	 	
IL12RB1-001	 IL12A-001-211	 8.10E+00	 2.70E+03	 0.94	
IL12RB1-001	 IL12A-001-82	 8.10E+00	 1.22E+02	 0.95	
IL12RB1-001	 IL12A-005	 8.10E+00	 4.18E+02	 0.94	
IL12RB1-001	 IL12A-005-115	 8.10E+00	 1.93E+02	 0.94	
IL12RB1-001	 IL12A-005-153	 8.10E+00	 8.05E+03	 0.93	
IL12RB1-001	 IL12A-005-164	 8.10E+00	 2.36E+02	 0.94	
IL12RB1-001	 IL12A-005-200	 8.10E+00	 2.32E+05	 0.93	
IL12RB1-001	 IL12A-005-3	 8.10E+00	 3.51E+03	 0.94	
IL12RB1-001	 IL12A-005-81	 8.10E+00	 2.78E+05	 0.93	
IL12RB1-001	 IL12A-006	 8.10E+00	 4.74E+00	 0.97	
IL12RB1-001	 IL12A-006-139	 8.10E+00	 4.61E+04	 0.93	
IL12RB1-001	 IL12A-006-157	 8.10E+00	 7.74E+03	 0.93	
IL12RB1-001	 IL12A-006-177	 8.10E+00	 7.32E+02	 0.94	
IL12RB1-001	 IL12A-006-224	 8.10E+00	 2.12E+02	 0.94	






IL12RB1-001	 IL12A-006-3	 8.10E+00	 3.71E+02	 0.94	
IL12RB1-001	 IL12A-006-81	 8.10E+00	 7.43E+02	 0.94	
IL12RB1-001-156	 IL12A-001	 8.10E+00	 2.62E-01	 0.44	
IL12RB1-001-214	 IL12A-001	 8.10E+00	 2.14E+01	 0.99	
IL12RB1-001-352	 IL12A-001	 8.10E+00	 4.41E-37	 0.15	
IL12RB1-001-365	 IL12A-001	 8.10E+00	 3.94E-11	 0.15	
IL12RB1-001-378	 IL12A-001	 8.10E+00	 1.59E+01	 1.00	
IL12RB1-001-91	 IL12A-001	 8.10E+00	 4.41E-17	 0.15	
IL12RB1-002-156	 IL12A-001	 8.10E+00	 2.62E-01	 0.44	
IL12RB1-002-214	 IL12A-001	 8.10E+00	 5.88E-18	 0.15	
IL12RB1-002-378	 IL12A-001	 8.10E+00	 1.59E+01	 1.00	
IL12RB1-002-47	 IL12A-001	 8.10E+00	 1.82E-24	 0.15	
IL12RB1-002-91	 IL12A-001	 8.10E+00	 4.41E-17	 0.15	
IL12RB1-003-201	 IL12A-001	 8.10E+00	 4.67E+04	 0.93	
IL18R1-001	 IL18-001	 8.10E+00	 8.10E+00	 	
IL18R1-001	 IL18-001-127	 8.10E+00	 2.67E-05	 0.15	
IL18R1-001	 IL18-001-164	 8.10E+00	 2.90E-02	 0.19	
IL18R1-001	 IL18-001-22	 8.10E+00	 6.35E+02	 0.94	
IL18R1-001	 IL18-001-47	 8.10E+00	 8.90E+00	 1.00	
IL18R1-001	 IL18-001-63	 8.10E+00	 5.63E+02	 0.94	
IL18R1-001	 IL18-003	 8.10E+00	 1.14E+03	 0.94	
IL18R1-001	 IL18-003-123	 8.10E+00	 2.06E+03	 0.94	
IL18R1-001	 IL18-003-160	 8.10E+00	 1.70E+01	 0.99	
IL18R1-001	 IL18-003-22	 8.10E+00	 4.01E-01	 0.52	
IL18R1-001	 IL18-003-43	 8.10E+00	 9.97E+00	 1.00	
IL18R1-001	 IL18-003-59	 8.10E+00	 2.92E+03	 0.94	
IL18R1-001	 IL18-006	 8.10E+00	 8.10E+00	 	
IL18R1-001	 IL18-006-127	 8.10E+00	 2.67E-05	 0.15	
IL18R1-001	 IL18-006-164	 8.10E+00	 2.90E-02	 0.19	
IL18R1-001	 IL18-006-22	 8.10E+00	 6.35E+02	 0.94	
IL18R1-001	 IL18-006-47	 8.10E+00	 8.90E+00	 1.00	
IL18R1-001	 IL18-006-63	 8.10E+00	 5.63E+02	 0.94	
IL18R1-001-170	 IL18-001	 8.10E+00	 7.42E+02	 0.94	
IL18R1-001-232	 IL18-001	 8.10E+00	 2.45E+05	 0.93	
IL18R1-001-423	 IL18-001	 8.10E+00	 2.04E+02	 0.94	
IL18R1-201	 IL18-001	 8.10E+00	 8.10E+00	 	
IL18R1-201-170	 IL18-001	 8.10E+00	 7.42E+02	 0.94	
IL18R1-201-232	 IL18-001	 8.10E+00	 2.45E+05	 0.93	
IL18R1-201-423	 IL18-001	 8.10E+00	 2.04E+02	 0.94	
IL18R1-202	 IL18-001	 8.10E+00	 1.13E+04	 0.93	
IL18R1-202-100	 IL18-001	 8.10E+00	 5.94E-03	 0.16	
IL18R1-202-117	 IL18-001	 8.10E+00	 1.10E+05	 0.93	
IL18R1-202-139	 IL18-001	 8.10E+00	 6.66E+03	 0.93	






IL18R1-202-53	 IL18-001	 8.10E+00	 8.41E+03	 0.93	
IL18R1-202-84	 IL18-001	 8.10E+00	 3.89E+03	 0.94	
IL1R1-001	 IL1B-001	 1.35E-01	 1.35E-01	 	
IL21R-001	 IL21-001	 6.64E+01	 6.64E+01	 	
IL21R-001	 IL21-001-135	 6.64E+01	 8.59E+04	 0.67	
IL21R-001	 IL21-001-40	 6.64E+01	 3.38E+06	 0.43	
IL21R-001	 IL21-201	 6.64E+01	 3.29E+01	 1.00	
IL21R-001	 IL21-201-135	 6.64E+01	 3.62E+05	 0.57	
IL21R-001	 IL21-201-40	 6.64E+01	 5.91E+01	 1.00	
IL21R-001-318	 IL21-001	 6.64E+01	 3.54E+01	 1.00	
IL21R-001-484	 IL21-001	 6.64E+01	 4.78E-04	 1.01	
IL21R-003	 IL21-001	 6.64E+01	 6.64E+01	 	
IL21R-003-318	 IL21-001	 6.64E+01	 3.54E+01	 1.00	
IL21R-003-484	 IL21-001	 6.64E+01	 4.16E+02	 0.98	
IL21R-006	 IL21-001	 6.64E+01	 6.64E+01	 	
IL21R-006-318	 IL21-001	 6.64E+01	 6.16E+01	 1.00	
IL21R-006-484	 IL21-001	 6.64E+01	 4.16E+02	 0.98	
IL4R-001	 IL4-001	 8.19E+00	 8.19E+00	 	
IL4R-001	 IL4-001-100	 8.19E+00	 2.44E-40	 1.00	
IL4R-001	 IL4-001-105	 8.19E+00	 1.63E+06	 0.11	
IL4R-001	 IL4-001-109	 8.19E+00	 2.34E+00	 1.00	
IL4R-001	 IL4-001-152	 8.19E+00	 9.10E+01	 0.83	
IL4R-001	 IL4-001-22	 8.19E+00	 2.97E-24	 1.00	
IL4R-001	 IL4-001-26	 8.19E+00	 1.74E+03	 0.38	
IL4R-001	 IL4-001-30	 8.19E+00	 1.29E+06	 0.11	
IL4R-001	 IL4-001-53	 8.19E+00	 9.38E+03	 0.19	
IL4R-001	 IL4-001-98	 8.19E+00	 2.11E+04	 0.14	
IL4R-001	 IL4-002	 8.19E+00	 3.78E+00	 1.00	
IL4R-001	 IL4-002-102	 8.19E+00	 8.26E-20	 1.00	
IL4R-001	 IL4-002-136	 8.19E+00	 1.86E+03	 0.37	
IL4R-001	 IL4-002-22	 8.19E+00	 1.47E+03	 0.41	
IL4R-001	 IL4-002-26	 8.19E+00	 8.40E+03	 0.20	
IL4R-001	 IL4-002-30	 8.19E+00	 1.04E+00	 1.00	
IL4R-001	 IL4-002-82	 8.19E+00	 1.20E+03	 0.44	
IL4R-001	 IL4-002-84	 8.19E+00	 3.77E+01	 0.99	
IL4R-001	 IL4-002-89	 8.19E+00	 1.12E+02	 0.79	
IL4R-001	 IL4-002-93	 8.19E+00	 5.37E+04	 0.12	
IL4R-001	 IL4-201	 8.19E+00	 4.81E-11	 1.00	
IL4R-001	 IL4-201-134	 8.19E+00	 1.72E+07	 0.10	
IL4R-001	 IL4-201-22	 8.19E+00	 1.71E+05	 0.11	
IL4R-001	 IL4-201-26	 8.19E+00	 1.24E+01	 1.00	
IL4R-001	 IL4-201-30	 8.19E+00	 4.33E-06	 1.00	
IL4R-001	 IL4-201-67	 8.19E+00	 5.25E+05	 0.11	






IL4R-001-185	 IL4-001	 8.19E+00	 1.17E+05	 0.12	
IL4R-001-400	 IL4-001	 8.19E+00	 3.79E+00	 1.00	
IL4R-001-436	 IL4-001	 8.19E+00	 9.03E+03	 0.19	
IL4R-001-503	 IL4-001	 8.19E+00	 1.09E+00	 1.00	
IL4R-001-576	 IL4-001	 8.19E+00	 2.88E+02	 0.65	
IL4R-001-579	 IL4-001	 8.19E+00	 5.99E+02	 0.55	
IL4R-001-75	 IL4-001	 8.19E+00	 4.15E-01	 1.00	
IL4R-001-752	 IL4-001	 8.19E+00	 1.29E+02	 0.77	
IL4R-001-82	 IL4-001	 8.19E+00	 2.16E+06	 0.11	
IL4R-001-97	 IL4-001	 8.19E+00	 1.50E-12	 1.00	
IL4R-004	 IL4-001	 8.19E+00	 4.07E-02	 1.00	
IL4R-004-185	 IL4-001	 8.19E+00	 1.50E+03	 0.41	
IL4R-004-400	 IL4-001	 8.19E+00	 3.91E+01	 0.99	
IL4R-004-431	 IL4-001	 8.19E+00	 9.10E+02	 0.48	
IL4R-004-436	 IL4-001	 8.19E+00	 2.00E-36	 1.00	
IL4R-004-503	 IL4-001	 8.19E+00	 1.22E+01	 1.00	
IL4R-004-576	 IL4-001	 8.19E+00	 1.27E-01	 1.00	
IL4R-004-579	 IL4-001	 8.19E+00	 1.11E+01	 1.00	
IL4R-004-75	 IL4-001	 8.19E+00	 1.36E+02	 0.76	
IL4R-004-752	 IL4-001	 8.19E+00	 1.87E+01	 1.00	
IL4R-004-786	 IL4-001	 8.19E+00	 1.32E+01	 1.00	
IL4R-004-82	 IL4-001	 8.19E+00	 6.07E+04	 0.12	
IL4R-004-97	 IL4-001	 8.19E+00	 3.42E+02	 0.63	
IL4R-201	 IL4-001	 8.19E+00	 2.08E-11	 1.00	
IL4R-201-170	 IL4-001	 8.19E+00	 3.49E-03	 1.00	
IL4R-201-385	 IL4-001	 8.19E+00	 7.35E+02	 0.52	
IL4R-201-416	 IL4-001	 8.19E+00	 4.25E+04	 0.13	
IL4R-201-421	 IL4-001	 8.19E+00	 2.06E+02	 0.70	
IL4R-201-488	 IL4-001	 8.19E+00	 5.72E+04	 0.12	
IL4R-201-561	 IL4-001	 8.19E+00	 3.93E+02	 0.61	
IL4R-201-564	 IL4-001	 8.19E+00	 2.34E-09	 1.00	
IL4R-201-60	 IL4-001	 8.19E+00	 8.82E+01	 0.84	
IL4R-201-660	 IL4-001	 8.19E+00	 1.51E+03	 0.41	
IL4R-201-67	 IL4-001	 8.19E+00	 1.14E+01	 1.00	
IL4R-201-737	 IL4-001	 8.19E+00	 6.38E+02	 0.54	
IL4R-201-771	 IL4-001	 8.19E+00	 3.05E-181	 1.00	
IL4R-201-82	 IL4-001	 8.19E+00	 5.44E+03	 0.24	
IL6R-001	 IL6-001	 6.64E+01	 6.64E+01	 	
IL6R-001	 IL6-001-104	 6.64E+01	 1.41E+03	 0.94	
IL6R-001	 IL6-001-116	 6.64E+01	 1.18E+01	 1.00	
IL6R-001	 IL6-001-152	 6.64E+01	 3.80E+01	 1.00	
IL6R-001	 IL6-001-162	 6.64E+01	 1.37E+01	 1.00	
IL6R-001	 IL6-001-2	 6.64E+01	 2.81E+02	 0.99	






IL6R-001	 IL6-001-32	 6.64E+01	 1.70E+02	 0.99	
IL6R-001	 IL6-001-55	 6.64E+01	 1.20E+02	 1.00	
IL6R-001	 IL6-001-6	 6.64E+01	 3.20E+02	 0.98	
IL6R-001	 IL6-001-7	 6.64E+01	 8.84E+01	 1.00	
IL6R-001	 IL6-001-79	 6.64E+01	 7.56E+02	 0.96	
IL6R-001	 IL6-003	 6.64E+01	 3.65E+02	 0.98	
IL6R-001	 IL6-003-110	 6.64E+01	 1.93E+02	 0.99	
IL6R-001	 IL6-003-28	 6.64E+01	 2.54E+01	 1.00	
IL6R-001	 IL6-003-3	 6.64E+01	 1.08E+02	 1.00	
IL6R-001	 IL6-003-40	 6.64E+01	 3.17E+03	 0.90	
IL6R-001	 IL6-003-76	 6.64E+01	 1.33E+01	 1.00	
IL6R-001	 IL6-003-89	 6.64E+01	 8.18E+01	 1.00	
IL6R-001	 IL6-003-92	 6.64E+01	 4.91E+02	 0.98	
IL6R-001	 IL6-004	 6.64E+01	 1.00E+02	 1.00	
IL6R-001	 IL6-004-28	 6.64E+01	 4.77E+02	 0.98	
IL6R-001	 IL6-004-3	 6.64E+01	 5.06E+02	 0.98	
IL6R-001	 IL6-004-40	 6.64E+01	 1.24E+02	 1.00	
IL6R-001	 IL6-004-76	 6.64E+01	 2.11E+00	 1.00	
IL6R-001	 IL6-004-86	 6.64E+01	 1.42E+00	 1.00	
IL6R-001	 IL6-005	 6.64E+01	 8.33E+00	 1.00	
IL6R-001	 IL6-005-129	 6.64E+01	 3.63E+01	 1.00	
IL6R-001	 IL6-005-139	 6.64E+01	 3.71E+01	 1.00	
IL6R-001	 IL6-005-2	 6.64E+01	 3.93E+01	 1.00	
IL6R-001	 IL6-005-32	 6.64E+01	 5.02E+01	 1.00	
IL6R-001	 IL6-005-56	 6.64E+01	 1.08E+02	 1.00	
IL6R-001	 IL6-005-6	 6.64E+01	 2.51E+01	 1.00	
IL6R-001	 IL6-005-8	 6.64E+01	 1.67E+02	 0.99	
IL6R-001	 IL6-005-81	 6.64E+01	 3.55E+01	 1.00	
IL6R-001	 IL6-005-9	 6.64E+01	 7.97E+01	 1.00	
IL6R-001	 IL6-005-93	 6.64E+01	 1.33E-01	 1.01	
IL6R-001	 IL6-006	 6.64E+01	 5.77E+00	 1.00	
IL6R-001	 IL6-006-104	 6.64E+01	 8.59E+01	 1.00	
IL6R-001	 IL6-006-116	 6.64E+01	 1.17E+02	 1.00	
IL6R-001	 IL6-006-152	 6.64E+01	 1.08E+01	 1.00	
IL6R-001	 IL6-006-165	 6.64E+01	 7.05E-01	 1.00	
IL6R-001	 IL6-006-168	 6.64E+01	 6.85E+00	 1.00	
IL6R-001	 IL6-006-186	 6.64E+01	 1.17E+01	 1.00	
IL6R-001	 IL6-006-2	 6.64E+01	 1.81E+00	 1.00	
IL6R-001	 IL6-006-31	 6.64E+01	 2.40E+03	 0.92	
IL6R-001	 IL6-006-32	 6.64E+01	 5.62E+02	 0.97	
IL6R-001	 IL6-006-55	 6.64E+01	 1.14E+03	 0.95	
IL6R-001	 IL6-006-6	 6.64E+01	 3.34E+02	 0.98	
IL6R-001	 IL6-006-7	 6.64E+01	 1.02E+03	 0.95	






IL6R-001	 IL6-201	 6.64E+01	 5.72E+01	 1.00	
IL6R-001	 IL6-201-104	 6.64E+01	 9.25E+00	 1.00	
IL6R-001	 IL6-201-116	 6.64E+01	 4.04E+01	 1.00	
IL6R-001	 IL6-201-152	 6.64E+01	 3.10E+00	 1.00	
IL6R-001	 IL6-201-162	 6.64E+01	 4.92E+01	 1.00	
IL6R-001	 IL6-201-2	 6.64E+01	 2.94E+02	 0.99	
IL6R-001	 IL6-201-31	 6.64E+01	 7.46E-01	 1.00	
IL6R-001	 IL6-201-32	 6.64E+01	 6.08E+02	 0.97	
IL6R-001	 IL6-201-55	 6.64E+01	 4.69E-06	 1.01	
IL6R-001	 IL6-201-6	 6.64E+01	 7.31E+03	 0.84	
IL6R-001	 IL6-201-7	 6.64E+01	 3.21E+00	 1.00	
IL6R-001	 IL6-201-79	 6.64E+01	 2.90E+02	 0.99	
IL6R-001-358	 IL6-001	 6.64E+01	 1.02E+01	 1.00	
IL6R-001-385	 IL6-001	 6.64E+01	 9.45E+01	 1.00	
IL6R-001-65	 IL6-001	 6.64E+01	 4.77E+01	 1.00	
IL6R-003	 IL6-001	 6.64E+01	 1.07E+02	 1.00	
IL6R-003-65	 IL6-001	 6.64E+01	 9.45E+01	 1.00	
IL6R-201	 IL6-001	 6.64E+01	 7.05E+01	 1.00	
IL6R-201-65	 IL6-001	 6.64E+01	 4.54E+01	 1.00	
MMP1-001	 CMA1-001	 2.00E-03	 2.00E-03	 	
MMP1-001	 CMA1-001-151	 2.00E-03	 1.20E-03	 1.00	
MMP1-001	 CMA1-001-157	 2.00E-03	 1.02E-02	 1.01	
MMP1-001	 CMA1-001-183	 2.00E-03	 3.96E-06	 1.00	
MMP1-001	 CMA1-001-221	 2.00E-03	 7.21E-03	 1.01	
MMP1-001	 CMA1-001-226	 2.00E-03	 7.76E-05	 1.00	
MMP1-001	 CMA1-001-33	 2.00E-03	 3.13E-04	 1.00	
MMP1-001	 CMA1-001-38	 2.00E-03	 4.71E-11	 1.00	
MMP1-001	 CMA1-001-46	 2.00E-03	 2.85E-04	 1.00	
MMP1-001	 CMA1-001-48	 2.00E-03	 2.66E-05	 1.00	
MMP1-001	 CMA1-001-63	 2.00E-03	 4.79E-04	 1.00	
MMP1-001	 CMA1-001-66	 2.00E-03	 1.44E-03	 1.00	
MMP1-001	 CMA1-001-69	 2.00E-03	 1.90E-01	 1.02	
MMP1-001	 CMA1-001-98	 2.00E-03	 1.29E-07	 1.00	
MMP1-001	 CMA1-002	 2.00E-03	 9.78E-05	 1.00	
MMP1-001	 CMA1-002-1	 2.00E-03	 1.56E-08	 1.00	
MMP1-001	 CMA1-002-106	 2.00E-03	 1.88E-06	 1.00	
MMP1-001	 CMA1-002-110	 2.00E-03	 3.06E-10	 1.00	
MMP1-001	 CMA1-002-115	 2.00E-03	 5.07E-02	 1.02	
MMP1-001	 CMA1-002-124	 2.00E-03	 2.28E-02	 1.01	
MMP1-001	 CMA1-002-126	 2.00E-03	 1.54E-02	 1.01	
MMP1-001	 CMA1-002-40	 2.00E-03	 7.21E-03	 1.01	
MMP1-001	 CMA1-002-46	 2.00E-03	 6.61E-04	 1.00	
MMP1-001	 CMA1-002-48	 2.00E-03	 1.28E-06	 1.00	






MMP1-001	 CMA1-002-72	 2.00E-03	 6.22E-03	 1.00	
MMP1-001	 CMA1-002-75	 2.00E-03	 2.02E-03	 1.00	
MMP1-001	 CMA1-002-77	 2.00E-03	 1.55E-02	 1.01	
MMP1-001	 CMA1-002-93	 2.00E-03	 4.95E-03	 1.00	
MMP1-001	 CMA1-002-95	 2.00E-03	 2.19E-02	 1.01	
MMP1-001-374	 CMA1-001	 2.00E-03	 7.92E-04	 1.00	
MMP1-001-406	 CMA1-001	 2.00E-03	 3.75E-03	 1.00	
MMP1-001	 TIMP1-001	 1.00E-07	 1.00E-07	 	
MMP1-001	 TIMP1-001-10	 1.00E-07	 6.21E-09	 1.00	
MMP1-001	 TIMP1-001-102	 1.00E-07	 4.11E-08	 1.00	
MMP1-001	 TIMP1-001-105	 1.00E-07	 3.46E-09	 1.00	
MMP1-001	 TIMP1-001-136	 1.00E-07	 3.13E-08	 1.00	
MMP1-001	 TIMP1-001-171	 1.00E-07	 1.09E-13	 1.00	
MMP1-001	 TIMP1-001-185	 1.00E-07	 1.21E-07	 1.00	
MMP1-001	 TIMP1-001-192	 1.00E-07	 1.41E-08	 1.00	
MMP1-001	 TIMP1-001-203	 1.00E-07	 2.75E-15	 1.00	
MMP1-001	 TIMP1-001-33	 1.00E-07	 1.34E-08	 1.00	
MMP1-001	 TIMP1-001-50	 1.00E-07	 1.24E-10	 1.00	
MMP1-001	 TIMP1-001-51	 1.00E-07	 1.37E-08	 1.00	
MMP1-001	 TIMP1-001-76	 1.00E-07	 1.00E-12	 1.00	
MMP1-001	 TIMP1-001-77	 1.00E-07	 1.94E-11	 1.00	
MMP1-001	 TIMP1-002	 1.00E-07	 1.56E-08	 1.00	
MMP1-001	 TIMP1-002-10	 1.00E-07	 6.85E-10	 1.00	
MMP1-001	 TIMP1-002-102	 1.00E-07	 1.14E-08	 1.00	
MMP1-001	 TIMP1-002-105	 1.00E-07	 2.66E-09	 1.00	
MMP1-001	 TIMP1-002-115	 1.00E-07	 5.49E-09	 1.00	
MMP1-001	 TIMP1-002-116	 1.00E-07	 4.04E-08	 1.00	
MMP1-001	 TIMP1-002-33	 1.00E-07	 2.92E-13	 1.00	
MMP1-001	 TIMP1-002-50	 1.00E-07	 4.79E-20	 1.00	
MMP1-001	 TIMP1-002-51	 1.00E-07	 1.85E-11	 1.00	
MMP1-001	 TIMP1-002-76	 1.00E-07	 3.23E-07	 1.00	
MMP1-001	 TIMP1-002-77	 1.00E-07	 4.04E-10	 1.00	
MMP1-001	 TIMP1-003	 1.00E-07	 4.91E-12	 1.00	
MMP1-001	 TIMP1-003-107	 1.00E-07	 1.20E-08	 1.00	
MMP1-001	 TIMP1-003-12	 1.00E-07	 2.40E-08	 1.00	
MMP1-001	 TIMP1-003-121	 1.00E-07	 1.44E-09	 1.00	
MMP1-001	 TIMP1-003-128	 1.00E-07	 1.77E-09	 1.00	
MMP1-001	 TIMP1-003-13	 1.00E-07	 5.40E-08	 1.00	
MMP1-001	 TIMP1-003-139	 1.00E-07	 3.65E-11	 1.00	
MMP1-001	 TIMP1-003-38	 1.00E-07	 1.37E-08	 1.00	
MMP1-001	 TIMP1-003-41	 1.00E-07	 2.16E-07	 1.00	
MMP1-001	 TIMP1-003-72	 1.00E-07	 2.92E-12	 1.00	
MMP1-001-374	 TIMP1-001	 1.00E-07	 3.41E-08	 1.00	






MMP1-001	 TIMP2-001	 1.00E-07	 1.00E-07	 	
MMP1-001	 TIMP2-003	 1.00E-07	 1.97E-09	 1.00	
MMP1-001	 TIMP2-003-130	 1.00E-07	 2.82E-08	 1.00	
MMP1-001	 TIMP2-003-139	 1.00E-07	 4.92E-03	 1.00	
MMP1-001	 TIMP2-008	 1.00E-07	 1.97E-09	 1.00	
MMP1-001	 TIMP2-008-130	 1.00E-07	 9.57E-03	 1.00	
MMP1-001	 TIMP2-008-139	 1.00E-07	 3.38E-04	 1.00	
MMP1-001	 TIMP2-008-42	 1.00E-07	 1.21E-05	 1.00	
MMP1-001	 TIMP2-008-54	 1.00E-07	 8.44E-09	 1.00	
MMP1-001	 TIMP2-008-69	 1.00E-07	 4.41E-06	 1.00	
MMP13-001	 TIMP1-001	 1.00E-07	 1.00E-07	 	
MMP13-001	 TIMP1-001-10	 1.00E-07	 1.36E-06	 1.00	
MMP13-001	 TIMP1-001-102	 1.00E-07	 7.30E-09	 1.00	
MMP13-001	 TIMP1-001-105	 1.00E-07	 1.97E-07	 1.00	
MMP13-001	 TIMP1-001-136	 1.00E-07	 1.73E-10	 1.00	
MMP13-001	 TIMP1-001-171	 1.00E-07	 5.27E-08	 1.00	
MMP13-001	 TIMP1-001-185	 1.00E-07	 6.05E-08	 1.00	
MMP13-001	 TIMP1-001-192	 1.00E-07	 2.40E-07	 1.00	
MMP13-001	 TIMP1-001-203	 1.00E-07	 2.20E-08	 1.00	
MMP13-001	 TIMP1-001-33	 1.00E-07	 1.29E-07	 1.00	
MMP13-001	 TIMP1-001-50	 1.00E-07	 4.61E-08	 1.00	
MMP13-001	 TIMP1-001-51	 1.00E-07	 2.92E-10	 1.00	
MMP13-001	 TIMP1-001-76	 1.00E-07	 2.35E-13	 1.00	
MMP13-001	 TIMP1-001-77	 1.00E-07	 2.72E-07	 1.00	
MMP13-001	 TIMP1-002	 1.00E-07	 2.99E-11	 1.00	
MMP13-001	 TIMP1-002-10	 1.00E-07	 4.80E-12	 1.00	
MMP13-001	 TIMP1-002-102	 1.00E-07	 2.62E-09	 1.00	
MMP13-001	 TIMP1-002-105	 1.00E-07	 4.22E-11	 1.00	
MMP13-001	 TIMP1-002-115	 1.00E-07	 5.86E-10	 1.00	
MMP13-001	 TIMP1-002-116	 1.00E-07	 2.41E-11	 1.00	
MMP13-001	 TIMP1-002-33	 1.00E-07	 1.60E-11	 1.00	
MMP13-001	 TIMP1-002-50	 1.00E-07	 1.62E-14	 1.00	
MMP13-001	 TIMP1-002-51	 1.00E-07	 1.26E-14	 1.00	
MMP13-001	 TIMP1-002-76	 1.00E-07	 8.48E-11	 1.00	
MMP13-001	 TIMP1-002-77	 1.00E-07	 2.44E-10	 1.00	
MMP13-001	 TIMP1-003	 1.00E-07	 5.51E-10	 1.00	
MMP13-001	 TIMP1-003-107	 1.00E-07	 2.11E-10	 1.00	
MMP13-001	 TIMP1-003-12	 1.00E-07	 1.92E-09	 1.00	
MMP13-001	 TIMP1-003-121	 1.00E-07	 8.32E-10	 1.00	
MMP13-001	 TIMP1-003-128	 1.00E-07	 5.66E-09	 1.00	
MMP13-001	 TIMP1-003-13	 1.00E-07	 1.15E-09	 1.00	
MMP13-001	 TIMP1-003-139	 1.00E-07	 1.27E-10	 1.00	
MMP13-001	 TIMP1-003-38	 1.00E-07	 5.94E-10	 1.00	






MMP13-001	 TIMP1-003-72	 1.00E-07	 7.19E-13	 1.00	
MMP13-001-158	 TIMP1-001	 1.00E-07	 1.56E-07	 1.00	
MMP13-002	 TIMP1-001	 1.00E-07	 5.59E-11	 1.00	
MMP13-002-158	 TIMP1-001	 1.00E-07	 4.26E-08	 1.00	
MMP13-201	 TIMP1-001	 1.00E-07	 5.08E-08	 1.00	
MMP13-201-158	 TIMP1-001	 1.00E-07	 5.55E-10	 1.00	
MMP13-001	 TIMP2-001	 1.00E-07	 1.00E-07	 	
MMP13-001	 TIMP2-001-119	 1.00E-07	 2.88E-06	 1.00	
MMP13-001	 TIMP2-003	 1.00E-07	 1.96E-08	 1.00	
MMP13-001	 TIMP2-003-130	 1.00E-07	 1.87E-07	 1.00	
MMP13-001	 TIMP2-003-139	 1.00E-07	 3.36E-19	 1.00	
MMP13-001	 TIMP2-008	 1.00E-07	 9.22E-09	 1.00	
MMP13-001	 TIMP2-008-130	 1.00E-07	 5.82E-08	 1.00	
MMP13-001	 TIMP2-008-139	 1.00E-07	 3.36E-19	 1.00	
MMP13-001	 TIMP2-008-42	 1.00E-07	 3.42E-07	 1.00	
MMP13-001	 TIMP2-008-54	 1.00E-07	 8.76E-09	 1.00	
MMP13-001	 TIMP2-008-69	 1.00E-07	 7.19E-10	 1.00	
MMP13-001-158	 TIMP2-001	 1.00E-07	 1.50E-08	 1.00	
MMP13-002	 TIMP2-001	 1.00E-07	 2.21E-07	 1.00	
MMP13-002-158	 TIMP2-001	 1.00E-07	 1.67E-08	 1.00	
MMP13-201	 TIMP2-001	 1.00E-07	 6.84E-09	 1.00	
MMP13-201-158	 TIMP2-001	 1.00E-07	 8.68E-09	 1.00	
MMP13-001	 TIMP3-001	 1.00E-07	 1.00E-07	 	
MMP13-001	 TIMP3-001-142	 1.00E-07	 2.96E-09	 1.00	
MMP13-001	 TIMP3-001-201	 1.00E-07	 5.48E-10	 1.00	
MMP13-001	 TIMP3-001-22	 1.00E-07	 2.31E-07	 1.00	
MMP13-001	 TIMP3-001-37	 1.00E-07	 5.61E-07	 1.00	
MMP13-001-158	 TIMP3-001	 1.00E-07	 2.76E-07	 1.00	
MMP13-002	 TIMP3-001	 1.00E-07	 1.92E-08	 1.00	
MMP13-201	 TIMP3-001	 1.00E-07	 2.40E-05	 1.00	
MMP13-201-158	 TIMP3-001	 1.00E-07	 8.02E-05	 1.00	
MMP2-001	 TIMP1-001	 1.00E-07	 1.00E-07	 	
MMP2-001	 TIMP1-001-10	 1.00E-07	 4.14E-07	 1.00	
MMP2-001	 TIMP1-001-102	 1.00E-07	 5.22E-08	 1.00	
MMP2-001	 TIMP1-001-105	 1.00E-07	 8.48E-09	 1.00	
MMP2-001	 TIMP1-001-136	 1.00E-07	 3.03E-11	 1.00	
MMP2-001	 TIMP1-001-171	 1.00E-07	 1.39E-14	 1.00	
MMP2-001	 TIMP1-001-185	 1.00E-07	 4.94E-09	 1.00	
MMP2-001	 TIMP1-001-192	 1.00E-07	 3.64E-07	 1.00	
MMP2-001	 TIMP1-001-203	 1.00E-07	 1.19E-09	 1.00	
MMP2-001	 TIMP1-001-33	 1.00E-07	 1.08E-07	 1.00	
MMP2-001	 TIMP1-001-50	 1.00E-07	 1.39E-09	 1.00	
MMP2-001	 TIMP1-001-51	 1.00E-07	 6.95E-08	 1.00	






MMP2-001	 TIMP1-001-77	 1.00E-07	 1.85E-07	 1.00	
MMP2-001	 TIMP1-002	 1.00E-07	 1.73E-09	 1.00	
MMP2-001	 TIMP1-002-10	 1.00E-07	 2.17E-11	 1.00	
MMP2-001	 TIMP1-002-102	 1.00E-07	 6.85E-09	 1.00	
MMP2-001	 TIMP1-002-105	 1.00E-07	 1.73E-14	 1.00	
MMP2-001	 TIMP1-002-115	 1.00E-07	 1.41E-14	 1.00	
MMP2-001	 TIMP1-002-116	 1.00E-07	 1.40E-11	 1.00	
MMP2-001	 TIMP1-002-33	 1.00E-07	 3.59E-09	 1.00	
MMP2-001	 TIMP1-002-50	 1.00E-07	 3.95E-08	 1.00	
MMP2-001	 TIMP1-002-51	 1.00E-07	 3.77E-09	 1.00	
MMP2-001	 TIMP1-002-76	 1.00E-07	 1.80E-10	 1.00	
MMP2-001	 TIMP1-002-77	 1.00E-07	 1.42E-09	 1.00	
MMP2-001	 TIMP1-003	 1.00E-07	 1.07E-14	 1.00	
MMP2-001	 TIMP1-003-107	 1.00E-07	 5.20E-09	 1.00	
MMP2-001	 TIMP1-003-12	 1.00E-07	 2.78E-09	 1.00	
MMP2-001	 TIMP1-003-121	 1.00E-07	 7.18E-09	 1.00	
MMP2-001	 TIMP1-003-128	 1.00E-07	 1.75E-10	 1.00	
MMP2-001	 TIMP1-003-13	 1.00E-07	 2.11E-15	 1.00	
MMP2-001	 TIMP1-003-139	 1.00E-07	 4.22E-10	 1.00	
MMP2-001	 TIMP1-003-38	 1.00E-07	 2.76E-10	 1.00	
MMP2-001	 TIMP1-003-41	 1.00E-07	 4.86E-09	 1.00	
MMP2-001	 TIMP1-003-72	 1.00E-07	 4.42E-14	 1.00	
MMP2-001-447	 TIMP1-001	 1.00E-07	 6.88E-07	 1.00	
MMP2-008	 TIMP1-001	 1.00E-07	 7.68E-08	 1.00	
MMP2-008-333	 TIMP1-001	 1.00E-07	 5.50E-06	 1.00	
MMP2-008-371	 TIMP1-001	 1.00E-07	 1.63E-07	 1.00	
MMP2-008-545	 TIMP1-001	 1.00E-07	 1.30E-08	 1.00	
MMP2-001	 TIMP2-001	 1.00E-07	 1.00E-07	 1.00	
MMP2-001	 TIMP2-001-119	 1.00E-07	 6.92E-03	 1.00	
MMP2-001	 TIMP2-001-146	 1.00E-07	 8.72E-03	 1.00	
MMP2-001	 TIMP2-003	 1.00E-07	 4.44E-02	 1.00	
MMP2-001	 TIMP2-003-130	 1.00E-07	 1.13E-01	 1.00	
MMP2-001	 TIMP2-003-139	 1.00E-07	 1.73E-03	 1.00	
MMP2-001	 TIMP2-008	 1.00E-07	 3.83E-04	 1.00	
MMP2-001	 TIMP2-008-130	 1.00E-07	 1.33E-03	 1.00	
MMP2-001	 TIMP2-008-42	 1.00E-07	 1.09E-03	 1.00	
MMP2-001	 TIMP2-008-54	 1.00E-07	 4.68E-02	 1.00	
MMP2-001	 TIMP2-008-69	 1.00E-07	 2.59E-04	 1.00	
MMP2-001-447	 TIMP2-001	 1.00E-07	 7.36E-05	 1.00	
MMP2-008	 TIMP2-001	 1.00E-07	 3.60E-02	 1.00	
MMP2-008-333	 TIMP2-001	 1.00E-07	 2.04E-03	 1.00	
MMP2-008-371	 TIMP2-001	 1.00E-07	 2.20E-03	 1.00	
MMP2-008-545	 TIMP2-001	 1.00E-07	 2.04E-01	 1.00	






MMP2-001	 TIMP3-001-121	 1.00E-07	 9.83E+00	 1.00	
MMP2-001	 TIMP3-001-186	 1.00E-07	 3.67E-07	 1.00	
MMP2-001-447	 TIMP3-001	 1.00E-07	 1.65E-02	 1.00	
MMP2-008-333	 TIMP3-001	 1.00E-07	 2.60E-05	 1.00	
MMP2-008-371	 TIMP3-001	 1.00E-07	 9.81E-06	 1.00	
MMP2-001	 TIMP4-001	 1.00E-07	 1.00E-07	 	
MMP2-001	 TIMP4-001-103	 1.00E-07	 4.16E-10	 1.00	
MMP2-001	 TIMP4-001-109	 1.00E-07	 1.06E-08	 1.00	
MMP2-001	 TIMP4-001-141	 1.00E-07	 1.36E-08	 1.00	
MMP2-001	 TIMP4-001-143	 1.00E-07	 2.87E-09	 1.00	
MMP2-001	 TIMP4-001-19	 1.00E-07	 1.66E-09	 1.00	
MMP2-001	 TIMP4-001-206	 1.00E-07	 1.20E-09	 1.00	
MMP2-001	 TIMP4-001-214	 1.00E-07	 1.72E-08	 1.00	
MMP2-001	 TIMP4-001-24	 1.00E-07	 1.55E-08	 1.00	
MMP3-001	 TIMP1-001	 1.00E-07	 1.82E-09	 1.00	
MMP3-001	 TIMP1-001-10	 1.00E-07	 2.33E-10	 1.00	
MMP3-001	 TIMP1-001-102	 1.00E-07	 1.64E-17	 1.00	
MMP3-001	 TIMP1-001-105	 1.00E-07	 1.31E-12	 1.00	
MMP3-001	 TIMP1-001-136	 1.00E-07	 6.59E-09	 1.00	
MMP3-001	 TIMP1-001-171	 1.00E-07	 5.54E-08	 1.00	
MMP3-001	 TIMP1-001-185	 1.00E-07	 1.26E-08	 1.00	
MMP3-001	 TIMP1-001-192	 1.00E-07	 1.56E-09	 1.00	
MMP3-001	 TIMP1-001-203	 1.00E-07	 1.01E-16	 1.00	
MMP3-001	 TIMP1-001-33	 1.00E-07	 1.29E-08	 1.00	
MMP3-001	 TIMP1-001-50	 1.00E-07	 7.15E-10	 1.00	
MMP3-001	 TIMP1-001-51	 1.00E-07	 8.58E-12	 1.00	
MMP3-001	 TIMP1-001-76	 1.00E-07	 7.85E-09	 1.00	
MMP3-001	 TIMP1-001-77	 1.00E-07	 5.86E-10	 1.00	
MMP3-001	 TIMP1-002	 1.00E-07	 8.36E-08	 1.00	
MMP3-001	 TIMP1-002-10	 1.00E-07	 6.52E-09	 1.00	
MMP3-001	 TIMP1-002-102	 1.00E-07	 2.03E-09	 1.00	
MMP3-001	 TIMP1-002-105	 1.00E-07	 6.89E-09	 1.00	
MMP3-001	 TIMP1-002-115	 1.00E-07	 3.27E-08	 1.00	
MMP3-001	 TIMP1-002-116	 1.00E-07	 1.80E-10	 1.00	
MMP3-001	 TIMP1-002-33	 1.00E-07	 3.76E-09	 1.00	
MMP3-001	 TIMP1-002-50	 1.00E-07	 3.41E-09	 1.00	
MMP3-001	 TIMP1-002-51	 1.00E-07	 1.21E-08	 1.00	
MMP3-001	 TIMP1-002-76	 1.00E-07	 9.65E-10	 1.00	
MMP3-001	 TIMP1-002-77	 1.00E-07	 4.16E-09	 1.00	
MMP3-001	 TIMP1-003	 1.00E-07	 5.68E-07	 1.00	
MMP3-001	 TIMP1-003-107	 1.00E-07	 2.02E-08	 1.00	
MMP3-001	 TIMP1-003-12	 1.00E-07	 2.76E-09	 1.00	
MMP3-001	 TIMP1-003-121	 1.00E-07	 3.43E-09	 1.00	






MMP3-001	 TIMP1-003-13	 1.00E-07	 4.51E-07	 1.00	
MMP3-001	 TIMP1-003-139	 1.00E-07	 2.10E-09	 1.00	
MMP3-001	 TIMP1-003-38	 1.00E-07	 1.97E-07	 1.00	
MMP3-001	 TIMP1-003-41	 1.00E-07	 7.48E-09	 1.00	
MMP3-001	 TIMP1-003-72	 1.00E-07	 2.21E-10	 1.00	
MMP3-001-45	 TIMP1-001	 1.00E-07	 1.41E-06	 1.00	
MMP3-001-96	 TIMP1-001	 1.00E-07	 5.63E-09	 1.00	
MMP3-001	 TIMP2-001	 1.00E-07	 4.67E-10	 1.00	
MMP3-001	 TIMP2-003	 1.00E-07	 3.48E-10	 1.00	
MMP3-001	 TIMP2-003-130	 1.00E-07	 1.19E-08	 1.00	
MMP3-001	 TIMP2-003-139	 1.00E-07	 1.13E-07	 1.00	
MMP3-001	 TIMP2-008	 1.00E-07	 1.80E-07	 1.00	
MMP3-001	 TIMP2-008-130	 1.00E-07	 4.91E-09	 1.00	
MMP3-001	 TIMP2-008-139	 1.00E-07	 2.50E-08	 1.00	
MMP3-001	 TIMP2-008-42	 1.00E-07	 5.44E-08	 1.00	
MMP3-001	 TIMP2-008-54	 1.00E-07	 3.53E-08	 1.00	
MMP3-001	 TIMP2-008-69	 1.00E-07	 7.43E-09	 1.00	
MMP3-001	 TIMP3-001	 1.00E-07	 2.08E-08	 1.00	
MMP3-001	 TIMP3-001-121	 1.00E-07	 2.99E-07	 1.00	
MMP3-001	 TIMP3-001-142	 1.00E-07	 2.90E-09	 1.00	
MMP3-001	 TIMP3-001-186	 1.00E-07	 7.13E-09	 1.00	
MMP3-001	 TIMP3-001-196	 1.00E-07	 2.00E-04	 1.00	
MMP3-001	 TIMP3-001-22	 1.00E-07	 1.68E-07	 1.00	
MMP3-001	 TIMP3-001-37	 1.00E-07	 2.22E-07	 1.00	
MMP3-001-45	 TIMP3-001	 1.00E-07	 1.31E-03	 1.00	
MMP3-001	 TIMP4-001	 1.00E-07	 1.16E-09	 1.00	
MMP3-001	 TIMP4-001-141	 1.00E-07	 2.78E-11	 1.00	
MMP3-001	 TIMP4-001-214	 1.00E-07	 5.02E-22	 1.00	
MMP3-001	 TIMP4-001-24	 1.00E-07	 2.50E-07	 1.00	
MMP3-001	 TIMP4-001-28	 1.00E-07	 1.80E-05	 1.00	
MMP3-001-45	 TIMP4-001	 1.00E-07	 5.14E-07	 1.00	
MMP9-001	 TIMP1-001	 1.00E-07	 1.00E-07	 	
MMP9-001	 TIMP1-001-10	 1.00E-07	 1.04E-06	 0.97	
MMP9-001	 TIMP1-001-102	 1.00E-07	 1.18E-03	 0.90	
MMP9-001	 TIMP1-001-105	 1.00E-07	 3.90E-03	 0.90	
MMP9-001	 TIMP1-001-136	 1.00E-07	 1.74E-03	 0.90	
MMP9-001	 TIMP1-001-171	 1.00E-07	 5.79E-09	 1.00	
MMP9-001	 TIMP1-001-185	 1.00E-07	 2.01E-04	 0.90	
MMP9-001	 TIMP1-001-192	 1.00E-07	 7.42E-04	 0.90	
MMP9-001	 TIMP1-001-203	 1.00E-07	 2.63E-09	 1.00	
MMP9-001	 TIMP1-001-33	 1.00E-07	 3.78E-09	 1.00	
MMP9-001	 TIMP1-001-50	 1.00E-07	 1.75E-05	 0.91	
MMP9-001	 TIMP1-001-51	 1.00E-07	 2.88E-06	 0.95	






MMP9-001	 TIMP1-001-77	 1.00E-07	 3.15E-04	 0.90	
MMP9-001	 TIMP1-002	 1.00E-07	 9.11E-04	 0.90	
MMP9-001	 TIMP1-002-10	 1.00E-07	 7.29E-03	 0.90	
MMP9-001	 TIMP1-002-102	 1.00E-07	 4.17E-05	 0.91	
MMP9-001	 TIMP1-002-105	 1.00E-07	 5.72E-03	 0.90	
MMP9-001	 TIMP1-002-115	 1.00E-07	 1.68E-05	 0.92	
MMP9-001	 TIMP1-002-116	 1.00E-07	 1.58E-03	 0.90	
MMP9-001	 TIMP1-002-33	 1.00E-07	 4.74E-06	 0.94	
MMP9-001	 TIMP1-002-50	 1.00E-07	 1.50E-03	 0.90	
MMP9-001	 TIMP1-002-51	 1.00E-07	 3.29E-08	 1.00	
MMP9-001	 TIMP1-002-76	 1.00E-07	 3.26E-06	 0.95	
MMP9-001	 TIMP1-002-77	 1.00E-07	 6.26E-06	 0.93	
MMP9-001	 TIMP1-003	 1.00E-07	 1.61E-03	 0.90	
MMP9-001	 TIMP1-003-107	 1.00E-07	 7.82E-06	 0.93	
MMP9-001	 TIMP1-003-12	 1.00E-07	 5.39E-05	 0.91	
MMP9-001	 TIMP1-003-121	 1.00E-07	 1.50E-06	 0.97	
MMP9-001	 TIMP1-003-128	 1.00E-07	 9.78E-06	 0.92	
MMP9-001	 TIMP1-003-13	 1.00E-07	 5.39E-08	 1.00	
MMP9-001	 TIMP1-003-139	 1.00E-07	 2.03E-06	 0.96	
MMP9-001	 TIMP1-003-38	 1.00E-07	 2.28E-04	 0.90	
MMP9-001	 TIMP1-003-41	 1.00E-07	 3.74E-05	 0.91	
MMP9-001	 TIMP1-003-72	 1.00E-07	 2.74E-07	 0.99	
MMP9-001-20	 TIMP1-001	 1.00E-07	 3.25E-08	 1.00	
MMP9-001-239	 TIMP1-001	 1.00E-07	 3.36E-06	 0.95	
MMP9-001-279	 TIMP1-001	 1.00E-07	 8.26E-04	 0.90	
MMP9-001-38	 TIMP1-001	 1.00E-07	 2.67E-03	 0.90	
MMP9-001-574	 TIMP1-001	 1.00E-07	 7.39E-07	 0.98	
MMP9-001-668	 TIMP1-001	 1.00E-07	 1.46E-03	 0.90	
MMP9-001	 TIMP2-001	 1.00E-07	 1.00E-07	 	
MMP9-001	 TIMP2-003	 1.00E-07	 1.19E-05	 0.92	
MMP9-001	 TIMP2-003-130	 1.00E-07	 1.63E-04	 0.90	
MMP9-001	 TIMP2-003-139	 1.00E-07	 2.28E-04	 0.90	
MMP9-001	 TIMP2-008	 1.00E-07	 1.19E-05	 0.92	
MMP9-001	 TIMP2-008-130	 1.00E-07	 4.76E-13	 1.00	
MMP9-001	 TIMP2-008-139	 1.00E-07	 2.28E-04	 0.90	
MMP9-001	 TIMP2-008-42	 1.00E-07	 4.25E-02	 0.90	
MMP9-001	 TIMP2-008-54	 1.00E-07	 4.84E-04	 0.90	
MMP9-001	 TIMP2-008-69	 1.00E-07	 1.12E-04	 0.90	
MMP9-001-279	 TIMP2-001	 1.00E-07	 1.06E-07	 1.00	
MMP9-001	 TIMP3-001	 1.00E-07	 1.00E-07	 	
MMP9-001	 TIMP3-001-121	 1.00E-07	 2.75E-04	 0.90	
MMP9-001	 TIMP3-001-142	 1.00E-07	 4.82E-08	 1.00	
MMP9-001	 TIMP3-001-186	 1.00E-07	 3.17E-04	 0.90	






MMP9-001	 TIMP3-001-201	 1.00E-07	 1.51E-04	 0.90	
MMP9-001	 TIMP3-001-22	 1.00E-07	 2.89E-05	 0.91	
MMP9-001	 TIMP3-001-37	 1.00E-07	 1.77E-05	 0.91	
MMP9-001-20	 TIMP3-001	 1.00E-07	 2.49E-08	 1.00	
MMP9-001-239	 TIMP3-001	 1.00E-07	 8.36E-06	 0.93	
MMP9-001-279	 TIMP3-001	 1.00E-07	 8.07E-02	 0.90	
MMP9-001-38	 TIMP3-001	 1.00E-07	 1.64E-03	 0.90	
MMP9-001-574	 TIMP3-001	 1.00E-07	 2.05E-06	 0.96	
MMP9-001-668	 TIMP3-001	 1.00E-07	 4.69E-14	 1.00	
MMP9-001	 TIMP4-001	 1.00E-07	 1.00E-07	 	
MMP9-001	 TIMP4-001-103	 1.00E-07	 5.73E-09	 1.00	
MMP9-001	 TIMP4-001-109	 1.00E-07	 5.99E-09	 1.00	
MMP9-001	 TIMP4-001-112	 1.00E-07	 6.04E-11	 1.00	
MMP9-001	 TIMP4-001-141	 1.00E-07	 6.17E-11	 1.00	
MMP9-001	 TIMP4-001-143	 1.00E-07	 4.01E-10	 1.00	
MMP9-001	 TIMP4-001-19	 1.00E-07	 2.79E-08	 1.00	
MMP9-001	 TIMP4-001-206	 1.00E-07	 9.74E-11	 1.00	
MMP9-001	 TIMP4-001-214	 1.00E-07	 1.64E-11	 1.00	
MMP9-001	 TIMP4-001-24	 1.00E-07	 7.87E-11	 1.00	
MMP9-001	 TIMP4-001-28	 1.00E-07	 2.27E-10	 1.00	
MMP9-001-20	 TIMP4-001	 1.00E-07	 2.05E-11	 1.00	
MMP9-001-239	 TIMP4-001	 1.00E-07	 2.19E-12	 1.00	
MMP9-001-279	 TIMP4-001	 1.00E-07	 2.23E-11	 1.00	
MMP9-001-38	 TIMP4-001	 1.00E-07	 9.43E-12	 1.00	
MMP9-001-574	 TIMP4-001	 1.00E-07	 5.86E-17	 1.00	
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